Technology - Investor's Business Daily00:16 Текст источника в новой вкладке

 
 
1. Tesaro Stock Flies 31% On Rumored Buyout Interest After Lung-Cancer FlopСб., 17 нояб.[−]

Tesaro stock rocketed late Friday on a rumor that the biotech could seek a sale after its lung-cancer treatment disappointed investors last week.

X

Before the close, Tesaro ( TSRO) leapt 31.5%, to 34.96, on the stock market today. Tesaro stock was flat after hours.

According to unnamed sources cited by Bloomberg, Tesaro has received takeover interest and is working with financial advisors. Those advisors also reportedly have begun seeking out other potential suitors.

A representative of Tesaro didn't immediately return a request for comment from Investor's Business Daily.

Last Friday, Tesaro stock plunged nearly 19% after its immunotherapy regimen in lung-cancer treatment disappointed. Of 31 patients who could be evaluated, four had partial responses and another 11 were stabilized after treatment.

YOU MIGHT ALSO LIKE:

New Option Strategy Limits Risk Around Earnings

Apple And Growth Stocks: Why Most Penny Stocks Fail To Make Investors Rich

When Will The Dow Jones Or Nasdaq Show A Major Stock Market Top? Here's The Easy Way To Find Out

The post Tesaro Stock Flies 31% On Rumored Buyout Interest After Lung-Cancer Flop appeared first on Investor's Business Daily.


2. Nvidia, Applied Materials Rocked By Anemic Sales GuidanceСб., 17 нояб.[−]

Graphics-chip maker Nvidia ( NVDA) and semiconductor equipment supplier Applied Materials ( AMAT) saw their shares pounded early Friday after offering weak guidance for the current quarter. Nvidia stock stayed down, but Applied Materials stock rebounded to end the day with a modest gain.

X

Nvidia stock plummeted 20.1% after the opening bell on the stock market today. It hit a 52-week low of 161.61. Nvidia stock ended the regular session down 18.8% to 164.43.

Applied Materials stock fell as much as 8.4% in early trading. It bounced back and ended the day up 1.1% to 35.40.

Nvidia late Thursday missed Wall Street's sales target for its fiscal third quarter ended Oct. 28. It also guided well below analyst views for the January quarter. Nvidia warned about excess inventory of gaming processors that could take a quarter or two to clear out.

Applied Materials reported in-line October-quarter results, but missed analyst views for sales and earnings in the current quarter. It spoke of "near-term market headwinds," but said overall chip industry spending remains robust.

At least 20 Wall Street analysts cut their price targets on Nvidia stock after its earnings report. B. Riley FBR downgraded shares to neutral from buy and slashed its price target to 190 from 240. Goldman Sachs removed Nvidia from its conviction buy list and reduced its price target to 200 from 283.

Nvidia Dealing With 'Crypto Hangover'

"Nvidia is a momentum stock that missed fiscal Q4 consensus revenue estimates by over 20%," Nomura Instinet analyst Romit Shah said in a note to clients. "This coupled with modest data-center growth will likely keep the stock under pressure until the next report (February)."

Shah reiterated his neutral rating on the stock and lowered his price target to 200 from 225.

The excess inventory of gaming chips is troubling, especially because of the "tepid customer response to the new Turing products," he said. The company attributed the weak sales to a decline in cryptocurrency mining. Chief Executive Jensen Huang said Nvidia is experiencing a "crypto hangover."

Goldman Sachs analyst Toshiya Hari admitted that his firm was "clearly wrong" on Nvidia stock.

"It could take a few quarters before the market regains confidence in the growth trajectory of the business, especially given the weak economic backdrop," he said in a report to clients.

There's a strong likelihood that Nvidia will not grow next year, BMO Capital Markets analyst Ambrish Srivastava said. He reiterated his market perform rating on the stock and cut his price target to 175 from 225.

Applied Materials Stock Gets Price-Target Cuts

At least 12 analysts cut their price targets on Applied Materials stock after its earnings report late Thursday.

Wafer fabrication equipment spending is expected to decline slightly in 2019, Applied Materials warned. The company cited elevated macroeconomic risks, global trade tensions and the pullback in memory chip investments.

Nvidia and Applied Materials are the latest chip stocks to offer a gloomy outlook this earnings cycle. The semiconductor industry has been hit by slowing smartphone sales and an oversupply of memory chips, among other issues.

The Philadelphia Semiconductor Index, known as SOX, fell 1.2% on Friday.

RELATED:

Nvidia Stock Falls On Sales Miss, Weak Guidance, Excess Inventory

Applied Materials Stock Drops On Soft Sales Guidance

The post Nvidia, Applied Materials Rocked By Anemic Sales Guidance appeared first on Investor's Business Daily.


3. Recent Breakout Stock Sacrifices Buy Zone On Lung-Cancer FailureСб., 17 нояб.[−]

AstraZeneca ( AZN) sacrificed a buy zone Friday after its immunotherapy regimen failed to improve overall survival in lung cancer patients. On the stock market today, AstraZeneca stock slipped 1.8%, to 40.67.

X

AstraZeneca stock briefly fell below an entry out of a flat base achieved last week at 40.26. At the same time, pharma stocks rose more than 1%.

The Phase 3 study, called Mystic, tested AstraZeneca's Imfinzi and a combination of Imfinzi and a drug known as tremelimumab in some patients with lung cancer. But the regimen didn't improve overall survival compared to chemotherapy.

"We are disappointed that these results missed statistical significance," Chief Medical Officer Sean Bohen said in a written statement.

AstraZeneca Stock: Immunotherapy In Lung Cancer

AstraZeneca tested the immunotherapy regimens in patients whose tumors have at least 25% of a protein called PD-L1. Researchers believe these patients respond better to treatment with Imfinzi, a PD-L1 inhibitor.

But neither Imfinzi alone nor the regimen of Imfinzi plus tremelimumab — another immunotherapy that is a CTLA-4 inhibitor — surpassed chemotherapy in terms of improving overall survival in lung cancer.

However, AstraZeneca said another analysis shows the combination could still work in other groups of patients. Further, Imfinzi alone and the immunotherapy regimen proved safe and tolerable for patients.

"We are encouraged to see that Imfinzi monotherapy activity is in line with that of the other anti-PD-1 class in previously untreated patients with Stage 4 non-small cell lung cancer," AstraZeneca's Bohen said.

Bristol Stock Rises

AstraZeneca isn't alone in testing an immunotherapy regimen using drugs to block PD-L1 or a related protein called PD-1 and CTLA-4.

Late Thursday, a European group recommended officials approve a regimen using Bristol-Myers Squibb's ( BMY) Opdivo and Yervoy as a first-time treatment in patients with kidney cancer. Opdivo is a PD-1 inhibitor and Yervoy blocks CTLA-4.

In the U.S., Bristol's immunotherapy regimen treats kidney cancer and a type of skin cancer called melanoma. The Food and Drug Administration is also set to consider the regimen as a first-time treatment in lung cancer in February.

Early Friday, Bristol stock rose 1.2%, near 53.90.

YOU MIGHT ALSO LIKE:

FANG Stocks News & Quotes: Facebook, Amazon, Netflix, Google

The Basics: How To Analyze A Stock's Cup-With-Handle Base

IBD 50 Growth Stocks To Watch

The post Recent Breakout Stock Sacrifices Buy Zone On Lung-Cancer Failure appeared first on Investor's Business Daily.


4. Sonos Upbeat Earnings Report Is Music To Wall Street's EarsСб., 17 нояб.[−]

Premium sound system maker Sonos ( SONO) got toes tapping with the upbeat tempo of its September-quarter earnings report. Sonos stock jumped Friday on the news.

X

The Santa Barbara, Calif.-based company late Thursday said it lost 2 cents a share on sales of $272.9 million in its fiscal fourth quarter ended Sept. 29. Analysts polled by Zacks Investment Research expected the Sonos earnings report to show a loss of 8 cents a share on sales of $249 million.

For the December quarter, Sonos predicted sales of $490 million vs. the Zacks estimate of $470 million.

Sonos stock rose 9% to 15.44 on the stock market today. The consumer electronics firm went public on Aug. 2 at 15 a share. Sonos stock hit a record high of 23.60 on its second day of trading.

Sonos credited strong September-quarter results to its recently launched Sonos Beam soundbar. The product is a voice-enabled smart speaker, music sound system and TV speaker.

"Sonos' new Beam soundbar product appears to have good initial momentum and the Sonos One is also performing well," Goldman Sachs analyst Rod Hall said in a report to clients. "Beam is seeing particularly strong adoption in Europe, which we see as evidence that Sonos' international expansion strategy continues to bear fruit."

Hall reiterated his buy rating on Sonos stock with a price target of 25.

Sonos Could Face Tough Holiday Competition

Other analysts remain cautious. For instance, Jefferies analyst Brent Thill reiterated his hold rating and cut his price target to 18 from 23.

Sonos is likely to face stiff competition this holiday season from smart speaker vendors such as Amazon ( AMZN), he said.

Morgan Stanley analyst Katy Huberty echoed those concerns. She rates the stock as equal-weight with a price target of 20.

"Management believes lower-priced entry-level smart speakers raise market awareness over time for higher quality solutions from Sonos, but the company saw headwinds last year from elevated promotional activity," she said in her note to clients.

Focused On Premium Audio, Not Smart Home Controls

Sonos is focused on premium audio while other smart speaker vendors are more interested in providing voice assistants and controlling smart home devices.

"Our ambition is to be the world's leading sound experience company," Michael Groeninger, Sonos vice president of finance, told Investor's Business Daily. "I can guarantee you that is not the ambition of Amazon, Google or Apple ( AAPL)."

Sonos doesn't compete in the low end of the market where Amazon and Alphabet's ( GOOGL) Google are selling $20 or $30 mini speakers this holiday season.

"Most of the headlines and discounting activity are really happening in the under-$100 price range," he said. "That's where the volume is happening, but that's not where our target customer lives. We're a premium product."

Sonos executives touted new products coming next year including outdoor speakers.

"For 16 years we've been focused only on products inside the home," Groeninger said. "We believe there are clear adjacencies whether it's outdoor, portable, commercial spaces, auto or personal audio like headphones. These are all adjacencies that make a lot of sense for us."

RELATED:

Sonos Stock Jumps On Better-Than-Expected Speaker Sales

Big-Screen TVs, Smart Speakers Are Hot Gadgets This Holiday Season

The post Sonos Upbeat Earnings Report Is Music To Wall Street's Ears appeared first on Investor's Business Daily.


5. Facebook Stock Hits 21-Month Low After New York Times Article BlowupСб., 17 нояб.[−]

Facebook stock fell to a 21-month low Friday, following an explosive New York Times article this week that raised questions about how the social media behemoth handled the spread of disinformation and other problems.

X

The Times report on Facebook ( FB) described how Chief Executive Mark Zuckerberg and Chief Operating Officer Sheryl Sandberg passed off many critical security and policy decisions. They delayed responses to abuse on Facebook or played down its significance, the article said. It also revealed how Facebook treats competitors and opponents.

Facebook stock dropped 3%, to 139.53 on the stock market today.

Facebook Stock Loses 36%

Facebook stock lost 36% since hitting a record high of 218.62 on July 25, the day it reported second-quarter earnings after the market closed. The quarterly results missed estimates on revenue. Facebook also lowered revenue guidance for the third and fourth quarters.

On July 26 Facebook stock plunged 19%. It was the first full quarter of Facebook results since the Cambridge Analytica data scandal surfaced earlier this year.

Facebook Under Scrutiny

Facebook came under scrutiny in early February after it was revealed that political consultant Cambridge Analytica wrongfully accessed personal data from 87 million Facebook users. Hackers allegedly used the data in the 2016 presidential election. It also led to Zuckerberg facing 10 hours of congressional testimony over two days. Analysts raised concerns as to whether the scandal would cause advertisers to slink away and user growth to slow. Such appeared to be the case.

With its third-quarter report Facebook revenue fell short of analyst estimates, as did monthly active users.

Facebook said there were a number of inaccuracies in the New York Times story. The Facebook board of directors responded to the article on Thursday with a prepared statement.

'Too Slow To Take Action'

"As Mark and Sheryl made clear to Congress, the company was too slow to spot Russian interference, and too slow to take action," it said. "As a board we did indeed push them to move faster. But to suggest that they knew about Russian interference and either tried to ignore it or prevent investigations into what had happened is grossly unfair. In the last eighteen months Facebook, with the full support of this board, has invested heavily in more people and better technology to prevent misuse of its services, including during elections."

YOU MIGHT ALSO LIKE:

Bid To Oust Zuckerberg As Facebook Chairman Joined By Major Investors

Facebook, Twitter And The Struggle To Stop Election Interference

Zuckerberg Apology Tour Calms Nerves, But Facebook Price Target Lowered

The post Facebook Stock Hits 21-Month Low After New York Times Article Blowup appeared first on Investor's Business Daily.


6. JD.com Earnings Due During China Roughness As Stock Near A New LowСб., 17 нояб.[−]

JD.com stock hovered near record lows Friday as the company prepares for earnings due Monday before the market open.

X

JD.com ( JD) is one of the largest e-commerce companies in China, with Alibaba ( BABA) being a main competitor.

The estimate on JD.com earnings among analysts polled by Zacks Investment Research calls for adjusted profit of 12 cents a share. That's 48% below what it reported in the year-ago quarter. Analysts see revenue of $15.3 billion, up 21%. That would be the third quarter in a row of decelerating revenue growth from the year-ago period.

JD.com stock plunged 4.8% to close at 23.05 on the stock market today. Last week, JD.com stock hit a low of 21.46. Its all-time low is 19.94, which it set just after its initial public offering in June 2014.

JD.com Stock Rating

KeyBanc Capital Markets analyst Hans Chung last month downgraded JD.com to sector weight from overweight, largely to reflect a weakening China economy. A rating of sector weight means Chung expects JD.com stock to trade relative to its peers over the next 6 to 12 months.

Chung also based the downgrade on concerns about ongoing weakness in smartphones and home appliance markets, "which account for 43% of total net revenue and could make JD more vulnerable than peers in the current environment," he wrote in a note to clients.

"We expect revenue growth of the two business segments could decelerate significantly in 2019," Chung said.

UBS analyst Jerry Liu has a buy rating on JD.com stock and price target of 28.

JD.com On Singles Day

Liu was encouraged by JD.com sales on Singles Day on Nov. 11, an annual shopping festival pioneered by Alibaba. On that day, JD.com said its sales rose 26% from the year-ago period to $23 billion. Alibaba reported sales of $31 billion.

"During the sales event, we observed JD's strong growth in premium products across various categories," Liu wrote in a note to clients. "We are also encouraged by JD's enhanced infrastructures like logistics, smart supply chain, and internet finance, as well as its initiatives in offline retailing integration."

JD.com earnings in the second quarter came in weaker than expected.

Alibaba early this month reported mixed fiscal second-quarter results as earnings easily beat views while revenue came in light. Alibaba curbed its full-year revenue growth amid "fluid macroeconomic conditions."

YOU MIGHT ALSO LIKE:

JD.com Earnings Fall Short In Rough Week For China Stocks

China Internet Stocks Fall On Quarterly Earnings, Disappointing Data

The post JD.com Earnings Due During China Roughness As Stock Near A New Low appeared first on Investor's Business Daily.


7. Trump's Biopharma Impasse Led To A Slowdown — Now Pfizer Is Fighting BackСб., 17 нояб.[−]

Drug-pricing pressure from the Trump administration likely contributed to a slowdown in revenue growth for the biopharma industry during the third quarter, an analyst said Friday.

X

But at least a piece of that brouhaha will reverse in 2019. On Friday, Pfizer ( PFE) said it will raise the prices on 41 drugs in January after holding back on price hikes this summer. Those medicines represent 10% of Pfizer's portfolio, according to a press release.

"The increase in list price to this subset of the company's portfolio will be 5%," Pfizer said in a news release. Three products will be exceptions as the prices on two drugs rise by 3% apiece. One will increase by 9% due to the completion of two extensive development programs.

A Dow Jones component, Pfizer doesn't expect to see much impact on revenue, however. It expects the higher list prices to be offset by higher rebates and discounts. As a result, the impact on revenue growth in the U.S. in 2019 "is expected to be zero."

Drug-Pricing Pressures Quarterly Sales

Leerink analyst Geoffrey Porges notes that eight of 17 large-cap biopharmas beat revenue views during the third quarter, and every one of them topped earnings expectations. But year-over-year sales growth of 3% slowed for the fourth straight quarter.

Biopharma sales collectively advanced 6.7% in the fourth quarter of 2017. But sales growth slowed to 5.8%, 4.9% and 3% in the following three periods. Drugmakers have largely held off on drug-pricing increases over the past two quarters, Porges said in a note.

"The decreases in positive price contribution to reported results is likely to have been a significant contributor to 200-300 basis points slowing in top-line growth in the third quarter," he said. "Unless pricing reverses itself soon, the negative effect in 2019 could be even greater."

Top Performers Include Alexion, Celgene, AbbVie

On a year-over-year basis, the 17 companies brought in $139.1 billion in the third quarter, up 3% or $4 billion. Total industry revenue has lingered around $140 billion since the fourth quarter of 2017, Porges said. Previously, it hovered around $130 billion.

The best performers in terms of revenue growth were Alexion Pharmaceuticals ( ALXN), Celgene ( CELG) and AbbVie ( ABBV), which rose 19%, 18% and 18%, respectively. Gilead Sciences ( GILD) and AstraZeneca ( AZN) were hit with massive erosion, declining 14% apiece.

Meanwhile, Amgen ( AMGN), GlaxoSmithKline ( GSK), Pfizer ( PFE) and Sanofi ( SNY) were all flat, Porges said.

In terms of rivaling the Street, the most significant sales beats came from Amgen, Biogen ( BIIB), Celgene, Gilead, Johnson & Johnson ( JNJ), Regeneron Pharmaceuticals ( REGN), AstraZeneca and Glaxo. The biggest misses were from Pfizer and Novartis ( NVS).

Biopharmas Top Earnings Views

Every one of the 17 biopharmas topped adjusted profit views. AbbVie, Alexion, Regeneron and Bristol were the fastest growers, rising a respective 52%, 40%, 47%, 45% and 43%, Porges said. Gilead and AstraZeneca were also the worst performers in this metric, dipping 19% and 37%, respectively.

On average, the 17 biopharmas beat analyst views by 8.4%. Relative to Porges' expectations, they topped by 6.4%.

The biggest adjusted earnings beats came from Alexion, Bristol, Gilead and Regeneron.

On the stock market today, Pfizer stock advanced 0.7%, to 43.51. Biotech stocks rose about 2% and pharma stocks climbed more than 1%.

YOU MIGHT ALSO LIKE:

Still The No. 1 Rule For Stock Market Investors: Always Cut Your Losses Short

Long-Term Retirement Investment Strategies With ETFs

How Much Money Do You Need To Start Investing In Stocks?

The post Trump's Biopharma Impasse Led To A Slowdown — Now Pfizer Is Fighting Back appeared first on Investor's Business Daily.


8. Google Cloud-Computing Unit Gets New Boss, A Former Oracle ExecutiveСб., 17 нояб.[−]

Alphabet ( GOOGL) on Friday said it's replacing the head of its Google cloud-computing business, Diane Greene, with former Oracle ( ORCL) executive Thomas Kurian.

X

Google said Kurian is joining the unit on Nov. 26. He will take over the leadership role in early 2019. Greene will remain chief executive of the business until then.

Kurian spent more than two decades at Oracle, rising to the level of president of product development.

Diane Bryant, a former Intel ( INTC) executive, in June resigned as the chief operating officer of Google's cloud-computing business. Bryant left after serving seven months as COO.

Greene joined Google's cloud-computing unit in late 2015. Greene previously co-founded and ran VMware ( VMW).

The Google cloud-computing business ranks third in the industry. The Amazon Web Services unit of Amazon.com ( AMZN) leads the infrastructure-as-a-service (or IaaS) market, followed by Microsoft ( MSFT).

To date, many of Google's cloud customers have been technology firms, such as social media firm Snap ( SNAP), Spotify, Evernote and Zulily. Under Greene, Google aimed to woo enterprise customers with cloud-based data-analytics and artificial-intelligence tools.

Google stock dipped 0.3% to 1,068.27 on the stock market today. Google stock is up 3% from a year ago.

YOU MAY ALSO LIKE:

Cloud Computing Spurs Business Communication Bonanza, Lifts RingCentral, Slack

Cloud Computing: Find Top Cloud Stocks And Track Industry Trends

Improve Your Investing Results With This Simple 3-Step Routine

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Google Cloud-Computing Unit Gets New Boss, A Former Oracle Executive appeared first on Investor's Business Daily.


9. Facebook (FB) Stock Quotes, Company News And Chart AnalysisПт., 16 нояб.[−]
X


FB Stock Quote
| FB Ratings

Facebook Stock News & Analysis

Facebook Stock Hits 21-Month Low After New York Times Article BlowupFacebook stock fell to a 21-month low Friday, following an explosive New York Times article this week that raised questions about how the social media behemoth handled the spread of disinformation and... Read More
Big-Screen TVs, Smart Speakers Are Hot Gadgets This Holiday SeasonHoliday shoppers plan to load up on consumer electronics this year, with big-screen TVs among the most sought-after items. "People want the biggest and best TV they can have in their living... Read More
Dow Jones Futures Rebound After Apple-Led Stock Market Sell-Off; What To Do NowDow Jones futures rose strongly early Tuesday, along with S&P 500 futures and Nasdaq futures. Apple sold off 5% in the stock market Monday, leading a big sell-off that raised more concerns... Read More
Tech Stocks Lead Stock Market Rally As Facebook Suspends More AccountsThe stock market opened slightly higher Tuesday, with technology stocks taking the early lead, as Wall Street pondered another avalanche of earnings reports. In FAANG stock news, shares of Facebook added 0.7%... Read More
Amazon Offering Free Shipping Without Minimum Purchase Over HolidaysAmazon.com on Monday said it's offering free shipping with no purchase minimum for the first time this holiday season. The move is expected to put pressure on Walmart and Target over competition... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

More Technology Stocks Coverage

FANG Stocks News: Facebook, Amazon, Netflix, Google

Apple (AAPL) Stock Quotes And Company News

Tesla (TSLA) Stock Quotes And Company News

View More Tech Stocks

The post Facebook (FB) Stock Quotes, Company News And Chart Analysis appeared first on Investor's Business Daily.


10. FANG Stocks News & Quotes: Facebook, Amazon, Netflix, GoogleПт., 16 нояб.[−]

Collectively known as the FANG stocks, Facebook ( FB), Amazon.com ( AMZN), Netflix ( NFLX) and Google parent Alphabet ( GOOGL) are among the tech titans of our time.

X

Facebook and Google alone capture the lion's share of all global online advertising, including in the fast-growing mobile format, while Amazon dominates e-commerce and cloud services with its Amazon Web Services business.

And although Netflix is facing increasing competition from Hulu and fellow FANG stocks — particularly Amazon and YouTube owner Google — its original programming and massive global expansion have cemented its leadership in the streaming industry.

Check this page regularly for ongoing coverage of the FANG stocks, including potential buy and sell signals.

FANG Stocks News & Quotes

Sonos Upbeat Earnings Report Is Music To Wall Street's EarsPremium sound system maker Sonos got toes tapping with the upbeat tempo of its September-quarter earnings report. Sonos stock jumped Friday on the news. The Santa Barbara, Calif.-based company late Thursday said... Read More
Facebook Stock Hits 21-Month Low After New York Times Article BlowupFacebook stock fell to a 21-month low Friday, following an explosive New York Times article this week that raised questions about how the social media behemoth handled the spread of disinformation and... Read More
Google Cloud-Computing Unit Gets New Boss, A Former Oracle ExecutiveAlphabet on Friday said it's replacing the head of its Google cloud-computing business, Diane Greene, with former Oracle executive Thomas Kurian. Google said Kurian is joining the unit on Nov. 26. He will... Read More
Big-Screen TVs, Smart Speakers Are Hot Gadgets This Holiday SeasonHoliday shoppers plan to load up on consumer electronics this year, with big-screen TVs among the most sought-after items. "People want the biggest and best TV they can have in their living... Read More
Stocks Fall, Fear Up, Natgas Skyrockets; 3 Reasons Why Apple Needs A BreakApple falls for a fifth session in a row, losing 11% of its market value in the process. Major indexes careen from the upside to the downside early, then up and down... Read More
Amazon Headquarters: $5 Billion And 50,000 Jobs For Two HubsAmazon.com will invest $5 billion and create more than 50,000 jobs across two new Amazon headquarters it's planning for New York City and the Washington, D.C., suburb of Arlington, Va., the company... Read More
Stocks Today: Nvidia Leads Technology Rally; Caterpillar Boosts DowThe Nasdaq composite held a modest gain in afternoon trading Tuesday, up 0.3%, after Monday's drubbing that saw the index plunge 2.8%. Stocks today on the move were plentiful. Intel outperformed in... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

RELATED:

Apple Stock Quotes & News

Tesla Stock Quotes & News

More Tech Stock News

Best Stocks To Buy And Watch

The post FANG Stocks News & Quotes: Facebook, Amazon, Netflix, Google appeared first on Investor's Business Daily.


11. Sonos Stock Jumps On Better-Than-Expected Speaker SalesПт., 16 нояб.[−]

Sound system maker Sonos ( SONO) late Thursday beat Wall Street's estimates for its fiscal fourth quarter ended Sept. 29, cheering investors. Sonos stock popped higher in extended trading.

X

The Santa Barbara, Calif.-based company lost 2 cents a share on sales of $272.9 million in the quarter. Analysts polled by Zacks Investment Research expected the Sonos earnings report to show a loss of 8 cents a share on sales of $249 million.

Sonos stock jumped 19% in after-hours trading on the stock market today. During the regular session, Sonos rose 1.7% to 14.16.

For the December quarter, Sonos guided to sales of $490 million, vs. the Zacks estimate of $470 million.

For its fiscal 2019, which ends Sept. 28, the company expects sales of $1.26 billion, based on the midpoint of its guidance. Wall Street was modeling $1.21 billion.

Sonos Beam Boosts September-Quarter Sales

Chief Executive Patrick Spence said it was a "record-breaking quarter" for Sonos earnings. Sales rose 27% year over year, and net income was near break-even.

"One of the drivers of our strong Q4 performance was Sonos Beam," he said in a letter to investors. "The only smart speaker designed specifically for the living room, Beam is a soundbar, voice-enabled smart speaker and music speaker rolled into a well-designed and immersive sound package."

Beam sales exceeded the company's forecast. It captured the No. 1 position in U.S. soundbar sales in dollar sales, with 8% market share, Spence said. Sonos launched the product in mid-July. The device also sold well in Europe, he said.

"With Sonos in over 7.4 million homes today, we are off to a great start," Spence said. "But we believe we are just scratching the surface considering that approximately 200 million subscribers are paying for streaming music, a number that is expected to grow to 333 million over the next three years," he said.

RELATED:

Big-Screen TVs, Smart Speakers Are Hot Gadgets This Holiday Season

Speaker Maker Sonos Takes A Dive After Muted Quarterly Results

The post Sonos Stock Jumps On Better-Than-Expected Speaker Sales appeared first on Investor's Business Daily.


12. Nvidia Stock Falls On Sales Miss, Weak Guidance, Excess InventoryПт., 16 нояб.[−]

Graphics-chip maker Nvidia ( NVDA) late Thursday missed Wall Street's sales target for its fiscal third quarter and guided below analyst views for the current period. Nvidia stock fell hard in extended trading.

X

Nvidia earnings rose 38% year over year to an adjusted $1.84 a share in its third quarter ended Oct. 28. Sales increased 21% to $3.18 billion. Analysts polled by Thomson Reuters expected Nvidia to earn $1.71 a share on sales of $3.24 billion.

For the January quarter, Nvidia expects sales of $2.7 billion, down 7% from $2.91 billion in the year-earlier period. It did not give a specific target for earnings per share. Wall Street forecast Nvidia to earn $1.81 a share, up just 2%, on sales of $3.4 billion, up 17%.

Nvidia stock tumbled 16.8% in after-hours trading on the stock market today. During the regular session, it rose 2.6% to 202.39.

Nvidia Warns Of Excess Inventory

"Our near-term results reflect excess channel inventory post the cryptocurrency boom, which will be corrected," Chief Executive Jensen Huang said in a news release.

He added, "Our market position and growth opportunities are stronger than ever."

Nvidia's data-center business is strong as customers use its graphics processors for artificial intelligence applications, Huang said.

The company's professional visualization and automotive platform businesses also are doing well, Chief Financial Officer Colette Kress said in a written statement.

However, Nvidia's gaming chip revenue fell short of expectations and was impacted by the excess inventory, she said. The inventory situation will take one to two quarters to resolve, Kress said.

RELATED:

After Hours: These 4 Bad Earnings Reports Hit Two Key Sectors

Nvidia, Xilinx Stocks Upgraded To Buy On Artificial Intelligence

Chip Stocks Seeing Red After Skyworks Misses On Guidance

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

The post Nvidia Stock Falls On Sales Miss, Weak Guidance, Excess Inventory appeared first on Investor's Business Daily.


13. Applied Materials Stock Drops On Soft Sales GuidanceПт., 16 нояб.[−]

Chip-gear maker Applied Materials ( AMAT) late Thursday met Wall Street's estimates for its fiscal fourth quarter, but guided well short of views for the current period. Applied Materials stock fell in extended trading.

X

Santa Clara, Calif.-based Applied Materials' earnings were an adjusted 97 cents a share. That was on sales of $4.01 billion for the quarter ended Oct. 28. On a year-over-year basis, earnings per share rose 4% while sales climbed 1%.

For the current quarter, Applied Materials earnings should reach 79 cents a share on sales of $3.71 billion, the company says. That's based on the midpoint of its guidance.

Wall Street predicted the semiconductor-equipment firm would earn 92 cents a share on sales of $3.94 billion. In the year-earlier period, Applied Materials earnings were $1.06 a share on sales of $4.2 billion.

CEO Points To 'Near-Term Market Headwinds'

Applied Materials stock sank 9% in after-hours trading on the stock market today. During the regular session, it rose 4.3% to 35.02.

"In fiscal 2018, each of Applied's major businesses delivered double-digit growth despite challenging conditions in the second half of the year," Chief Executive Gary Dickerson said in a news release.

He added, "While near-term market headwinds remain, overall industry spending remains robust, and we are focused on positioning Applied Materials for the long term, expanding our role in the A.I.-Big Data era and winning the major technology inflections ahead."

YOU MIGHT ALSO LIKE:

After Hours: These Are 4 Big Movers On Earnings

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Applied Materials Stock Drops On Soft Sales Guidance appeared first on Investor's Business Daily.


14. This Biotech Just Rocketed 35% On Its Pfizer-Rivaling Gene TherapyПт., 16 нояб.[−]

Uniqure ( QURE) stands a chance of rivaling Pfizer ( PFE) and Spark Therapeutics ( ONCE) in hemophilia B treatment, two analysts said Thursday after its gene therapy results sent Uniqure stock flying.

X

On the stock market today, Uniqure stock rocketed 35.7%, to 30.93, after spiking as much as 53.5%. At the same time, Spark stock toppled 4.4%, to 39, and Pfizer stock lifted a fraction, to 43.21. Biotech stocks collectively rose around 2%.

The study tested Uniqure's gene therapy, known as AMT-061, in patients with hemophilia B. Hemophilia B is caused by lacking Factor IX, a blood-clotting protein. Without enough Factor IX, a patient's blood doesn't clot properly, leading to extensive bleeding.

Six weeks after receiving Uniqure's gene therapy, all three patients in the study showed a sustainable level of Factor IX. On average, patients had Factor IX levels at 31%, which is considered mild hemophilia. Normal levels are 50%-150%.

"We believe today's data elevates AMT-061 as a noteworthy competitor to (Spark's) SPK-9001, the latter of which has commenced a Phase 3 trial under Pfizer," Leerink analyst Joseph Schwartz said in a note to clients.

Pre-existing Immunity To Gene Therapy

In Uniqure's study, the first patient reached Factor IX levels of 37% at 10 weeks post gene therapy. The second patient reached 23% at week eight, and the third patient was at 30% at six weeks after treatment.

"We remind investors that at 12 weeks, SPK-9001 also showed Factor IX levels in the mid-to-high 30% range with a larger sample size," Schwartz said. "Assuming similar kinetics, we would anticipate AMT-061-treated patients to reach similar levels by week 12."

None of the patients required Factor IX transfusions, experienced any bleeding episodes or required immunosuppressive medicine over a combined 24 weeks of observation, Uniqure said in a news release.

The latter point is particularly important to gene therapy studies. Researchers create gene therapies using viruses that are empty of harmful attributes. Then, they use these viruses to insert genetic material at specific sites on the chromosome.

If patients have already been exposed to the virus, their bodies will protect against it. In those cases, physicians may add an immune system-suppressing medicine. Two of the patients in Uniqure's study couldn't participate in other tests due to pre-existing immunities.

But in Uniqure's gene therapy test, "there were no (immune system)-cell responses and no immunosuppression was needed over a combined 24 weeks of observation," Chardan analyst Gbola Amusa said in a note. "This is in contrast to Pfizer's results."

Analysts Bullish On Hemophilia B Treatment

In fact, across four study sites, Uniqure found no patients with pre-existing immunities to its gene therapy, Leerink's Schwartz said in a report.

"Going forward, enrollees are not excluding on the basis of pre-existing antibodies," he said.

Schwartz increased his expectations for Uniqure's success to 75% vs. 60% previously. That is in line with his view on Spark and Pfizer's hemophilia B treatment. He raised his price target on Uniqure stock to 76 from 61. He has an outperform rating on Uniqure stock.

Chardan's Amusa reiterated his 70 price target and buy rating on Uniqure stock. He notes BioMarin Pharmaceutical ( BMRN) is leading the pack in using a gene therapy in hemophilia B treatment. He says it's likely that BioMarin will attempt to buy Uniqure.

"We think, based on these data, the odds of Uniqure being acquired are now materially increased," he said.

YOU MIGHT ALSO LIKE:

How To Trade: Should You Buy A Stock Ahead Of Its Earnings Report?

How To Tame A Volatile Swing Trade With A Half Position

Making Money In Stocks: How To Find The Correct Buy Point

The post This Biotech Just Rocketed 35% On Its Pfizer-Rivaling Gene Therapy appeared first on Investor's Business Daily.


15. Biotech Flies On What CEO Calls A 'Transformative' Deal For 2 PlayersПт., 16 нояб.[−]

Arena Pharmaceuticals ( ARNA) rocketed in bullish fashion Thursday on what Chief Executive Amit Munshi calls a "transformative" licensing deal for it and United Therapeutics ( UTHR).

X

Under terms of the deal, United will receive an exclusive, worldwide license to ralinepag, a potential treatment for pulmonary arterial hypertension. The disease is a form of high blood pressure in the lungs that commonly affects young women.

The agreement puts ralinepag in the hands of an expert in pulmonary arterial hypertension, Munshi said. United has a handful of drugs approved to treat the disease. Further, it allows Arena to focus more closely on two experimental inflammatory bowel disease treatments.

"It gives us a balance sheet that gives us a lot of flexibility so we don't have to go back to the markets to raise capital," he told Investor's Business Daily in an interview. "It allows us to execute broadly on our two compounds."

On the stock market today, Arena stock jumped 21.6%, to 39.55, after soaring as much as 30.6%, in huge volume. United stock popped 4.8% higher, to 116.31. Broadly, biotech stocks advanced around 2%.

'A Devastating Disease'

Significant progress has been made in treating pulmonary arterial hypertension. United has spent two decades working in the disease and a number of approved treatments. But there's still a big, unmet need, Munshi said.

"It's still a devastating disease," he said. "We don't know what causes most forms of the disease."

Patients will often exhibit symptoms like those in asthma, chronic obstructive pulmonary disease and heart failure. The average 29-year-old woman diagnosed with the disease won't make it to age 40, even with current medications, according to Arena.

Blood flow to the heart becomes restricted, causing pressure in the arteries and forcing the heart to work harder. As a result, many pulmonary arterial hypertension patients die of heart failure, Munshi said.

The life expectancy in pulmonary arterial hypertension is worse than that of some cancers, Munshi added. His hope is that ralinepag can "make a world of difference."

Up To $400 Million In Milestone Payments

Arena has already initiated Phase 3 efforts for ralinepag. The agreement grants United the right to develop, manufacture and commercialize ralinepag worldwide. In return, Arena will receive $800 million up front and up to $400 million in potential milestone payments.

Further, Arena will receive low, double-digit tiered royalties on annual net sales of the drug, if approved. It also gives Arena the flexibility to focus deeper on drugs called etrasimod and olorinab, Munshi said. As a small biotech, Arena has to be "judicious" with its resources.

Etrasimod has completed Phase 2 testing in ulcerative colitis. Arena is also looking at it in Crohn's disease, primary biliary cholangitis and eczema. Olorinab has shown promise in treating pain associated with inflammatory bowel disorder.

Like ralinepag, he says these two drugs could serve a huge unmet medical need. Only about a quarter of patients enter remission, even with the best therapies. Eventually, the disease breaks back through and patients must cycle onto the next drug.

Rivaling Others In Ulcerative Colitis

Munshi expects etrasimod to easily take on other ulcerative colitis treatments from Celgene ( CELG), Gilead Sciences ( GILD), AbbVie ( ABBV) and Eli Lilly ( LLY).

The latter three are working on drugs that belong to a class called JAK inhibitors. But these drugs have shown some safety issues, Munshi said. Etrasimod appears to have a faster onset and offset of action than its competitors.

"We were able to demonstrate in Phase 2 that a third of patients (who took etrasimod) were in remission at 12 weeks," he said. "That's unprecedented for an oral agent."

YOU MIGHT ALSO LIKE:

Chart Reading For Beginners: 3 Telltale Clues To Look For In Your Stocks

How Many Shares Do You Buy For A Position? This Tool Does The Math

How To Build Long-Term Profits In Stocks? Take Many Gains At 20%-25%

The post Biotech Flies On What CEO Calls A 'Transformative' Deal For 2 Players appeared first on Investor's Business Daily.


16. PayPal Stock Rated A Top Investing Pick Among Fintech CompaniesПт., 16 нояб.[−]

PayPal Holdings ( PYPL) can deliver 20%-plus annual revenue growth mostly from digital payment channels, says Barclays. It ranked PayPal stock as a top pick while initiating coverage of 20 fintech companies.

X

"We believe PayPal deserves a premium given the scarcity value of a $100 billion-plus market-cap company that can grow normalized organic revenue at a 20% clip," said Ramsey El-Assal, a Barclays analyst, in a report published on Wednesday.

"In addition, the company's revenues come from tech-enabled digital channels, often in global markets where the secular trend favoring electronic payments has the most momentum," he added.

EBay spun-off PayPal in 2015. PayPal has evolved from an online payment button to a broad service provider. It has expanded from online checkout to mobile payments and person-to-person money transfers.

PayPal stock climbed 3.2% to close at 86.74 on the stock market today. Shares in the digital payment processor are up about 18% from a year ago.

PayPal Stock Consolidating

PayPal stock has been consolidating. It now trades near its 50-day-moving-average with a technical buy point of 93.80.

Barclay's El-Assal also favors WorldPay among 20 fintech companies. The payment-processing industry spans e-commerce, business-to-business payments, capital markets, cloud finance software, and online and mobile technology.

Vantive acquired U.K. payments processor WorldPay in 2017 for $10.4 billion and renamed itself WorldPay. The company specializes in business-to-business payment processing.

"Worldpay is well-positioned for the continued global mix shift to tech-enabled, software-centric payment channels," said the Barclays analyst.

YOU MAY ALSO LIKE:

Cloud Computing Spurs Business Communication Bonanza, Lifts RingCentral, Slack

Cloud Computing: Find Top Cloud Stocks And Track Industry Trends

Improve Your Investing Results With This Simple 3-Step Routine

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post PayPal Stock Rated A Top Investing Pick Among Fintech Companies appeared first on Investor's Business Daily.


17. Apple Stock Treated Like Hardware Play Despite Services PushПт., 16 нояб.[−]

Despite Apple's ( AAPL) efforts to get investors to think of it more as a services company, the stock market is still treating it as a smartphone maker. That thinking has pounded Apple stock the past two weeks amid reports of slowing iPhone demand.

X

Since it gave disappointing guidance on Nov. 1, Apple stock has fallen 13.9% through Thursday's close. Apple stock on Wednesday dropped below its 200-day moving average line, a key technical support level. It attempted to retake that level on Thursday. Apple stock climbed 2.5% to close at 191.41 on the stock market today.

Austria's AMS, which makes facial recognition technology, late Wednesday became the latest Apple supplier to cut its revenue forecast. In the past week, other iPhone component suppliers have lowered their sales forecasts including Japan Display, Lumentum Holdings ( LITE), Skyworks Solutions ( SWKS) and Qorvo ( QRVO).

Morgan Stanley analyst Katy Huberty said the recent decline in Apple stock has created a buying opportunity. On Thursday, she reiterated her overweight rating on the stock with a price target of 253.

Investors Still Focused On iPhone Unit Sales

In a note to clients, Huberty said investors have overreacted to reports of slowing iPhone production from Apple's supply chain partners.

"Investors remain narrowly focused on units, despite the increasing value of Apple Services," she said. Apple's growing services business is tied to its installed base of hardware rather than new shipments, she said.

Apple's services revenue growth accelerated to 26% year over year in fiscal 2018, despite iPhone unit sales falling 6% in the two years leading up to fiscal 2018, which ended Sept. 29, she said.

"While investors generally support our services thesis, news flow around units is creating volatility and a buying opportunity while the investor base is still in the process of transitioning away from units," she said.

Apple's services include the App Store, Apple Music, Apple Pay, AppleCare, iCloud and other offerings.

RELATED:

Warren Buffett's Berkshire Hathaway Just Bought, Sold These Shares

Apple Stock Downgraded On Slowing iPhone Demand

Apple iPhone Sales Estimates Cut On Negative Supplier Reports

The post Apple Stock Treated Like Hardware Play Despite Services Push appeared first on Investor's Business Daily.


18. Big-Screen TVs, Smart Speakers Are Hot Gadgets This Holiday SeasonЧт., 15 нояб.[−]

Holiday shoppers plan to load up on consumer electronics this year, with big-screen TVs among the most sought-after items.

X

"People want the biggest and best TV they can have in their living room," said Stephen Baker, an analyst with the NPD Group. And retailers are promoting 4K ultra-high-definition big-screen TVs at "aggressive price points" ahead of Black Friday, he said.

For instance, Walmart ( WMT) plans to offer 65-inch 4K Roku ( ROKU) smart TVs from Sharp and TCL for $398, 20% off the regular price, on Black Friday.

The sweet spot for television screen sizes this holiday season is 55 inches, said Ben Arnold, senior director of innovation and trends for the Consumer Technology Association. Most TVs of that size and larger are 4K models.

"We've had 4K TVs for several holiday cycles now, but what's beginning to come together is the content ecosystem," Arnold said. More video services such as Netflix ( NFLX) and Amazon.com ( AMZN) are offering 4K programming, he said.

Record Spending On Consumer Electronics Forecast

The Consumer Technology Association predicts that spending on technology products in the U.S. will reach a record $96.1 billion during the holiday sales quarter. That would be up 3.4% from last year's period.

The Christmas buying season kicks off next weekend with Thanksgiving and Black Friday doorbuster sales. Steeply discounted consumer electronics, as usual, will be bait to lure shoppers into stores, both physical and online.

A survey by the Consumer Technology Association found that televisions and smartphones are the top tech products that shoppers intend to buy in the opening weekend of the holiday season. Other top items include portable Bluetooth speakers, video game consoles, laptop computers, streaming video devices and smartwatches.

The trade group says 85% of U.S. shoppers plan to buy tech devices during Black Friday weekend, which runs from Thanksgiving through the following Monday, known as Cyber Monday.

Smart Speakers, Smartwatches, Wireless Earbuds Fast Growers

Among newer categories of tech products, the fastest-growing gadgets include smart speakers, smartwatches and wireless earbuds, CTA reported.

U.S. sales of smart speakers, such as Amazon's Echo devices and Alphabet's ( GOOGL) Google Home, are projected to hit 22 million units this holiday season. That would be a 44% increase over last year's holiday season.

"Both Amazon and Google have a vested interest in driving the installed base larger and larger," Baker said. They want to become the go-to platform for controlling the smart home.

Amazon will be selling entry-level smart speakers for as cheap as $19.99, half off the regular price, during the Black Friday sales period. This year will see more smart speakers with displays, such as the Amazon Echo Show, Google Home Hub and Facebook ( FB) Portal, Arnold said.

The rise of smart speakers is fueling sales of other smart home devices, including security cameras and video doorbells. That's partly because devices like smart thermostats, lighting and door locks can be controlled with voice commands through smart speakers.

"Smart home is a category that's on the cusp of really getting big," Baker said.

Smartwatches, led by Apple's ( AAPL) Apple Watch, are forecast to sell more than 7 million units this holiday season, CTA said. That would be a 26% rise from a year ago. Wireless earbuds, such as Apple's Air Pods, are anticipated to sell 5.3 million units, up 60%, CTA said.

U.S. Teens Crave Apple Products As Gifts

Apple products claimed the top four spots for most-desired gifts this holiday season among U.S. teens, according to a survey by Piper Jaffray.

The investment bank asked teens to name the top items on their wish lists in an unaided, open response format.

The iPhone was No. 1 with 4.5% of responses. It was No. 1 last year too, but with 6.3% of responses.

Apple Watch came in second at 2.6% of responses. It was third last year.

MacBook is third this year, followed by AirPods wireless earbuds. The only other tech product in the top 10 was video game "NBA 2K19" from Take-Two Interactive Software ( TTWO) in a tie for ninth place.

RELATED:

Apple Stock Downgraded On Slowing iPhone Demand

Activision Is Latest Game Publisher To Not Feel The Holiday Spirit

Roku Stock Dives As Streaming Video Platform Disappoints On Growth

The post Big-Screen TVs, Smart Speakers Are Hot Gadgets This Holiday Season appeared first on Investor's Business Daily.


19. Cisco Stock Climbs As Earnings Top Expectations; Guidance In LineЧт., 15 нояб.[−]

Cisco Systems ( CSCO) late Wednesday reported first-quarter profit that topped views as revenue rose for the fourth straight quarter. Cisco stock climbed on the news.

X

Earnings for the fiscal first-quarter were an adjusted 75 cents a share, up 23% from a year ago. Revenue rose 8% to $13.1 billion, ahead of forecasts. A year earlier, Cisco earnings were 61 cents a share on sales of $12.14 billion.

Analysts expected Cisco earnings of 72 cents on sales of $12.87 billion for the period ended Oct. 31.

For the fiscal second quarter, Cisco forecast earnings of 72 cents a share, in line with estimates. The company said it expects revenue of $12.86 billion at its midpoint of guidance. The maker of computer networking gear and security software topped estimates of $12.53 billion.

Cisco stock climbed more than 3%, near 45.75, during after-hours trading on the stock market today.

Cisco stock fell 1.7% in Wednesday's regular session. Shares have gained 30% from a year ago.

The company is shifting away from its core business of selling network switches and routers. With acquisitions, Cisco aims to increase revenue from software and services.

Analysts expected computer security services and sales of new Catalyst 9000 network switches to be bright spots for the fiscal first quarter. Lower corporate taxes boosted Cisco's fiscal Q1 profit. It's also driving higher customer spending on IT budgets.

YOU MAY ALSO LIKE:

Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The Edge

Cloud Computing: Find Top Cloud Stocks And Track Industry Trends

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Cisco Stock Climbs As Earnings Top Expectations; Guidance In Line appeared first on Investor's Business Daily.


20. Smart Home Firm Resideo Technologies Pops On Earnings ReportЧт., 15 нояб.[−]

Smart home technology provider Resideo Technologies ( REZI) saw its stock rise Wednesday following its first quarterly earnings report as an independent company.

X

Resideo, a spinoff of Honeywell ( HON), late Tuesday reported better-than-expected sales for the September quarter and guided higher for the full year.

Resideo Technologies stock rose 1.1% to 21.49 on the stock market today. In intraday trading, it climbed as high as 22.95. Resideo began trading on Oct. 29 at 28 and hit a low point of 19.31 two days later.

The Austin, Texas-based company posted third-quarter sales of $1.2 billion, up 4% year over year. That edged Wall Street's estimate of $1.19 billion, according to Zacks Investment Research. It earned $2.53 a share in the period.

Resideo Technologies Reaffirms Full-Year Guidance

Resideo Technologies expects full-year sales at the high end of its previous guidance range of $4.77 billion to $4.83 billion. It also reaffirmed its 2019 outlook of 4% organic revenue growth.

"Resideo had a solid third quarter as part of Honeywell, preceding a successfully executed spinoff," Chief Executive Mike Nefkens said in a news release. "Our performance as part of Honeywell over the past three years demonstrates a well-run business that is on-track to deliver continued growth in 2018 and beyond."

The company makes comfort and security systems for primarily residential environments. Its products include thermostats, humidifiers, security systems and other devices.

Oppenheimer analyst Ian Zaffino reiterated his outperform rating on Resideo stock with a price target of 35.

Resideo Technologies is benefiting more from repair and remodel business than new housing, Zaffino said.

"Overall, an in-line quarter with a favorable outlook for the core business," he said. "The company has made key customer wins and should continue to tap into alternative market channels, including utility providers."

RELATED:

Resideo Technologies Completes Spinoff From Honeywell

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Smart Home Firm Resideo Technologies Pops On Earnings Report appeared first on Investor's Business Daily.


21. Tencent Stock Rises As Profit Tops Views, Advertising Revenue JumpsЧт., 15 нояб.[−]

Tencent Holdings ( TCEHY) said Wednesday that adjusted third-quarter earnings were 2.06 yuan a share, up 15% from a year ago, edging past analyst estimates. Tencent stock climbed more than 4% on Wednesday, though it's still down 25% from a year ago.

X

Advertising sales growth offset a slowdown in gaming as the company reported in-line revenue. The Chinese messaging and gaming giant, which owns the super-app WeChat, said revenue climbed 24% to 80.6 billion yuan, meeting expectations. Total advertising revenue jumped 47% to 16.2 billion yuan.

A year earlier, Tencent earnings came in at 1.79 yuan a share on sales of 65.2 billion yuan.

Tencent Investment Gain

Analysts expected Tencent earnings of an adjusted 2.04 yuan on sales of 80.6 billion yuan for the period ended Sept. 30, according to Reuters.

The company reported an 8.8 billion yuan investment gain from the initial public offering of Meituan Dianping in September. Meituan is a food delivery and local services giant.

Tencent stock is listed in Hong Kong and trades over the counter in the U.S. The stock ended Wednesday's regular session 4.3% higher to 36.60 on the stock market today.

Chinese internet giants such as Tencent archrival Alibaba ( BABA) are struggling with slowing online sales growth and a cooling Chinese economy. Chinese regulators also have clamped down on the licensing of new video games.

YOU MAY ALSO BE INTERESTED IN:

Best Chinese Stocks To Buy And Watch

Singles Day Sales Top $31 Billion, Reflect Macroeconomic Headwinds

Cloud Computing: Find Top Cloud Stocks And Track Industry Trends

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Tencent Stock Rises As Profit Tops Views, Advertising Revenue Jumps appeared first on Investor's Business Daily.


22. Apple Stock Downgraded On Slowing iPhone DemandЧт., 15 нояб.[−]

A Wall Street analyst threw in the towel on Apple stock on Wednesday, saying increased average selling prices won't be enough to offset slowing iPhone demand.

X

Guggenheim Securities analyst Robert Cihra lowered his rating on Apple ( AAPL) to neutral from buy. He also removed his prior price target of 245 on the stock.

"Over the past 10 years, Apple's iPhone ASP has increased a dramatic +$220, or 40%, reflecting its growing value to both consumer and business markets, but nearly half of all that just came in fiscal 2018 alone, making a period of digestion now likely," he said in a report to clients. The average selling price for the iPhone was $793 in its fiscal fourth quarter ended Sept. 29.

Apple stock dropped 2.8% to 186.80 on the stock market today. It fell below its 200-day moving average line, a key technical support level. Since it gave disappointing guidance on Nov. 1, Apple stock has fallen 15.9% through Wednesday's close.

Apple Stock: Downside Risk For iPhone Demand In Emerging Markets

Cihra now estimates that iPhone unit sales will fall 5% year over year in Apple's current fiscal 2019. That compares with flat unit sales growth in fiscal 2018, he said.

But unlike last year, he does not see average selling prices boosting total iPhone revenue. He is forecasting blended iPhone selling prices increasing just 3%, leaving iPhone revenue down 2% year over year.

"Moreover, we see growing risk of even softer iPhone unit demand, with downside in China, India and other emerging markets, where Apple may need to start considering lower price points," Cihra said.

"With (smartphone) replacement cycles having already elongated from 2 years to 3 years, we think it may not be until 5G launches that the next genuine upgrade cycle can start again, but with that not likely until calendar 2020," he said.

Also Wednesday, UBS analyst Tim Arcuri cut his 12-month price target on Apple stock to 225 from 240. He maintained his buy rating on the stock.

He also lowered his iPhone unit sales forecast for the current quarter to 73.5 million from 75 million based on guidance cuts by Apple suppliers like Lumentum Holdings ( LITE).

RELATED:

Apple iPhone Sales Estimates Cut On Negative Supplier Reports

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Apple Stock Downgraded On Slowing iPhone Demand appeared first on Investor's Business Daily.


23. Migraine-Focused Biotech Has A Headache On Quarterly LossesЧт., 15 нояб.[−]

Biohaven Pharmaceutical ( BHVN) plunged Wednesday after the biotech reported greater-than-expected losses for its third quarter.

X

On the stock market today, Biohaven stock toppled 8.7%, to 33.68. However, Biohaven stock remained within the bounds of a consolidation and a buy point at 44.38. Shares received support at Biohaven's 200-day moving average.

During the third quarter, adjusted losses widened to $1.53 per share from $1.19 per share in the year-earlier period. Leerink analyst Marc Goodman had called for losses of $1.24 per share. The consensus polled by FactSet had modeled adjusted losses of $1.07 a share.

Biohaven Stock: Migraine Treatment Grabs Attention

Still, Goodman initiated coverage of Biohaven stock with an outperform rating and a 50 price target. Biohaven is a clinical-stage biotech, meaning it doesn't yet have any sales. It targets neurological and neuropsychiatric diseases.

Biohaven is testing a late-stage migraine treatment called rimegepant. It belongs to a class of drugs that target a receptor called CGRP. Biohaven is studying the drug in five clinical tests in migraine treatment and prevention.

The latter use could pit Biohaven against Amgen ( AMGN)/Novartis ( NVS), Teva Pharmaceutical ( TEVA) and Eli Lilly ( LLY), all of which gained approval this year for migraine prevention drugs in the same drug class.

"We think the migraine space could be a significant market, that the branded acute migraine space is underappreciated and that Biohaven will monetize the strong clinical profile most likely through a commercial partner or potentially with a 'go it alone' strategy," Goodman said.

Efforts In Alzheimer's disease, Anxiety, Pain

Goodman also noted Biohaven's efforts with an amino acid known as glutamine. Biohaven is investigating its use in amyotrophic lateral sclerosis, or ALS. ALS is a group of rare neurological diseases involving nerve cells necessary for controlling muscle movement.

Biohaven is also examining glutamine drugs in a variety of other conditions, including Alzheimer's disease, anxiety and pain.

"The glutamine platform/pipeline gets minimal attention due to significant investor focus on the CGRP platform, but the company has multiple shots on goal in this area that could be a source of upside," Goodman said.

Further, he noted a recently licensed product for multiple system atrophy has a potential $250 million sales opportunity in 2030. Multiple system atrophy is a rare neurodegenerative disorder in which patients exhibit tremors, slow movement, muscle rigidity or instability.

"Given how recently the deal was completed, the product is not in the conversation yet," he said. Biohaven licensed the drug from AstraZeneca ( AZN) in September.

YOU MIGHT ALSO LIKE:

FANG Stocks News & Quotes: Facebook, Amazon, Netflix, Google

Hold Or Sell Alibaba Stock? It Depends On Your Time Frame

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The post Migraine-Focused Biotech Has A Headache On Quarterly Losses appeared first on Investor's Business Daily.


24. This Potential Blockbuster Drug Is Plateauing — But Analyst Remains BullishЧт., 15 нояб.[−]

Regeneron Pharmaceuticals' ( REGN) eczema treatment Dupixent appears to have hit a speed bump, an analyst said Wednesday.

X

According to an early October survey of dermatologists, the average number of patients per Dupixent prescriber rose just 0.2 to 15.7 from the prior quarter. That follows an earlier survey suggesting that prescribers would add 8.6 new patients quarter over quarter.

This is "the first hint of plateauing atopic dermatitis trends" for Dupixent, Piper Jaffray analyst Christopher Raymond said in a note to clients. "This survey marks the first time that patients/prescribing physicians have been flat quarter over quarter."

On the stock market today, Regeneron stock dipped 1.4%, to 337.29.

Expanding Dupixent Into Asthma Treatment

The data were surprising considering Dupixent's strong quarterly beat. During the third quarter, Regeneron and pharma partner Sanofi ( SNY) reported $262.6 million in revenue from the eczema treatment. That topped expectations for $249 million.

But Raymond remained bullish on Regeneron stock. Prescription trends indicate that strong uptake for Dupixent is continuing. Dermatologists surveyed expect to add an average of 6.5 patients to Dupixent over the next three months.

"We see this feedback as something worth monitoring, but not thesis-changing," he said, noting that Regeneron and Sanofi are working to expand Dupixent's uses.

Recently, Dupixent grabbed approval in the U.S. as an asthma treatment. In March, the Food and Drug Administration will also consider approving Dupixent as an eczema treatment for adolescents. It's currently only allowed in adults.

Raymond calls for Regeneron to bring in $921 million in 2018 sales before becoming a massive blockbuster in 2019 with $2.05 billion in sales. He expects about $3.5 billion and $4.4 billion in 2020-21 sales, respectively.

He also reiterated his overweight rating on Regeneron stock.

Eczema Treatment Trends Otherwise Positive

Other survey points were stronger for Dupixent. It has been on the market since mid-2017. Since then, the discontinuation rate has held strong at 12%. Raymond called that "remarkable," now roughly 20 months into the drug's launch.

The most frequent reasons cited for discontinuing the eczema treatment — after lacking effectiveness — include out-of-pocket expenses and insurance reasons.

Further, rates of Dupixent effectiveness and safety are seemingly improving, he said. Of the 102 dermatologists surveyed, 85% prescribe Dupixent as an eczema treatment. That metric has remained stable over the past several quarters.

"Prescription data trends also remain robust with total prescriptions tracking up 25% and new prescriptions up 31% quarter over quarter for the first five weeks of the fourth quarter," he said.

YOU MIGHT ALSO LIKE:

How To Trade Growth Stocks: Why You Should Buy On The Stock Market Follow-Through Day

Looking For The Next Nvidia? Start With These 3 Steps

Making Money In Stocks: How To Find The Correct Buy Point

The post This Potential Blockbuster Drug Is Plateauing — But Analyst Remains Bullish appeared first on Investor's Business Daily.


25. Shorting A Stock: Short Selling Carries Big Risks, Offers Big ReturnsСр., 14 нояб.[−]

Shorting a stock, also known as short selling, is a distinct trading technique used by investors that can provide big returns when done right but also carries the risk of big losses.

By short selling stocks, investors are positioned to profit if the stock goes down in price. It's the exact opposite of the investing adage of "buy low, sell high." When shorting a stock the plan is to "sell high, buy low." A typical reason an investor will sell a stock short is because they believe the company is overvalued.

The practice is sometimes criticized and periodically faces hostility from company executives, policymakers and the public. But it's perfectly legal. The Securities and Exchange Commission has broad authority to regulate short sales in order to prevent abusive practices. Short selling is common among traders of public securities, futures or currency markets.

Shorting A Stock: What Does It Mean?

The practice of shorting a stock occurs when shares are borrowed from a broker, with an agreement they will be returned later. The stock is then sold. If the stock falls, the short seller can repurchase the shares and return them to the lender. The price spread from where the shares were sold to when they were repurchased is the profit that a short seller can pocket.

That's the reward part. The risky part is that, rather than going down in price, the stock rises. If a stock starts to rise and the upward trend escalates, short sellers can be pressured to get out. That can lead to what's called a short squeeze. As more short sellers cover their position by purchasing the stock, the increased volume can push the stock price higher. That can lead to big losses.

Shorting A Stock: How To Do It

Here's how a successful short sale works. A short seller borrows 100 shares of company XYZ that's selling for $10 a share. The shares are immediately sold for a total of $1,000.

Subsequently, in this example, the stock price falls to $7 per share. The short seller could then buy 100 shares of XYZ for $700 and return them to the lender. The short seller makes a $300 profit, minus associated fees.

A short seller will typically borrow shares from a broker, who is usually holding the securities for another investor that has a large amount of shares. In most cases there is a ready supply of securities to be borrowed, held by pension funds, mutual funds and other investors.

Sometimes shares aren't available to short. That could be because all the shares that are lendable are borrowed and already sold short. Sometimes, brokers choose to not participate in the short-selling practice.

Companies With Large Short Positions

Among companies with the largest short positions on a dollar basis are Tesla ( TSLA), Apple ( AAPL), Amazon.com ( AMZN), Qualcomm ( QCOM) and Starbucks ( SBUX), according to market tracker S3 Partners, as of August 2018.

Short sellers can be a big annoyance for some. Tesla Chief Executive Elon Musk has been very vocal in his extreme dislike for short sellers. He frequently lashes out at the media and analysts when they post negative articles that he believes are false or misleading.

Advocates of short selling are often outspoken, such as Citron Research. They'll pound the table to tell investors why they believe a company is a high-risk investment. And, occasionally, they'll reverse course, as when Citron switched from shorting Tesla stock to going long.

Short-Selling Tips

In a bear market or extended downtrend, short selling can be an effective way to make money. But just like with buying stocks on the long side, you need to know how to manage risk and keep the odds in your favor before you start shorting stocks.

For more information on shorting a stock, check out this Investor's Business Daily topics page on short selling. It includes tips on when to take profits, stock patterns to identify and short-selling rules.

YOU MIGHT ALSO LIKE:

Short Selling: Uncover The Head-And-Shoulders Pattern

A Little Knowledge Can Make A Mess Of Short Selling Stocks

How Do You Prepare For A Fantastic Short Sale?

Before Shorting, Find Clues That Institutions Are Selling With Abandon

The post Shorting A Stock: Short Selling Carries Big Risks, Offers Big Returns appeared first on Investor's Business Daily.


26. This Recent Big Pharma Breakout Spiked Again On A $1.5 Billion DealСр., 14 нояб.[−]

AstraZeneca ( AZN) stock jumped Tuesday after the U.K.-based pharma giant said it would sell the U.S. rights to an infant respiratory drug for $1.5 billion.

X

On the stock market today, AstraZeneca stock advanced 1.4%, to 41.49, after earlier rising as much as 2%. AstraZeneca stock broke out of a flat base last week and is now about 3.1% extended from that entry.

Swedish Orphan Biovirtum AB, or Sobi, will commercialize the drug, Synagis, in the U.S. Synagis aims to prevent serious lower respiratory tract infections in babies. About 130 AstraZeneca employees will transfer to Sobi as part of the deal.

AstraZeneca Chief Executive Pascal Soriot says the company is continuing to "streamline" its portfolio to "allocate resources more effectively."

"While Sobi's focus on Synagis will enable infants in the U.S. to continue benefiting from this important treatment," he said in a written statement.

Cash-And-Stock Deal

Under the terms of the deal, AstraZeneca will receive $1 billion upfront and $500 million in ordinary shares of Sobi stock. The deal grants AstraZeneca about 8% ownership of Sobi. Sobi stock trades outside the U.S.

Sobi will also have a right to AstraZeneca's share of U.S. profits and losses related to a new medicine, called MEDI8897. AstraZeneca is developing MEDI8897 with Sanofi ( SNY) to prevent lower respiratory tract infection in infants and at-risk children.

AstraZeneca will also receive up to $470 million in sales-related payments for Synagis. Further, Sobi will pay AstraZeneca milestones based on MEDI8897 development. The deal is expected to close in early 2019.

YOU MIGHT ALSO LIKE:

How To Trade: Should You Buy A Stock Ahead Of Its Earnings Report?

Making Money In Stocks: How To Find The Correct Buy Point

Breakouts Identify Stocks On The Rise With Big Potential

The post This Recent Big Pharma Breakout Spiked Again On A $1.5 Billion Deal appeared first on Investor's Business Daily.


27. Apple iPhone Sales Estimates Cut On Negative Supplier ReportsСр., 14 нояб.[−]

More Wall Street analysts lowered their iPhone sales estimates on Tuesday following reports of production cuts by Apple's ( AAPL) supply chain partners. Apple stock dipped on the news.

X

Goldman Sachs analyst Rod Hall cut his iPhone sales estimate for Apple's fiscal 2019 by 5.5%. He now expects Apple to sell 202.9 million units in its fiscal year, which started Sept. 30. He previously forecast sales of 214.8 million units.

He also trimmed his 12-month price target on Apple stock to 209 from 222 and reiterated his neutral rating. Apple stock fell 1% to 192.23 on the stock market today.

Hall made the changes after Lumentum Holdings ( LITE) on Monday slashed its fiscal second-quarter revenue and profit guidance because an unnamed customer, believed to be Apple, materially reduced its orders. Lumentum makes 3D sensors that power the facial recognition technology on Apple's latest iPhones. Other iPhone parts suppliers have lowered their estimates as well, including Japan Display and Skyworks Solutions ( SWKS).

Hall reduced his unit sales estimates for the high-end iPhone XS and XS Max and the midrange iPhone XR. But he increased his estimates for older, lower-priced iPhone models.

IPhone Chipmaker Qorvo Cuts Forecast

On Tuesday, iPhone chip supplier Qorvo ( QRVO) cut its December-quarter revenue and profit forecast "due to recent demand changes for flagship smartphones."

The Greensboro, N.C.-based company now expects revenue in its fiscal third quarter of $800 million to $840 million. That's down from its prior target range of $880 million to $900 million. Qorvo gets about 40% of its revenue from Apple business.

"Qorvo's forecast of demand from China-based handset manufacturers remains measured and largely unchanged," the company said in a news release. "Qorvo's current forecast of demand across markets served by Qorvo's Infrastructure and Defense Products segment are tracking within the range of its prior expectations."

Qorvo also lowered its forecast for earnings per share to $1.70 from $1.95 in the December quarter.

Analyst Predicts Decline In iPhone Sales

TF International analyst Ming-Chi Kuo on Monday cut his estimates for iPhone XR shipments significantly, to 70 million from 100 million units, through September 2019, 9to5Mac reported.

Kuo kept his December-quarter iPhone sales forecast of about 80 million units. He believes higher sales of XS handsets and legacy models will offset weakness in XR sales. Apple sold 77.3 million iPhone units in the December quarter last year.

But Kuo believes iPhone unit sales will turn negative in the March quarter. He estimates Apple will ship 47 million to 52 million iPhones in the March quarter, vs. 52.2 million in the year-earlier period.

Apple announced earlier this month that it will no longer report iPhone unit sales.

JPMorgan on Monday lowered its iPhone sales forecasts for this calendar year and the next two years. It cut its iPhone sales forecast by 2 million units for this year to 214 million handsets. It reduced its expectations for 2019 by 10 million units to 208 million and for 2020 by 10 million units to 210 million.

RELATED:

This Is Arguably The Best-Looking Big Tech Stock Right Now: Futures

Apple iPhone XR Inventories 'Bloated,' Production Slowed

Apple Stock Dives On Light Outlook, Move To Hide iPhone Unit Sales

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Apple iPhone Sales Estimates Cut On Negative Supplier Reports appeared first on Investor's Business Daily.


28. Nvidia, Xilinx Stocks Upgraded To Buy On Artificial IntelligenceСр., 14 нояб.[−]

A Wall Street brokerage on Tuesday upgraded chip stocks Nvidia ( NVDA) and Xilinx ( XLNX) to positive from neutral on their prospects in artificial intelligence.

X

Susquehanna Financial Group analyst Christopher Rolland said Nvidia and Xilinx should benefit as the AI inferencing market shifts from central processing units to graphics processors and field-programmable gate arrays. Nvidia is a leader in graphics processors and Xilinx is a specialist in field-programmable gate arrays.

In artificial intelligence, an inferencing system applies logical rules to a knowledge base to deduce new information.

"The market for A.I. inferencing in the data center is relatively small (less than $1 billion today) and is primarily served by Intel ( INTC) Xeon CPUs," Rolland said in a report. "We believe the market for A.I. inferencing will grow to $6.5 billion by 2025. While inferencing is mainly addressed by CPUs today, recent GPU and FPGA platforms appear to be bona fide challengers."

Nvidia Gets Price-Target Cuts Ahead Of Earnings Report

Rolland raised his price target on Xilinx to 95 from 82. Xilinx stock rose 1.5% to 83.56 on the stock market today.

But he cut his price target on Nvidia to 230 from 250 ahead of its fiscal third-quarter earnings report Thursday. The odds are high that Nvidia will miss views with its fourth-quarter guidance, Rolland said.

Nvidia stock jumped 5.2% to 199.31 on Tuesday.

B. Riley FBR analyst Craig Ellis on Tuesday lowered his price target on Nvidia stock to 240 from 250, but kept his buy rating.

Nvidia faces "an unusual number of crosscurrents" that could disrupt its outlook in the second half of its fiscal year, Ellis said. A slowing of high-end European auto manufacturing and the impact of tariffs could hurt Nvidia's prospects, he said.

For the quarter ended Oct. 28, analysts expect Nvidia to earn $1.71 a share on sales of $3.24 billion. If it hits those marks, earnings per share would rise 29% while sales would climb 23%

For the January quarter, Wall Street is modeling Nvidia to earn $1.82 a share on sales of $3.41 billion. That would translate to growth of 2% in earnings per share and 17% in sales.

RELATED:

Chip Stocks Seeing Red After Skyworks Misses On Guidance

Qualcomm Stock Falls On Weak December-Quarter Sales Guidance

AMD Stock Rises As Amazon Web Services Uses Its Epyc Chips

The post Nvidia, Xilinx Stocks Upgraded To Buy On Artificial Intelligence appeared first on Investor's Business Daily.


29. Which Pharmaceutical Stocks Are Outperforming All Other Stocks?Вт., 13 нояб.[−]

Pharmaceutical stocks have rallied 11% this year, outperforming the S&P 500 and the Dow Jones Industrial Average. But the best pharmaceutical stocks to buy have a commonality: Strong Composite Ratings and Relative Strength Ratings.

X

In the first week of November, pharmaceutical stocks reversed from a prior month sell-off to climb 5%. The industry group of 40 pharmaceutical stocks is now ranked No. 18 out of 197 groups Investor's Business Daily tracks, clawing its way up from No. 82 earlier in the year.

But there is an art to buying stocks. So which are the best pharmaceutical stocks to watch now? As of November 2018, here's the cream of the crop among pharmaceutical stocks.

Pharmaceutical Stocks With High Composite Ratings

The best pharmaceutical stocks to watch have high Composite Ratings. The CR measures a stock's overall strength. A best-possible CR of 99 means a stock is performing in the top 1% of all stocks in terms of key growth metrics. Just two pharmaceutical stocks can make that boast.

Horizon Pharma ( HZNP) stock is ranked first among pharma stocks. It has a CR of 99, which puts it in the top 2% of all stocks, regardless of industry group. Horizon's biggest drug is a gout treatment called Krystexxa. During the third quarter, sales of the gout treatment spiked 64% to top views.

Its other rare disease drugs, Ravicti and Procysbi, also saw traction in the third quarter, growing a respective 19% and 23%. Horizon focuses on rare and rheumatic diseases. It's also working on newer gout treatments and a treatment for a thyroid condition.

Another leader among pharma stocks is Zoetis ( ZTS), which makes drugs for pets and livestock. Zoetis stock has a CR of 99, also putting it in the top 1% of all stocks in terms of strength. Zoetis stock rocketed to a record in November after topping third-quarter views.

Keep chart patterns in mind, however, when looking for pharmaceutical stocks. Horizon stock broke out of a consolidation at 21.35 earlier in the month and has managed to stay in a buy zone since. Zoetis stock is not forming a clear pattern at this point.

Relative Strength Among Pharma Stocks

A greater number of pharma stocks have high Relative Strength Ratings. The RS Rating considers a stock's performance over the past 12 months. Six pharma stocks are topping at least 96% of all stocks in terms of performance.

The best-possible RS Rating is 99. Endo International ( ENDP) and Mallinckrodt ( MNK) stocks come close with RS Ratings of 98 and 97, respectively. Behind them, Bausch Health Companies ( BHC) — formerly Valeant Pharmaceuticals — has an RS Rating of 96. Horizon has an RS Rating of 95.

Endo's biggest drug is Xiaflex, which treats a disease that causes painful erections and a condition that hinders full finger movement. Endo also makes an authorized generic of Merck's ( MRK) antibiotic, Invanz.

Mallinckrodt is known for its H.P. Acthar Gel, a treatment for spasms in babies and exacerbations of multiple sclerosis.

Bausch has several business units — courtesy of acquisitions — focusing on eye drugs, gastrointestinal medicines and dermatology.

When looking at pharmaceutical stocks to buy, keep in mind chart patterns. One of the five pharma stocks with high RS Ratings is consolidating. Mallinckrodt stock has a potential buy point at 36.75.

YOU MIGHT ALSO LIKE:

Breakouts Identify Stocks On The Rise With Big Potential

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

IBD 50 Growth Stocks To Watch

The post Which Pharmaceutical Stocks Are Outperforming All Other Stocks? appeared first on Investor's Business Daily.


30. Speedy Medtech: Why These Fast-Growing Stocks Should Be On Your RadarВт., 13 нояб.[−]

Medical technology stocks hit record highs earlier this year — though have pulled back amid a broader correction — and three of the fastest-growing stocks among them have tacked on double-digit earnings growth over the past five years.

X

Analysts say strength for medical technology stocks comes from the aging U.S. population and innovation among device makers. Meanwhile, these medtech companies tend to avoid the same political pitfalls that plague biotech and pharmaceutical stocks.

As of November 2018, Investor's Business Daily's MarketSmith.com includes four medical technology stocks on its list of the 150 fastest-growing stocks. Three of those meet stringent criteria from IBD and are considered highly rated.

Abiomed, A Giant In Medtech

Abiomed ( ABMD) is No. 49 out of MarketSmith.com's 150 fastest-growing stocks. Abiomed makes heart pumps, including the world's smallest, known as Impella. Over the past five years, Abiomed's adjusted earnings have grown 78%.

To compare, the No. 1 slot goes to Chinese lending marketplace Hexindai ( HX), which has tacked on a five-year adjusted earnings growth rate of 356%.

But Abiomed is no slouch. It has a best-possible IBD Composite Rating of 99, meaning it performs in the top 1% of all stocks in terms of key growth metrics. Abiomed stock also has a Relative Strength Rating of 96, a measure of stock performance over the last 12 months.

In the third quarter, Abiomed's adjusted profit grew 84% to 81 cents per share, as sales advanced 37% to $181.8 million. That added a 10th quarter in which both metrics have increased by at least a double-digit percentage.

Revenue is stronger still. Abiomed's sales have grown by double digits each quarter since at least June 2014. In 2017, sales grew by a third to $594 million.

Inogen Makes Oxygen Concentrators

Medical technology stock Inogen ( INGN) is No. 73 out of 150. The stock has a five-year adjusted income growth rate of 64%.

Inogen makes portable oxygen concentrators for patients in need of oxygen therapy. The stock went public about the same time as PRA stock in 2014. In every quarter since, the medtech company's sales have grown by at least double digits.

Earnings have been especially strong in the past three quarters. Inogen reported adjusted profit that grew 121%, 71% and 78% for the periods ended in September, June and March, respectively. Adjusted income has risen by at least a double-digit percentage for the past five quarters.

Only once in the past 17 quarters did quarterly adjusted profit decline on a year-over-year basis.

Like the other medical technology stocks on the list, Inogen stock has high ratings. It has a CR of 99 and an RS Rating of 94. Six of 118 medical technology companies in the Medical-Products industry group have Composite Ratings of 99. The group itself is ranked No. 18 out of 197 industry groups.

Medical Researcher PRA Among Fastest-Growing Stocks

Among the fastest-growing stocks, PRA Health Sciences ( PRAH) is listed as No. 81. Over the past five years, the medtech company has grown adjusted earnings per share by 60%.

PRA is a medical research outlet that biotech and pharmaceutical companies can contract to provide drug development services. The medtech firm says it's been involved in helping to bring 75 drugs to fruition in the U.S. and/or internationally.

PRA stock is No. 25 on the IBD 50. The list is also deep with other medical technology stocks, including Illumina ( ILMN) and Globus Medical ( GMED).

The medical technology stock is the top stock in the Medical-Research/Equipment industry group. That group ranks No. 17 out of 197 groups tracked by IBD. PRA stock has a CR of 99 and an RS Rating of 89, out of a best-possible 99.

PRA's sales and adjusted profit have grown by double digits for the past 12 quarters. The medical research firm's adjusted earnings have risen by at least a double-digit percentage since June 2014.

YOU MIGHT ALSO LIKE:

How To Invest In Stocks For Free: New Apps Aim For Beginners

How To Trade Stocks: Why Most Penny Stocks Fail To Make Investors Rich

Looking For The Best Stocks To Buy And Watch? Start Here

The post Speedy Medtech: Why These Fast-Growing Stocks Should Be On Your Radar appeared first on Investor's Business Daily.


31. AI News: Artificial Intelligence Trends And Leading StocksВт., 13 нояб.[−]

Investors beware: there's plenty of buzz around artificial intelligence (AI) as more and more companies say they're using it. In some cases, companies are using older data analytics tools and labeling it as AI for a public relations boost. But identifying companies actually getting material revenue growth from AI can be tricky.

X

AI uses computer algorithms to replicate the human ability to learn and make predictions. AI software needs computing power to find patterns and make inferences from large quantities of data. The two most common types of AI tools are called "machine learning" and "deep learning networks."

Nvidia ( NVDA) is one company that can lay claim to AI-driven growth. Internet and tech companies buy its processors for cloud computing. Nvidia's AI chips also are helping guide some self-driving cars in early trials.

Startups are racing to build AI chips for data centers, robotics, smartphones, drones and other devices. Tech giants Apple ( AAPL), Google-parent Alphabet ( GOOGL), Facebook ( FB) and Microsoft ( MSFT) have forged ahead in applying AI software to speech recognition, internet search, and classifying images. Amazon.com's AI prowess spans cloud-computing services and voice-activated home digital assistants.

Then, there are tech companies that embed AI tools in their own products to make them better. Those include video streamer Netflix ( NFLX), payment processor PayPal ( PYPL), Salesforce.com ( CRM) and Facebook.

Customers of tech companies — spanning banks and finance, health care, energy, retail, agriculture and other sectors — are expected to increase spending on AI to get productivity gains or a strategic edge on rivals.

Bookmark this page to stay on top of the latest AI trends and developments.

Artificial Intelligence News

Nvidia Stock Falls On Sales Miss, Weak Guidance, Excess InventoryGraphics-chip maker Nvidia late Thursday missed Wall Street's sales target for its fiscal third quarter and guided below analyst views for the current period. Nvidia stock fell hard in extended trading. Nvidia... Read More
Nvidia, Xilinx Stocks Upgraded To Buy On Artificial IntelligenceA Wall Street brokerage on Tuesday upgraded chip stocks Nvidia and Xilinx to positive from neutral on their prospects in artificial intelligence. Susquehanna Financial Group analyst Christopher Rolland said Nvidia and Xilinx... Read More
Stocks Today: Stock Market Loses Big Gains As 3 Dow Giants WeighStocks today ended mostly lower after searching for direction through much of the session. The Nasdaq pared its shrinking gains into the close to finish flat. The Nasdaq composite fared best with... Read More
Who Joins Square On This List Of Today's Fastest-Growing Companies?What do Square, Abiomed and ServiceNow have in common with Momo and IPO stocks PetIQ and Vici Properties? They've all earned a spot on the latest list of today's fastest-growing companies. The biggest stock market... Read More
Web-Browser Maker Opera Touts Advertising, User GrowthWeb-browser maker Opera has had a rough ride as a publicly traded company, but its second quarterly report since its initial public offering provided investors with some good news. Opera stock soared... Read More
Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The EdgeHangar Technology wants to shake up the drone market by getting rid of human pilots. But the bigger story might be how the startup uses the next big thing in cloud computing,... Read More
Cloud Computing Vendor Lock-In A Growing Customer ConcernAs the cloud computing market continues to consolidate around several large vendors, major customers are starting to split up their cloud business to avoid giving too much power to one company. That's... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

RELATED:

Technology Stocks And Related News

Looking For The Next Nvidia? Start With This Simple Investing Routine

The post AI News: Artificial Intelligence Trends And Leading Stocks appeared first on Investor's Business Daily.


32. Apple (AAPL) Stock Quotes, Company News And Chart AnalysisВт., 13 нояб.[−]

AAPL Stock Quote | AAPL Ratings

Apple Stock News & Analysis

Stock Market Volatile As Apple, Macy's, Home Depot, Nvidia Tumble: Weekly ReviewThe new stock market uptrend quickly came under pressure as the Dow Jones, S&P 500 and Nasdaq composite's extended losses continued into the new week. Apple plunged as suppliers and analysts pointed... Read More
Sonos Upbeat Earnings Report Is Music To Wall Street's EarsPremium sound system maker Sonos got toes tapping with the upbeat tempo of its September-quarter earnings report. Sonos stock jumped Friday on the news. The Santa Barbara, Calif.-based company late Thursday said... Read More
Stocks Set A Minor Goal, But Can Market Get It Done?Stocks erased most losses and turned mixed Friday morning, increasing hopes for the market to climb a second straight day. Such a minor goal for the stock market illustrates the challenges that... Read More
Dow Jones Futures: Nvidia, Applied Materials Dive On Guidance, Slam Chip StocksDow Jones futures, S&P 500 futures and especially Nasdaq futures lost significant ground. Late Thursday, Nvidia, Applied Materials, Nordstrom and Williams-Sonoma plunged on earnings reports and guidance. Worse, that had a ripple effect... Read More
Has Apple Found A Bottom As Techs Rally In Stock Market Today?Bulls came out on top Thursday after another volatile session for the key indexes in the stock market today. The Nasdaq led the charge as hard-hit tech stocks rebounded. The Nasdaq romped... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

More Technology Stocks Coverage

FANG Stocks News: Facebook, Amazon, Netflix, Google

Tesla (TSLA) Stock Quotes And Company News

View More Tech Stocks

The post Apple (AAPL) Stock Quotes, Company News And Chart Analysis appeared first on Investor's Business Daily.


33. Lumentum Slashes Guidance As Customer Cuts Orders, Apple Stock FallsВт., 13 нояб.[−]

Shares in iPhone parts supplier Lumentum Holdings ( LITE) plunged after the maker of optical devices on Monday cut its fiscal second-quarter revenue guidance by roughly 17% and its profit outlook by 25%. The slashed guidance sent down shares in presumed customer Apple ( AAPL).

X

Lumentum stock plummeted 33% to close at 37.50 on the stock market today. Apple stock swooned 5% to 194.17.

Lumentum did not name a customer behind the slashed guidance. Lumentum, Finisar ( FNSR) and II-VI ( IIVI) are presumed to be suppliers of 3D sensor devices to Apple. Apple uses 3D sensors in its iPhones to support facial recognition for unlocking screens.

Lumentum now expects net revenue of $335 million to $355 million, compared with its prior range of $405 million to $430 million, and earnings per share of $1.15 to $1.34, down from $1.60 to $1.75.

"We recently received a request from one of our largest industrial and consumer customers for laser diodes for 3D sensing to materially reduce shipments during out fiscal second quarter for previously placed orders that were originally scheduled for delivery during the quarter," Lumentum said in a written statement.

At a UBS conference on Monday, Lumentum management indicated the issue was inventory-related at the customer. The company indicated it was not a competition or 3D sensor market share issue, Bloomberg reported.

Apple Suppliers Jockey For Business

Lumentum's slashed guidance comes after some analysts have speculated that orders for Apple's iPhone XR have been weaker than expected.

In its fourth quarter earnings report released in October, Apple reported a 4% drop in iPhone unit sales. Apple told analysts on the subsequent earnings call that it plans to withhold unit sales figures for iPhones, iPads and Mac products in future financial releases.

On the other hand, analysts have said there could be market share shifts among Lumentum, Finisar and II-VI as suppliers to Apple.

"Assuming Finisar has about 20% share of the overall 3D sensing market and II-VI has 10% share, this is likely roughly a 33% reduction in demand across the entire segment," said Alex Henderson, a Needham analyst in a report. "With Lumentum accounting for 70% of 3D sensing, we think the company is taking on the full brunt of the impact."

II-VI said its shipments of 3D sensors popped 200% in the September quarter. The company reported earnings on Nov. 1 and upped guidance.

II-VI last week agreed to buy Finisar for $3.2 billion in a cash-and-stock deal.

II-VI Stock Falls More

Investors may not be sure if there's upside for II-VI in Lumentum's slashed guidance.

II-VI stock was down 11% to 33.78 on Monday in early trading. II-VI crashed 19% on Friday after announcing the Finisar deal.

Apple invested $390 million in Finisar in December 2017 so it could ramp up manufacturing of 3D sensors in a new plant.

The market for consumer electronics, such as Apple iPhones, is a new one for companies like II-VI, Finisar and Lumentum. They mainly sell devices used in telecom networks and data centers.

YOU MIGHT ALSO LIKE:

How Cloud Computing Upgrade Cycle To 400G Could Drive Tech Stocks

Fabrinet Stock Jumps As Earnings, Guidance Top Views Amid China Tariffs

The Big Picture: Stock Market Keeps Its Cool As Breakouts Pick Up

Why You Should Buy On The Stock Market Follow-Through Day

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

The post Lumentum Slashes Guidance As Customer Cuts Orders, Apple Stock Falls appeared first on Investor's Business Daily.


34. Singles Day Sales Top $31 Billion, Reflect Macroeconomic HeadwindsВт., 13 нояб.[−]

Alibaba ( BABA) reported a record $31.8 billion in gross merchandise volume for its annual "Singles Day" shopping festival, up 27% from the year-ago period but a deceleration from growth of 39% the previous year. Alibaba stock fell.

X

Total sales came in below some estimates. Alibaba, the largest provider of e-commerce services in China, suggested that sales growth trends remained healthy despite "cyclical and geopolitical economic challenges," Alibaba Executive Vice Chairman Joe Tsai said.

Tsai, in remarks to the media after the event ended, said that despite macroeconomic headwinds, the rise of China's middle class will remain the predominant driver of growth trends.

"I think you have to understand Alibaba and what Alibaba's doing in the context of the long-term secular trend that's developing in China, which is the rise of the Chinese middle class," said Tsai. "That trend is not going to stop, trade war or no trade war."

China stocks have fallen sharply this year due to economic weakness in China and concerns about the growing trade war with the U.S.

Alibaba Stock Falls

Alibaba stock fell 1.4% to 142.82 on the stock market today.

Shares of Baozun ( BZUN), which helps companies execute their e-commerce strategies in China, plunged 20.6%, to close at 31.88. Baozun said orders of $940 million across its platform on Singles Day were up 31% from last year. But that was well below growth rates of previous years.

JD.com ( JD) stock closed at 22.01, up 1.4%. The company is Alibaba's closest competitor in e-commerce and, just like Alibaba, offers special deals on Singles Day. JD.com reported sales of $23 billion for the event.

Alibaba last week reported mixed fiscal second-quarter results as earnings easily beat views while revenue came in light. Alibaba curbed its full-year revenue growth forecast by 4% to 6% amid "fluid macroeconomic conditions."

Singles Day History

It was the 10th anniversary of what Alibaba now calls the 11.11 Global Shopping Festival, which lasts 24 hours.

The 11.11 festival initially began as Singles Day, in which college students picked Nov. 11 to celebrate being single. Alibaba adopted and promoted the theme starting in 2009. It has since evolved into a day when consumers in China — single or not — buy gifts and celebrate. It's the single largest online shopping day worldwide.

Numerous brands and merchants participate in the event, selling their products on Alibaba's various e-commerce websites.

On Monday, Raymond James analyst Aaron Kessler reiterated a strong buy on Alibaba and price target of 260. He based that on "continued strong core commerce revenue growth," in addition to Alibaba's strength in cloud computing and expectations of narrowing losses in investment areas, such as digital media.

Baird analyst Colin Sebastian in a report Monday maintained an outperform rating on Alibaba and price target of 178.

"We believe investors with longer-term perspectives should continue adding to positions on pullbacks given the multiple growth opportunities across retail/e-commerce, logistics/delivery, cloud computing, and media," Sebastian wrote in a note to clients.

YOU MIGHT ALSO LIKE:

Alibaba Shares Rebound Ahead Of Quarterly Earnings Report

Alibaba Begins Countdown To Singles Day Annual Shopping Festival

The post Singles Day Sales Top $31 Billion, Reflect Macroeconomic Headwinds appeared first on Investor's Business Daily.


35. Nektar Bounds Higher On 'Promising Contender' In Cancer ImmunotherapyВт., 13 нояб.[−]

Nektar Therapeutics ( NKTR) bounded higher Monday after its immunotherapy combination with Bristol-Myers Squibb ( BMY) showed promise as a melanoma treatment.

X

On the stock market today, Nektar stock jumped 8.7%, to 36.99, in above-average volume. Meanwhile, biotech stocks sank more than 3%.

The study looked at an immunotherapy combination using Nektar' NKTR-214 and Bristol's drug, Opdivo. Overall, 53% of patients responded to treatment. Nektar presented the data during the Society for Immunotherapy of Cancer meeting on Friday.

'Promising Contender' In Immunotherapy

Following the data presentation, Canaccord Genuity analyst Arlinda Lee called NKTR-214 a "promising contender in cancer immunotherapy." She kept her buy rating on Nektar stock, though she cut her price target to 86 from 94.

Nektar evaluated 38 patients. Overall, 20 responded to the immunotherapy regimen. Nine patients, or 24%, had complete responses. Of the 20 patients, 17 were still responding to the immunotherapy regimen as of the data cutoff.

Opdivo is thought to work better in patients who have more of a protein called PD-L1. But 43% of patients whose tumors don't have that protein responded. Responses were slightly higher in patients with PD-L1, at 68%.

The most common side effects were flu-like symptoms, rash, fatigue, itching, nausea, and joint or muscle pain. Eight out of a total 41 patients experienced a severe or worse side effect. Two patients discontinued treatment.

YOU MIGHT ALSO LIKE:

Breakouts Identify Stocks On The Rise With Big Potential

Semiconductor Stocks To Consider Buying When The Time Is Right

Apple And Growth Stocks: Why Most Penny Stocks Fail To Make Investors Rich

The post Nektar Bounds Higher On 'Promising Contender' In Cancer Immunotherapy appeared first on Investor's Business Daily.


36. These Biopharmas Could Cure Genetic Diseases — At $5 Million ApieceВт., 13 нояб.[−]

Novartis ( NVS) and Audentes Therapeutics ( BOLD) could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.

X

During its investor update this month, Novartis suggested its acquired gene therapy, AVXS-101, could be cost-effective at $4 million to $5 million. Novartis based the suggestion on a measure of the cost to treat the disease without the treatment, which takes into account quality and quantity of life lived.

The pharma giant is testing AVXS-101 as a treatment for spinal muscular atrophy. It would rival Biogen ( BIIB) and Ionis Pharmaceuticals' ( IONS) already-approved treatment, Spinraza. Novartis bought AveXis, the creator of AVXS-101, in May for $8.7 billion.

Chardan analyst Gbola Amusa sees major implications in the gene therapy market if Novartis is successful.

"To the extent that Novartis is able to price AVXS-101 in the $4 million to $5 million range and see a commercial success, we believe the implications for the adeno-associated virus-based gene therapy sector would be profound," he said in a note to clients.

Gene Therapies Still Not Proven

Adeno-associated viral vectors are used to create some gene therapies, like AVXS-101 and Audentes' AT132. The virus is harmless on its own. Researchers are testing the theory that they can use these viruses to insert genetic material at a specific site on the chromosome.

The SMA Foundation estimates that as many as 10,000 to 25,000 children and adults in the U.S. have spinal muscular atrophy. So success could be huge for Novartis.

Novartis' gene therapy could be "a breakthrough success in a devastating pediatric disease," Amusa said. He noted there's a "lack of satisfactory treatments in a market large enough to justify a mega-blockbuster."

It's important to note, gene therapies haven't yet been proven in the long run. There is one gene therapy approved in the U.S. Spark Therapeutics ( ONCE) gained approval for Luxturna, which treats an inherited eye disease, last year.

Other Gene Therapy Players Could Benefit

But if Novartis is successful, other gene therapies could benefit, Amusa said. Audentes is working on AT132 as a treatment for X-linked myotubular myopathy, an ultrarare disease that affects the skeletal muscles. He sees $4.94 million as a cost-effective price for AT132.

"We think Audentes is a beneficiary if Novartis prices in the communicated range and succeeds commercially," he said.

Solid Biosciences ( SLDB), Pfizer ( PFE) and Sarepta Therapeutics ( SRPT) are working on rival gene therapies to treat Duchenne muscular dystrophy, a muscle-wasting disease. Amusa imagines that Solid could charge $2 million for a one-time dose of its gene therapy.

At 10,000-22,500 patients in the U.S., this implies a $21 billion to $47 billion opportunity in the U.S., he said.

On the stock market today, Novartis stock dipped 1.1%, to 88.23, as Audentes stock fell 1.7%, to 23.60. Biotech stocks were routed, losing more than 3%.

YOU MIGHT ALSO LIKE:

Looking For The Next Nvidia? Start With These 3 Steps

Sell And Take The Profit In Growth Stocks, Or Hold? Several Guidelines To Follow

When Will The Dow Jones Or Nasdaq Show A Major Stock Market Top? Here's The Easy Way To Find Out

The post These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece appeared first on Investor's Business Daily.


37. Autohome Stock Falls Even As Quarterly Results Beat EstimatesВт., 13 нояб.[−]

Autohome stock fell Monday despite the company reporting quarterly results before the market open that beat consensus estimates on the top and bottom lines.

X

Beijing-based Autohome ( ATHM) reported third-quarter revenue of $275 million, up 33.5% in local currency. That beat the consensus estimate of $267 million.

It posted adjusted earnings of 90 cents per share, up 55% in local currency. Analysts expected 81 cents.

Autohome stock fell 6.1% to 64.46 on the stock market today.

China Stocks Under Pressure

China stocks have been under pressure all year over concerns of a slowing China economy and a trade war with the U.S. Autohome stock is down a fraction so far this year.

Autohome is a destination for Chinese consumers, providing a wide range of automotive information.

For the fourth quarter, Autohome estimated revenue in the range of $303 million to $305.8 million. The midpoint of $304.4 million is above the consensus estimate of $302 million.

Autohome reported having 279 million mobile users during the quarter, up 48% from the year-ago period.

The number of average daily unique visitors who accessed the company's mobile websites and primary application combined reached 27.9 million. That's a year-over-year increase of 48%.

YOU MIGHT ALSO LIKE:

Singles Day Sales Top $31 Billion, Reflect Macroeconomic Headwinds

Best Chinese Stocks To Buy And Watch

The post Autohome Stock Falls Even As Quarterly Results Beat Estimates appeared first on Investor's Business Daily.


38. Apple iPhone XR Inventories 'Bloated,' Production SlowedВт., 13 нояб.[−]

Evidence continues to mount that Apple's ( AAPL) latest iPhones aren't spurring the kind of sales uptick that Wall Street expected. One analyst said iPhone XR inventories are "bloated," resulting in cuts to production plans, and Apple stock fell.

X

JPMorgan on Monday said it now expects modest year-over-year declines in iPhone shipments for both calendar 2018 and 2019. It trimmed its earnings estimates on its lowered iPhone sales forecast.

JPMorgan analyst Samik Chatterjee cut his price target on Apple stock to 266 from 270 but kept his overweight rating. Apple stock fell 5% to 194.17 amid a down day for Wall Street on the stock market today.

He blamed a weaker macroeconomic backdrop in emerging markets and "tepid" iPhone XR demand for the lower-than-expected iPhone sales.

Better-than-expected demand for the higher-end iPhone XS and XS Max is partially offsetting lower sales of the midrange iPhone XR, he said.

IPhone XR Production Cuts Hitting Suppliers

Longbow Research on Monday said "sharp iPhone production cuts" are hitting component suppliers. Longbow rates Apple stock as neutral.

Spot checks with suppliers late last week highlighted iPhone order cuts of 20% to 30%, Longbow analysts Shawn Harrison and Gausia Chowdhury said in a report. The cuts were related mostly to the iPhone XR and XS Max. Apple increased orders for less-expensive, older-model iPhones including the iPhone 8, they said.

Also, internet search trends for iPhone in China "fell off a cliff for October," they said. That is a sign of "faltering China demand."

Apple iPhone Story 'Showing Cracks'

"The iPhone story is showing cracks with contacts now citing weaker iPhone orders year over year and Baidu ( BIDU) iPhone search trends highlighting a red flag," they wrote.

IPhone component supplier Lumentum Holdings ( LITE) on Monday slashed its fiscal second-quarter revenue guidance by roughly 17% and its profit outlook by 25% after an unnamed customer, believed to be Apple, materially reduced its orders. Lumentum makes 3D sensors that power the facial recognition technology on Apple's latest iPhones.

Also Monday, Japan Display, one of the main suppliers of liquid crystal display screens for iPhones, cut its full-year guidance, citing "volatile customer demand."

Last Thursday, another iPhone parts supplier Skyworks Solutions ( SWKS) gave December-quarter guidance that was well below Wall Street's targets. Skyworks blamed declines in sales of high-end smartphones and overall softness in China for the guidance miss. Skyworks makes power control, radio frequency and other chips for the iPhone.

KeyBanc Capital Markets said its latest survey of wireless carriers indicated in-line demand for the iPhone XS and XS Max. But "iPhone XR sell-through has been underwhelming," analyst John Vinh said in a note to clients Friday. He called iPhone XR inventories "bloated."

RELATED:

Apple Stock Gets Price-Target Hike On Services Potential

Apple iPhone XR Sales Called 'Weaker Than Expected'

The post Apple iPhone XR Inventories 'Bloated,' Production Slowed appeared first on Investor's Business Daily.


39. Netflix Outlook Brightens As Content Quality ImprovesВт., 13 нояб.[−]

The quality of content on Netflix ( NFLX) has improved over the past year, according to a new subscriber survey. However, the positive news didn't lift Netflix stock.

X

Investment bank Piper Jaffray surveyed over 1,100 U.S. Netflix subscribers to gauge their opinions of the internet television network. Some 71% of those surveyed said the content on Netflix has improved in the past year. Meanwhile, 29% said the content has worsened, Piper Jaffray said in a report Monday.

"The majority feel the quality of Netflix content has improved in the past year," Piper Jaffray analyst Michael Olson said. "As Netflix continues to leverage data and invest in the content library, we believe the company will be well positioned to further raise price."

Olson reiterated his overweight rating on Netflix stock with a price target of 430. On the stock market today, Netflix stock fell 3.1% to 294.07.

Netflix Stock Pressured By Growing Competition

Competitive concerns have pounded Netflix stock recently. It currently faces rivals such as Amazon.com ( AMZN), CBS ( CBS) and Hulu. Apple ( AAPL), AT&T's ( T) Warner Media and Walt Disney ( DIS) are preparing to launch new services.

If Netflix can continue to improve its content, including original series and movies, it will be better positioned to raise its subscription prices, Olson said.

Netflix could get a reputation boost from possible Oscar nominations, which will be announced on Jan. 22. Several Netflix movies scheduled for release in the fourth quarter are in contention for Academy Awards, he said. They include "The Ballad of Buster Scruggs," "Bird Box" and "Roma."

Netflix stock hit a record high of 423.21 back on June 21. It tumbled late last month after its third-quarter earnings report and a plan to take on more debt to finance original content.

RELATED:

Roku Stock Dives As Streaming Video Platform Disappoints On Growth

Netflix Stock Soars On Heady Subscriber-Growth Figures

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Netflix Outlook Brightens As Content Quality Improves appeared first on Investor's Business Daily.


40. Netflix (NFLX) Stock Quotes, Company News And Chart AnalysisПн., 12 нояб.[−]
X

NFLX Stock Quote | NFLX Ratings

Netflix Stock News & Analysis

Big-Screen TVs, Smart Speakers Are Hot Gadgets This Holiday SeasonHoliday shoppers plan to load up on consumer electronics this year, with big-screen TVs among the most sought-after items. "People want the biggest and best TV they can have in their living... Read More
Stocks Today: Apple, Netflix, Nvidia Lead Nasdaq 100 LowerThe stock market pared losses significantly in afternoon trading Wednesday. Stocks today under pressure included Apple, Netflix and Nvidia in the Nasdaq 100. After an intraday gain of nearly 1.2%, the Nasdaq... Read More
Netflix Outlook Brightens As Content Quality ImprovesThe quality of content on Netflix has improved over the past year, according to a new subscriber survey. However, the positive news didn't lift Netflix stock. Investment bank Piper Jaffray surveyed over... Read More
Stock Market News: Nasdaq Walloped As Netflix Dives 5%; Disney Leads DowStock market news was abundant again Friday, but sellers dictated the action, with the Nasdaq composite down 2% in afternoon trading. Wall Street weighed another big drop in oil prices, a hotter-than-expected... Read More
Roku Stock Dives As Streaming Video Platform Disappoints On GrowthRoku stock fell Thursday after the streaming video platform reported decelerating growth in the third quarter. Roku also is facing new competition from cable giant Comcast. On the stock market today, Roku... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

More Technology Stocks Coverage

FANG Stocks News: Facebook, Amazon, Netflix, Google

Apple (AAPL) Stock Quotes And Company News

Tesla (TSLA) Stock Quotes And Company News

View More Tech Stocks

The post Netflix (NFLX) Stock Quotes, Company News And Chart Analysis appeared first on Investor's Business Daily.


41. Biotech Stocks To Watch And Pharma Industry NewsПн., 12 нояб.[−]

One minute Dow Jones industrial average component Merck ( MRK) might be doing battle with fellow drugmaker Bristol-Myers Squibb ( BMY) over drugs that can ward off cancer.

X

The next, biotech giants like Amgen ( AMGN) and Sanofi ( SNY) are tussling in court over the fate of cholesterol-busting drugs. Meanwhile, a company like Gilead Sciences ( GILD) might be raked over the coals in Congress for charging $1,000 a day to treat hepatitis.

It's a brave — and contentious — new world for pharmaceutical and biotechnology companies. It's a realm where science is trying to develop landmark medicines that cure cancer, hepatitis and other life-threatening illnesses.

All the while it does a delicate dance with Wall Street and regulators — balancing public health issues with the demands of shareholders. Investors will find it tricky to navigate the sector, as companies can rise and fall at the drop of a hat.

Bookmark this page to stay on top of the latest news in the biopharma sector.

Biotech And Pharma News

Tesaro Stock Flies 31% On Rumored Buyout Interest After Lung-Cancer FlopTesaro stock rocketed late Friday on a rumor that the biotech could seek a sale after its lung-cancer treatment disappointed investors last week. Before the close, Tesaro leapt 31.5%, to 34.96, on the... Read More
Recent Breakout Stock Sacrifices Buy Zone On Lung-Cancer FailureAstraZeneca sacrificed a buy zone Friday after its immunotherapy regimen failed to improve overall survival in lung cancer patients. On the stock market today, AstraZeneca stock slipped 1.8%, to 40.67. AstraZeneca stock briefly... Read More
IBD Stock Of The Day Nears Breakout On Medical-Research BuzzPRA Health Sciences is the IBD Stock Of The Day as shares of the medical-research outlet approach a breakout amid the likelihood of double-digit growth in 2019. Like other medical-research players, PRA... Read More
Trump's Biopharma Impasse Led To A Slowdown — Now Pfizer Is Fighting BackDrug-pricing pressure from the Trump administration likely contributed to a slowdown in revenue growth for the biopharma industry during the third quarter, an analyst said Friday. But at least a piece of... Read More
Can Medication Management Leader Omnicell Deliver A New Breakout?Omnicell provides medication management systems for hospitals, health care systems and pharmacies. Now the question is, can it provide a fresh breakout for investors? In the face of stock market volatility, Omnicell... Read More
Stocks Slide At Open; This Dow Jones Name Bucks Chip Sell OffStocks sliced lower at Friday's open, but quickly trimmed declines as energy and utility stocks fought to counter heavy losses among retail names, and Dow Jones stock Intel snubbed an early chip... Read More
Biomarin Pharmaceutical Shows Market Leadership With Jump To 81 RS RatingWhen considering what names to put on your watch list, focus on stocks with an 80 or higher RS Rating. Biomarin Pharmaceutical now meets that criteria, with an increase from 75 to... Read More

View More Biotech And Pharma Stock News

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

RELATED:

Best Stocks To Buy And Watch

The post Biotech Stocks To Watch And Pharma Industry News appeared first on Investor's Business Daily.


42. Biotech Stock Pops After FDA Approves Mylan-Partnered Lung Disease DrugСб., 10 нояб.[−]

Theravance Biopharma ( TBPH) popped Friday after its chronic lung disease treatment with Mylan ( MYL) gained Food and Drug Administration approval. Theravance stock jumped 5.1% to close at 25.81.

X

Mylan stock, on the other hand, dipped fractionally to close at 36.95 on the stock market today.

U.S. regulators approved the drug, called Yupelri, as a treatment for chronic obstructive pulmonary disease, or COPD, the companies said in a news release. COPD is a chronic inflammatory lung disease that causes restricted airflow from the lungs.

According to the Mayo Clinic, smokers are often diagnosed with COPD. There are several methods of lung disease treatment to relax the muscles around the airways or reduce inflammation.

Yupelri is the first long-acting bronchodilator approved to treat COPD. Bronchodilators aim to relax the muscles in the airway.

YOU MIGHT ALSO LIKE:

New Option Strategy Limits Risk Around Earnings

How To Tame A Volatile Swing Trade With A Half Position

CAN SLIM Trading: Can You Make Big Profits With Just A Little Cash? Yes, Here's The Way

The post Biotech Stock Pops After FDA Approves Mylan-Partnered Lung Disease Drug appeared first on Investor's Business Daily.


43. This Biotech Stock Just Boomeranged On Cancer Treatment StudiesСб., 10 нояб.[−]

Tesaro ( TSRO) shares boomeranged late Friday after the biotechnology company reported results for its immunotherapy combination in lung cancer treatment. Tesaro stock plunged 18.8% to close at 25.10.

X

After the close, though, on the stock market today, Tesaro stock climbed 5.6% in extended action.

Biotech Tesaro tested its immunotherapy drugs, known as TSR-022 and TSR-042, in patients with previously treated non-small cell lung cancer. These patients already failed on a prior immunotherapy regimen involving a drug known as a PD-1 checkpoint.

Among the 31 patients who could be evaluated, four had partial responses to the immunotherapy regimen. Another 11 had stabilized after the lung cancer treatment, or kept the tumor from either growing or shrinking. All the responses were in patients whose tumors have more of a protein known as PD-L1, Tesaro said in a news release.

There were 16 patients whose tumors showed the PD-L1 protein. Of those, researchers could evaluate 12 patients. In that group, four patients had partial responses and six had stabilized after receiving the immunotherapy combination.

A second study looked at TSR-042 alone as a cancer treatment for patients with uterine cancer or lung cancer. Of 47 patients, 15 had partial responses — two of those responses haven't been confirmed — and 14 additional patients had stabilized.

Nine of the 15 patients are still responding to the immunotherapy regimen.

YOU MIGHT ALSO LIKE:

Looking For The Next Breakout Stocks? Start With These Lists

How To Build Long-Term Profits In Stocks? Take Many Gains At 20%-25%

CAN SLIM Trading: Can You Make Big Profits With Just A Little Cash? Yes, Here's The Way

The post This Biotech Stock Just Boomeranged On Cancer Treatment Studies appeared first on Investor's Business Daily.


44. II-VI Buys Finisar In Merger Of Two Apple 3D Sensor SuppliersСб., 10 нояб.[−]

II-VI ( IIVI) has agreed to buy Finisar ( FNSR) for $3.2 billion in a cash-and-stock deal that combines two suppliers of 3D sensors to Apple ( AAPL). II-VI stock plunged in midday trading on Friday while Finisar stock soared.

X

Apple invested $390 million in Finisar in December 2017 so it could ramp up manufacturing of 3D sensors in a new plant. Apple uses 3D sensors in its iPhones to support facial recognition for unlocking screens.

Needham analyst Alex Henderson says that II-VI's purchase of Finisar could have upside for Lumentum Holding ( LITE). Lumentum sells the most 3D sensors to Apple.

"The consolidation of the 3D VCSEL suppliers is a positive for Lumentum and for II-VI," Henderson said in a report to clients. The Needham analyst told IBD in an email that Apple may be cool to the merger if it reduces price competition.

"Assuming the deal completes, we expect the merger of II-VI and Finisar to create a stronger competitor to Lumentum for the 3-D sensing market than either company on its own," D.A. Davidson analyst Mark Kelleher said in his note to clients. "With the reduction in competition, however, pricing could also be less aggressive."

Finisar's stockholders receive $15.60 per share in cash and 0.2218 share of II-VI stock on a pro-rated basis. That's valued at 10.40 per share based on the II-VI's Thursday's close of 46.88.

The II-VI-Finisar deal values Finisar at $26 per share, or approximately $3.2 billion in equity value and represents a premium of 37.7% to Finisar stock's close Thursday. Finisar shareholders would own approximately 31% of the combined company.

Consumer Electronics A New Market

"Disruptive megatrends driven by innovative uses of lasers and other engineered materials present huge growth opportunities for both of our companies,"II-VI Chief Executive Vincent Mattera said in a prepared statement.

The company reported third-quarter earnings that topped expectations in October. But II-VI said its shipments of 3D sensors jumped 200% from a year earlier. II-VI forecast December quarter sales and profit above estimates.

Consumer electronics, such as Apple iPhones, is a new market for companies like II-VI, Finisar and Lumentum. They mainly sell devices used in telecom networks and data centers.

II-VI stock plunged nearly 19% to close at 38.01 on the stock market today. Finisar stock jumped 15.4% to finish at 21.79. Lumentum fell 4% to 55.95.

Apple stock slid 1.9% as futures indicated a tech-led stock market retreat.

YOU MIGHT ALSO LIKE:

How Cloud Computing Upgrade Cycle To 400G Could Drive Tech Stocks

Fabrinet Stock Jumps As Earnings, Guidance Top Views Amid China Tariffs

The Big Picture: Stock Market Keeps Its Cool As Breakouts Pick Up

Why You Should Buy On The Stock Market Follow-Through Day

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

The post II-VI Buys Finisar In Merger Of Two Apple 3D Sensor Suppliers appeared first on Investor's Business Daily.


45. Ubiquiti Stock Soars As Earnings Beat On Enterprise Market GrowthСб., 10 нояб.[−]

Shares in Ubiquiti Networks ( UBNT) surged on Friday after the maker of wireless networking equipment reported fiscal first-quarter earnings and revenue that blew past estimates. Ubiquiti stock roared into a buy zone, gaining more than 17%.

X

Ubiquiti said adjusted earnings jumped 27% to $1.17 a share, with revenue rising 15% to $282.9 million. Sales to large companies jumped 41% to $178 million, topping estimates of $165 million.

Analysts expected Ubiquiti earnings to hit $1.05 cents a share on sales of $270.6 million for the period ended Sept 30, according to Thomson Reuters.

Ubiquiti stock gear surged 17.6% to close at 111.13 on the stock market today.

Ubiquiti Margins Growing

With Friday's gain, Ubiquit stock is up 62% from a year ago. The stock blew past a buy point of 101.43.

Ubiquiti's fiscal Q1 gross margin expanded to 46.5% from 44.7% the previous quarter.

Selling wireless networking gear to enterprise customers has lifted Ubiquiti profit margins. San Jose, Calif.-based Ubiquiti also sells wireless networking gear to rural, wireless internet service providers.

IBD's Telecom-Infrastructure group is ranked No. 36 out of 197 industry groups. Ubiquiti, Ceragon Networks ( CRNT) and Calix ( CALX) have the highest Composite Ratings.

YOU MAY ALSO LIKE:

Cloud Computing Spurs Business Communication Bonanza, Lifts RingCentral, Slack

Cloud Computing: Find Top Cloud Stocks And Track Industry Trends

Improve Your Investing Results With This Simple 3-Step Routine

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Ubiquiti Stock Soars As Earnings Beat On Enterprise Market Growth appeared first on Investor's Business Daily.


46. Chip Stocks Seeing Red After Skyworks Misses On GuidanceСб., 10 нояб.[−]

Chip stocks fell Friday after Skyworks Solutions ( SWKS) provided negative data points on the smartphone market. Skyworks stock tanked after the chipmaker gave December-quarter guidance that was well below Wall Street's estimates.

X

Skyworks late Thursday reported roughly in-line fiscal fourth-quarter results. It earned an adjusted $1.94 a share on sales of $1.008 billion in the quarter ended Sept. 28. Analysts expected Skyworks earnings of $1.92 a share on $1 billion in sales, according to Thomson Reuters. On a year-over-year basis, Skyworks earnings per share rose 7% while sales climbed 2%.

For the current quarter, the Woburn, Mass.-based company guided to adjusted earnings per share of $1.91 on revenue of $1.01 billion. Wall Street was modeling Skyworks earnings per share of $2.08 on sales of $1.07 billion.

"Skyworks' continued strength in broad markets coupled with the launch of a diverse set of high-performance mobile solutions is offsetting unit declines in premium smartphones and overall China softness," Chief Financial Officer Kris Sennesael said in a news release. "Despite the near-term industry weakness, we intend to deliver our 10th consecutive fiscal year of revenue and non-GAAP earnings growth."

Skyworks Stock Fall Leads Chip Stocks Lower

Skyworks stock dropped 8.1% to 76.66 on the stock market today. It pulled down other chip stocks as well, especially smartphone chip suppliers.

The Philadelphia semiconductor index, known as SOX, fell 1.7% on Friday. The SOX tracks the performance of a basket of key chip stocks.

Skyworks stock received at least three ratings downgrades and a host of price target cuts on Friday.

Apple iPhone XR Production Cuts Likely Hit Skyworks

"This was Skyworks' weakest EPS guidance relative to Street expectations in 2.5 years, since the March 2016 quarter during the disappointing iPhone 6S cycle," Morgan Stanley analyst Craig Hettenbach said in a report.

Skyworks management attributed the December-quarter shortfall to weakness in high-end smartphones and China smartphone weakness more broadly, he said. Apple's ( AAPL) reported move to cut production targets for the iPhone XR likely impacted Skyworks, Hettenbach said. Skyworks gets about 35% to 40% of its revenue from Apple, he said.

"While we had been anticipating a shortfall, the magnitude was greater and likely speaks to real-time iPhone revisions," Hettenbach said. He rates Skyworks stock as underweight and cut his price target to 76 from 79.

Earlier this week, chipmakers Qualcomm ( QCOM) and Microchip Technology ( MCHP) each reported better-than-expected September-quarter results but disappointed with their December-quarter outlook.

RELATED:

Qualcomm Stock Falls On Weak December-Quarter Sales Guidance

AMD Stock Rises As Amazon Web Services Uses Its Epyc Chips

NXP Semiconductors Pops On Third-Quarter Earnings Beat

The post Chip Stocks Seeing Red After Skyworks Misses On Guidance appeared first on Investor's Business Daily.


47. Activision Is Latest Game Publisher To Not Feel The Holiday SpiritСб., 10 нояб.[−]

Activision Blizzard ( ATVI) shares fell hard on Friday as investors showed their disappointment in the video game publisher's holiday-quarter guidance. Activision stock is the latest in the industry to be punished for its weak outlook.

X

The Santa Monica, Calif.-based company late Thursday reported mixed third-quarter results. Activision earnings per share topped views for the September quarter, while sales were in line with expectations. But investors keyed in on its guidance.

Activision guided to adjusted earnings per share of $1.27 on net bookings of $3.05 billion. Wall Street was modeling Activision earnings of $1.34 a share on sales of $3.06 billion, according to Thomson Reuters.

Activision stock slid 12.4% to 55.01 on the stock market today. Just five weeks ago, Activision stock notched an all-time high of 84.68 on Oct. 1.

Other video game stocks are in the same boat. Electronic Arts ( EA) and Take-Two Interactive Software ( TTWO) also fell after giving disappointing December-quarter guidance. Their cautious outlook is surprising given the launch of several big games to the large installed base of current-generation consoles, analysts said.

Activision Stock Gets Flurry Of Price-Target Cuts

Activision stock received at least 12 price-target cuts from Wall Street analysts after its third-quarter report.

Activision's cautious tone despite the early success of "Call of Duty: Black Ops 4" could signal softness in its Destiny and Hearthstone franchises, Baird analyst Colin Sebastian said in a report. Its guidance also could reflect "the strong competitive landscape for holiday game releases" this year, he said.

Morgan Stanley analyst Brian Nowak said Activision needs to revitalize some of its core franchises, including Destiny and Overwatch.

"The fact that the core franchises are facing both engagement and monetization headwinds speaks to recent misexecution, particularly at Blizzard," Nowak said in a report to clients. "The company appears focused on these issues, as evidenced by its decision to bring a new management team in at Blizzard."

RELATED:

Activision Stock Tumbles On Weak Holiday-Quarter Outlook

Take-Two Stock Drops Despite Upbeat Quarterly Earnings Report

Electronic Arts Tops Quarterly Views, But EA Stock Falls On Outlook

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Activision Is Latest Game Publisher To Not Feel The Holiday Spirit appeared first on Investor's Business Daily.


48. IBD 50 Stock Plunges As Revenue Growth Hits Brakes In Third QuarterСб., 10 нояб.[−]

Globus Medical ( GMED) stock toppled Friday after the IBD 50 medical technology outlet beat third-quarter expectations but said revenue growth slowed on seasonal weakness.

X

On the stock market today, Globus Medical stock plunged 9.7% to close at 51.86. On Thursday, before the medical technology firm reported earnings, Globus Medical stock briefly topped a buy point out of a consolidation at 57.65, before closing at 57.44.

During the quarter, Globus Medical earnings showed that revenue growth slowed to 11.8% in constant currency from 13.3% in the prior period, Needham analyst Mike Matson said in a report to clients. Capital sales were seasonally weak and emerging technology sales of $6.3 million lagged his view for $9 million.

Still, Matson kept this buy rating and 65 price target on Globus Medical stock.

"We believe Globus Medical's emerging technology segment, sales force expansion, new products and conservative guidance should enable it to continue to deliver upside," he said.

Globus Medical Earnings: Sales, Profit Beat

Globus Medical makes products that ease spinal surgeries, including a robotic system.

For the third quarter, Globus Medical earnings were an adjusted to 39 cents a share, above analyst predictions for 32 cents, Matson said. Year over year, adjusted profit grew 29.2%. Sales of $169.2 million also topped forecasts for $168 million.

Sales of spine products grew 7.4% to about $163 million, above Matson's view for $157.8 million. That also accelerated from 4.7% growth in the prior quarter "due primarily to the sales force expansion and secondarily to robot pull-through," he said.

Emerging Technologies Falter

But emerging technologies sales were short on seasonal weakness, Matson said. The third quarter tends to be weak with regard to capital sales. The medical technology firm says that, in general, about 30% of its capital placements occur in the fourth quarter.

"Importantly, they noted that Globus Medical sold more robots in the U.S. in October than in the entire third quarter," he said.

The medical technology company raised its 2018 outlook. Now, the company expects to earn $1.62 per share, excluding items, on $705 million in sales. That's up from $1.55 a share and $700 million, respectively.

Globus Medical stock is highly rated by Investor's Business Daily standards. Globus Medical stock has a Composite Rating of 98 out of a best-possible 99, meaning it performs in the top 2% of all stocks in terms of key growth metrics.

YOU MIGHT ALSO LIKE:

Looking For The Next Breakout Stocks? Start With These Lists

Which Stocks Are Showing Rising Relative Strength?

How To Tame A Volatile Swing Trade With A Half Position

The post IBD 50 Stock Plunges As Revenue Growth Hits Brakes In Third Quarter appeared first on Investor's Business Daily.


49. These Five Big-Name IPOs Could Rival Dot-Com Era — If They WantedПт., 09 нояб.[−]

A number of big-name Silicon Valley companies could go public next year and bring about the largest year for initial public offerings since the dot-com peak in 2000. The question is, will they take the IPO plunge?

X

Among the most anticipated IPOs are ride-sharing leaders Uber and Lyft. The others are data mining company Palantir Technologies, workplace collaboration developer Slack Technologies and accommodation services provider Airbnb.

If they follow through, 2019 could be a record-breaking year for the IPO market. In terms of dollars raised, it could top the year 2000, the pinnacle for initial public offerings, when tech companies raced to cash in on lofty valuations during the dot-com boom, said Kathleen Smith at Renaissance Capital. Renaissance is a provider of IPO-based exchange traded funds and a provider of IPO institutional research.

"If everything works out, this could be an amazing year for IPOs," Smith said. "These companies can't stay private forever and they've been private much longer than normal."

Here's a rundown on five of the most-watched companies with IPO expectations in 2019.

IPO 1: Uber Technologies

Uber is eyeing an early 2019 IPO listing that could place a valuation on the ride-sharing pioneer near $120 billion. Facebook ( FB) had a valuation of $104 billion when it went public in 2012.

At $120 billion, Uber's IPO would be the biggest since Alibaba Group ( BABA) began trading on the New York Stock Exchange in 2014. At the time Alibaba had a market valuation of $230 billion.

Founded in 2009, San Francisco-based Uber has yet to achieve sustained profitability. It did turn a profit in the first quarter of 2018 thanks to the sale of some assets. But in the second quarter Uber reported an $891 million loss on revenue of $2.8 billion. Uber is not required to publicly disclose its quarterly results but has revealed basic financial information to provide investors with a better sense of its overall health.

The company is aggressively trying to increase business for UberEats, its food delivery business. It's also expanding into rentals of electric bikes and scooters. Further, Uber is developing self-driving vehicles.

IPO 2: Lyft

On top of Uber, Lyft is considering an initial public offering in early 2019 that could value the San Francisco-based company at $15 billion or more. But it could go higher, depending on investments it could receive before its IPO launch.

Lyft is much smaller than Uber but is currently its toughest competitor in the U.S.

Lyft started expanding outside the country last year. Like Uber, Lyft sees bike and scooter rentals as a way to expand. In July, Lyft acquired Motivate, one of the largest bike-sharing companies in the U.S., for a reported $250 million. Self-driving vehicles also are on Lyft's agenda, as is the case with Uber.

In March, Lyft said revenue for 2017 was $1 billion, up 168% from the year before. But it did not disclose its profit or loss for the year.

IPO 3: Palantir Technologies

Palantir Technologies was founded in 2003 in the San Francisco suburb of Palo Alto by famed investor Peter Thiel, a PayPal ( PYPL) co-founder, and Alex Karp, Palantir's current chief executive.

The company might debut next year or in 2020 at a valuation that could reach $41 billion, according to the Wall Street Journal. People familiar with Palantir's plans caution that they remain in flux, the Journal said.

Palantir expects to take in $750 million in revenue this year. The secretive company provides data analytics tools to companies and governments. Its technology also has been used by counterterrorism experts.

IPO 4: Airbnb

Founded in 2008 and based in San Francisco, Airbnb has been less specific than its peers in committing to an IPO. At a technology conference in May, Chief Executive Brian Chesky said he expected to go public in 2019, "but I don't know if we will."

Chesky said he wanted to be sure the move would benefit investors before going forward.

The company currently has a valuation near $30 billion.

Last month Airbnb hired a new chief technology officer, Aristotle "Ari" Balogh. He most recently served as a Google vice president of engineering. Balogh helped build the infrastructure and data platforms behind Google Search.

IPO 5: Slack Technologies

Founded in 2009, Slack Technologies is the developer of a cloud-based set of proprietary team collaboration tools and services. Slack is based in San Francisco.

Slack is reportedly primed for an initial public offering in early 2019, with an estimated valuation above $7 billion. That's based on a $427 million funding round received in August. The company's name is an acronym for "Searchable Log of All Conversation and Knowledge."

The IPO will build on Slack's recent moves to expand its platform and improve existing tools. In May, Slack said it had 8 million daily active users, with 3 million paid users.

YOU MIGHT ALSO LIKE:

Buying IPOs Can Be Tricky, So Do Your Homework

The 2017 Market For IPOs Was Supposed To Be Huge — What Happened?

IPOs' Stock News And Analysis: Find Today's Top New Issues

The post These Five Big-Name IPOs Could Rival Dot-Com Era — If They Wanted appeared first on Investor's Business Daily.


50. Amazon (AMZN) Stock Quotes, Company News And Chart AnalysisПт., 09 нояб.[−]
X

AMZN Stock Quote | AMZN Ratings

Amazon Stock News & Analysis

Sonos Upbeat Earnings Report Is Music To Wall Street's EarsPremium sound system maker Sonos got toes tapping with the upbeat tempo of its September-quarter earnings report. Sonos stock jumped Friday on the news. The Santa Barbara, Calif.-based company late Thursday said... Read More
Big-Screen TVs, Smart Speakers Are Hot Gadgets This Holiday SeasonHoliday shoppers plan to load up on consumer electronics this year, with big-screen TVs among the most sought-after items. "People want the biggest and best TV they can have in their living... Read More
Retail Sales Rebound 0.8% In October As Amazon, E-Commerce Gain; Dow Stays FlatRetail sales grew 0.8% in October, the Commerce Department reported Thursday. Outside of autos, retail sales rose 0.7%. The confirmation that consumer spending remains solid came as Dow Jones component Walmart topped earnings... Read More
IBD Stock Of The Day: Kornit Digital Breaks Out On EarningsKornit Digital is the IBD Stock Of The Day as the maker of digital printing technologies for the garment, apparel and textile industries continues its streak of triple-digit earnings growth. Kornit Digital stock... Read More
Amazon Headquarters: $5 Billion And 50,000 Jobs For Two HubsAmazon.com will invest $5 billion and create more than 50,000 jobs across two new Amazon headquarters it's planning for New York City and the Washington, D.C., suburb of Arlington, Va., the company... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

More Technology Stocks Coverage

FANG Stocks News: Facebook, Amazon, Netflix, Google

Apple (AAPL) Stock Quotes And Company News

Tesla (TSLA) Stock Quotes And Company News

View More Tech Stocks

The post Amazon (AMZN) Stock Quotes, Company News And Chart Analysis appeared first on Investor's Business Daily.


51. Chip Stocks To Watch And Semiconductor Industry NewsПт., 09 нояб.[−]

Chip stocks range from giants like Intel ( INTC), Qualcomm ( QCOM) and Taiwan Semiconductor ( TSM) down to lesser-known names like Qorvo ( QRVO) and Microchip Technology ( MCHP), providing the underpinnings for all types of devices, from giant servers down to smartphones.

X

The chipmakers power much of the world's technology, making it possible for loved ones to talk face-to-face from across an ocean or for Wall Street to move billions of dollars in the blink of an eye.

Never has the sector been more competitive, with more than 750 companies vying globally to build the insides of the next hot device or power future megacomputers. Investors will find it tricky to navigate the sector.

Bookmark this page to stay on top of the latest news on chip stocks and the semiconductor sector as a whole.

Chip Stocks & Semiconductor Industry News And Analysis

Nvidia, Applied Materials Rocked By Anemic Sales GuidanceGraphics-chip maker Nvidia and semiconductor equipment supplier Applied Materials saw their shares pounded early Friday after offering weak guidance for the current quarter. Nvidia stock stayed down, but Applied Materials stock rebounded to... Read More
Dow Leads Stock Market Today As These 5 Big Caps RallyThe key market indexes ended mixed after sharply paring early losses in the stock market today. The Nasdaq was in the black heading into the close, but gave up its gains to... Read More
Stock Market Volatile As Apple, Macy's, Home Depot, Nvidia Tumble: Weekly ReviewThe new stock market uptrend quickly came under pressure as the Dow Jones, S&P 500 and Nasdaq composite's extended losses continued into the new week. Apple plunged as suppliers and analysts pointed... Read More
Tech Stocks Recover After Early Downdraft; Applied Materials Reverses HigherIt was another volatile session for the stock market Friday as earnings from Nvidia and Applied Materials cast a pall on tech stocks early. But after falling 1.2% intraday, the Nasdaq composite... Read More
Trump Trade Comments Boost Dow Jones; These 6 Growth Stocks Take Market HelmWire reports pointing to a willingness by President Donald Trump to prevent a further escalation in the U.S.-China trade war boosted Wall Street on Friday. The Dow Jones industrial average led other... Read More
Sell-Off In Semiconductor Stocks Hits Nasdaq In Another Volatile SessionA wreck in semiconductor stocks sent the Nasdaq composite down nearly 1% at midday Friday, as the main indexes pared losses, but the rebound faded. The Nasdaq was down 0.9% after opening... Read More
Dow Jones Futures: Nvidia, Applied Materials Dive On Guidance, Slam Chip StocksDow Jones futures, S&P 500 futures and especially Nasdaq futures lost significant ground. Late Thursday, Nvidia, Applied Materials, Nordstrom and Williams-Sonoma plunged on earnings reports and guidance. Worse, that had a ripple effect... Read More
View More Chip Stock News

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

RELATED:

Best Stocks To Buy And Watch

View More Tech News & Analysis

The post Chip Stocks To Watch And Semiconductor Industry News appeared first on Investor's Business Daily.


52. Activision Stock Tumbles On Weak Holiday-Quarter OutlookПт., 09 нояб.[−]

Video game publisher Activision Blizzard ( ATVI) late Thursday delivered mixed third-quarter results and gave disappointing guidance for the holiday quarter. Activision stock fell in extended trading.

X

The Santa Monica, Calif.-based company earned an adjusted 52 cents a share on net bookings of $1.66 billion in the September quarter. Analysts expected Activision earnings of 50 cents a share on sales of $1.66 billion, according to Thomson Reuters. In the year-earlier period, Activision earnings were 60 cents a share and sales were $1.9 billion.

For the current quarter, Activision guided to adjusted earnings per share of $1.27 on net bookings of $3.05 billion. Wall Street was modeling Activision earnings of $1.34 a share on sales of $3.06 billion.

Activision stock sank more than 9% in after-hours trading on the stock market today. During the regular session, Activision stock dropped 3.5% to 62.79.

Activision Earnings: New Games Released

"Activision Blizzard's results for Q3 exceeded our prior outlook as we continue to entertain large audiences, drive deep engagement, and attract significant audience investment across our franchises," Chief Executive Bobby Kotick said in a news release.

Over the last three months, the company's three divisions have delivered major content releases for their global franchises. Activision launched "Call of Duty: Black Ops 4." Blizzard released "World of Warcraft: Battle for Azeroth." And King launched "Candy Crush Friends Saga."

For the full year, Activision expects adjusted earnings per share of $2.58 on sales of $7.475 billion. Wall Street was modeling earnings of $2.64 and sales of $7.48 billion.

RELATED:

After Hours: These 5 Stocks Are Notable Movers On Earnings; Futures

Take-Two Stock Drops Despite Upbeat Quarterly Earnings Report

Activision Blizzard Mobile Game 'Diablo Immortal' Gets Upbeat Outlook

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Activision Stock Tumbles On Weak Holiday-Quarter Outlook appeared first on Investor's Business Daily.


53. Yelp Stock Plunges As Quarterly Results Fall Short, Guidance LoweredПт., 09 нояб.[−]

Yelp earnings beat estimates during the third quarter but revenue fell short, as the company lowered revenue guidance in its report Thursday. Yelp stock plunged on the news.

X

Reporting after the close, Yelp ( YELP) also lowered 2018 guidance below expectations.

The company reported earnings of 17 cents a share, beating analyst estimates for 10 cents, as polled by Thomson Reuters. Yelp said revenue was $241 million, missing views for $245 million.

The company provides a local-search service powered by crowd-sourced reviews.

Yelp stock fell 26%, near 31.85, during after-hours trading on the stock market today.

Yelp Earnings: Revenue Falls Short

The company said it now expects revenue for 2018 to be in the range of $938 million to $942 million. The midpoint of $940 million is below the $963 million analyst estimate average.

In its letter to shareholders, Yelp said the pace of new account growth that it saw in the first half of 2018 slowed in the third quarter.

'This deceleration was unexpected given the strong momentum and positive customer feedback we saw throughout the first half of the year," Yelp said.

YOU MIGHT ALSO LIKE:

After Hours: These 5 Stocks Are Notable Movers On Earnings; Futures

The Big Picture: Stock Market Keeps Its Cool As Breakouts Pick Up

Why You Should Buy On The Stock Market Follow-Through Day

The post Yelp Stock Plunges As Quarterly Results Fall Short, Guidance Lowered appeared first on Investor's Business Daily.


54. Dropbox Stock Jumps As Quarterly Earnings Stomp EstimatesПт., 09 нояб.[−]

Dropbox earnings and revenue came in after the market close Thursday ahead of expectations. Dropbox stock rose in after-hours trading.

X

The company reported adjusted earnings of 11 cents per share, beating analyst estimates for 6 cents, as polled by Zacks Investment Research. A provider of data-storage and business-collaboration services, Dropbox ( DBX) reported revenue of $360.3 million, up 26% from the year-ago period. That beat predictions of $352 million.

Dropbox stock was up 8.7%, near 26.85 during after-hours trading on the stock market today. The company held its initial public offering in March, pricing Dropbox stock at 21.

Paying users in the third quarter totaled 12.3 million, up from 10.4 million for the same period last year.

The company ended the quarter with cash and equivalents of $1 billion.

"We delivered another quarter of strong execution, driving healthy top line growth and expanding free cash flow margins," Dropbox Chief Executive Drew Houston said in prepared remarks.

YOU MIGHT ALSO LIKE:

After Hours: These 5 Stocks Are Notable Movers On Earnings; Futures

The Big Picture: Stock Market Keeps Its Cool As Breakouts Pick Up

Why You Should Buy On The Stock Market Follow-Through Day

The post Dropbox Stock Jumps As Quarterly Earnings Stomp Estimates appeared first on Investor's Business Daily.


55. Trade Desk Stock Falls As Earnings Beat, Guidance Edges By EstimatesПт., 09 нояб.[−]

Trade Desk ( TTD) on Thursday reported third-quarter profit that topped estimates and revenue that edged by views. The ad technology firm also issued December-quarter guidance just above expectations. Trade Desk stock fell in after-hours trading.

X

Earnings came in at 65 cents a share, up 86% from a year ago, with revenue rising 50% to $118.8 million, topping analyst estimates. A year earlier, Trade Desk earnings were 35 cents a share on sales of $79.4 million.

Analysts expected Trade Desk earnings of 49 cents on sales of $117.4 million for the period ended Sept. 30, according to Zacks Investment Research.

Trade Desk reported Q3 EBITDA — earnings before interest, taxes, depreciation and amortization — of $36.6 million, edging by estimates of $34.4 million.

For the December quarter, Trade Desk forecast revenue of $147 million. Analysts had projected $144.7 million.

Trade Desk Guidance Light

Trade Desk said it expects fourth-quarter EBITDA of $53 million. Analysts had modeled $52 million.

Trade Desk stock tumbled 11.7% to 107.84 on the stock market today. The advertising firm's stock had been ranked No. 5 in the IBD 50 roster of growth companies.

The company enables agencies and other ad buyers to purchase online advertising through its self-service platform. Automated buying tools, called programmatic advertising, are used in nearly 80% of U.S. digital ad purchases, says eMarketer.

Widely used in social and mobile media, programmatic tools are also making their way into connected TV. Trade Desk stock has been getting a boost from mobile video and web TV. The company also has expanded into China.

YOU MAY ALSO LIKE:

After Hours: These 5 Stocks Are Notable Movers On Earnings; Futures

Google & Facebook Vs. Amazon & AT&T: The Digital Ad Showdown Begins

Cloud Computing Spurs Business Communication Bonanza, Lifts RingCentral, Slack

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Trade Desk Stock Falls As Earnings Beat, Guidance Edges By Estimates appeared first on Investor's Business Daily.


56. CommScope To Acquire Arris For $7.4 Billion In Telecom Equipment MergerПт., 09 нояб.[−]

CommScope Holding ( COMM) has agreed to buy Arris International ( ARRS) in a $7.4 billion merger that combines a wireless network gear maker with a cable equipment provider. CommScope stock plunged on the deal's announcement.

X

Telecom gear maker CommScope will pay $5.9 billion in cash and assume $1.5 billion in debt. CommScope agreed to pay $31.75 a share, a 14% premium of Arris's closing price on Wednesday. Arris stock had jumped 11.3% Wednesday on word of a deal. Arris stock surged another 10.4% on Thursday to close at 30.68.

Shares in CommScope tumbled 20% to 19.56 on the stock market today, continuing a sell-off that began when negotiations with Arris first surfaced.

The Carlyle Group will invest $1 billion in CommScope to provide financing for the deal, the telecom gear maker said.

CommScope Diversifies With Acquisition

CommScope Chief Executive Eddie Edwards will run the combined company. Arris CEO Bruce McClelland will join the combined company.

McClelland could succeed Edwards long-term, analysts say. CommScope will remain headquartered in Hickory, N.C.

Arris manufactures cable set-top boxes and other equipment. The acquisition enables CommScope to diversify its customer base away from wireless, said George Notter, a Jefferies analyst in a report. The deal also comes as cable firms such as Comcast ( CMCSA) and Charter Communications ( CHTR) start selling wireless services.

YOU MAY ALSO LIKE:

How Cloud Computing Upgrade Cycle To 400G Could Drive Tech Stocks

Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The Edge

Cybersecurity Stocks To Watch Amid Shift To Cloud, AI Software Tools

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post CommScope To Acquire Arris For $7.4 Billion In Telecom Equipment Merger appeared first on Investor's Business Daily.


57. Web-Browser Maker Opera Touts Advertising, User GrowthПт., 09 нояб.[−]

Web-browser maker Opera ( OPRA) has had a rough ride as a publicly traded company, but its second quarterly report since its initial public offering provided investors with some good news. Opera stock soared on Thursday.

X

The Oslo, Norway-based software firm early Thursday said it earned an adjusted 12 cents a share on revenue of $44.7 million in the third quarter. On a year-over-year basis, Opera earnings per share were flat while sales climbed 17%.

For the fourth quarter, the company expects revenue to rise 29% year over year to about $50 million. It did not give a target for earnings per share. Analyst estimates have yet to be posted.

In addition to third-quarter earnings, Opera also announced a share-repurchase program of up to 1.5 million U.S. shares.

Earnings Report Lifts Opera Stock

Opera stock surged 14.7% to 7.42 on the stock market today. It went public on July 27 at $12 per American depositary share. It spiked to a record high of 15.62 on its first day on the market. Opera stock had been on a downward trajectory since late August. It hit an all-time low of 6.23 on Tuesday.

Opera makes web browsers for personal computers and mobile devices. It also is a player in digital content discovery and recommendation platforms.

In the Opera earnings report for the September quarter, the company generated 42.7% of its revenue from search and 39.4% from advertising. The remaining revenue came from technology licensing and sale of prepaid airtime and data. Advertising revenue rose 57% year over year in the quarter.

"We are excited to report another record quarter for both revenue and profits, as well as all-time highs for both smartphone and PC users," Chief Executive Yahui Zhou said in a news release. "We are successfully executing on our strategy to build new and engaging services and offerings on top of our existing assets."

He added, "We continue to focus our growth efforts on Africa, where our strong technology platform positions us on an attractive trajectory on top of compelling macro trends."

A top priority for Opera is its content platform Opera News, which reached 121.4 million monthly active users last quarter. The service added over 20 million users compared with the second-quarter average. Opera News uses artificial intelligence to present content to users.

The company's OPay service, a platform for mobile money, microcredit and e-commerce, also has been showing fast growth, Zhou said.

RELATED:

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Web-Browser Maker Opera Touts Advertising, User Growth appeared first on Investor's Business Daily.


58. Take-Two Stock Drops Despite Upbeat Quarterly Earnings ReportПт., 09 нояб.[−]

Take-Two Interactive Software ( TTWO) received at least nine price-target increases from Wall Street analysts following its better-than-expected September-quarter earnings report. But Take-Two stock dropped on Thursday.

X

Earnings for New York City-based Take-Two came in at an adjusted $1.05 a share. Net bookings were $583.4 million for its fiscal second quarter ended Sept. 30. Analysts expected Take-Two earnings of 93 cents a share on sales of $549.9 million, according to Thomson Reuters.

For the December quarter, the video game publisher predicted adjusted earnings of $2.55 a share on net bookings of $1.425 billion. That's based on the midpoint of its outlook. Wall Street was predicting $2.59 a share on sales of $1.35 billion.

The Take-Two earnings report disappointed investors with a profit forecast that was below views, despite the release of major game "Red Dead Redemption 2." The Western action game came out on Oct. 26 to rave reviews. It generated worldwide retail sales of over $725 million in its first three days of release.

Take-Two Stock Gunned Down On Earnings Outlook

Take-Two stock fell 5.3% to 119.14 on the stock market today.

Bernstein analyst Todd Juenger reiterated his outperform rating on Take-Two stock and raised his price target to 178 from 175.

"For RDR2 to exceed the expectations priced into the stock, step one was to sell at least 25 million units (lifetime)," Juenger said in a report to clients. "The game has already sold in 17 million units. The 25-million hurdle will clearly be exceeded."

Up next is the pending launch of an online service for Red Dead. The online component should keep players engaged for years and generate millions of dollars in microtransactions, he said. Red Dead Online will launch in beta test mode this month.

'Red Dead' Not Cannibalizing 'Grand Theft Auto'

In other news, "Red Dead" does not appear to be drawing players away from Take-Two's lucrative Grand Theft Auto Online service, Jefferies analyst Timothy O'Shea said in his note to clients.

"This is important because there is clear upside to numbers if Red Dead Online and GTA Online can coexist," he said.

O'Shea maintained his buy rating on Take-Two stock and upped his price target to 155 from 150.

In the September quarter, top performers for Take-Two included its Grand Theft Auto and NBA 2K game franchises.

'Red Dead' Launch Called 'Phenomenal Success'

Chief Executive Strauss Zelnick said he is ecstatic about the early success of "Red Dead Redemption 2."

"We had the biggest opening weekend in entertainment history: $725 million in retail sales," he told Investor's Business Daily. "That's bigger than any movie or video game or album or anything."

The game's sales of more than 17 million units in the first 10 days are more than the original "Red Dead" game sold in its eight years of sales.

"It's been phenomenally successful and we're incredibly excited," he said of RDR2.

RELATED:

'Red Dead' Game Publisher Take-Two Blasts Through Quarterly Estimates

Activision Blizzard Mobile Game 'Diablo Immortal' Gets Upbeat Outlook

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Take-Two Stock Drops Despite Upbeat Quarterly Earnings Report appeared first on Investor's Business Daily.


59. Endo Plans For Cellulite Drug In 2020 — Here's Why Investors BalkedПт., 09 нояб.[−]

Endo International ( ENDP) stock crashed Thursday as the generic drugmaker reportedly said it plans to launch its cellulite treatment in 2020. The drop came even though Endo earnings beat analyst expectations.

X

The results from two Phase 3 studies of the cellulite treatment failed to impress analysts. In one study, 7.6% of patients showed a highly significant improvement in the appearance of cellulite. In the other study, only 5.6% of patients met the same mark.

Although the results support Food and Drug Administration approval, Mizuho analyst Irina Koffler noted the responses in the late-stage studies were well below the 10.6% mark set in an earlier test.

"We were expecting stronger results," she said in a note to clients.

Still, Endo said on the post-earnings conference call with analysts that it plans to submit an application to the FDA for approval in the second half of 2019, according to Reuters. Then, it would launch the cellulite treatment in the latter part of 2020.

On the stock market today, Endo stock plunged 17.7%, to 13.19, in high volume. Endo stock has a best-possible Investor's Business Daily Relative Strength Rating of 99. The key metric tracks a stock's performance over the past 12 months.

Endo Earnings: Third-Quarter Sales, Profits Beat

For the third quarter, Endo earned 71 cents per share, excluding items, on $745.5 million in sales. Both metrics handily beat estimates from analysts polled by Zacks Investment Research for 59 cents and $697 million, respectively.

On a year-over-year basis, revenue dipped 5.3% and adjusted earnings fell nearly 22%.

Mizuho's Koffler attributed the sales beat to new launches and a lower tax rate. During the quarter, Endo's new antibiotic called ertapenem generated $25.8 million in sales. The drug is an authorized generic version of Merck's ( MRK) Invanz.

Endo reported strong growth for sales of emergency allergic reaction treatment Adrenalin, which jumped 40% to $35.5 million.

Sales of Xiaflex, Endo's biggest drug, increased 22% to $64.2 million. Xiaflex treats a disease that causes painful erections and a condition that can hinder proper finger movement.

For the year, Endo expects to earn $2.65-$2.75 per share, excluding items, on $2.87 billion to $2.92 billion in sales. The low end of both pieces of guidance topped analysts' estimates for $2.60 and $2.82 billion, respectively.

YOU MIGHT ALSO LIKE:

The Basics: How To Analyze A Stock's Cup-With-Handle Base

IBD Stock Of The Day

How To Trade: Should You Buy A Stock Ahead Of Its Earnings Report?

The post Endo Plans For Cellulite Drug In 2020 — Here's Why Investors Balked appeared first on Investor's Business Daily.


60. This Biotech Stock Briefly Edged Into Buy Zone On Earnings CrushПт., 09 нояб.[−]

Vanda Pharmaceuticals ( VNDA) flirted with a breakout Thursday after the biotech topped quarterly sales views and obliterated profit expectations thanks largely to a sleeping-disorder drug. Vanda stock rocketed 14.7%, to 23.46, in higher-than-average volume.

X

On the stock market today, Vanda stock briefly broke out of a consolidation with a buy point at 23.60. Shares were well above their 50-day moving average for the first time this month. But Vanda stock closed below that entry.

During the third quarter, Vanda earnings came in at 20 cents per share, excluding items. That crushed the view of analysts polled by Zacks Investment Research for 1 cent. In the year-earlier period, Vanda earnings posted a 3-cent loss per share.

Total revenue also climbed nearly 19% to $49.1 million, slightly above forecasts for $49 million. The lion's share of sales growth in Vanda earnings came from Hetlioz, which treats a sleeping disorder. Hetlioz sales jumped more than 34% to $29.9 million.

Sales of schizophrenia treatment Fanapt ticked up a fraction to $19.2 million.

Vanda Earnings: Sales Outlook

Vanda reiterated its full-year outlook for $180 million to $200 million in net product sales. Analysts called for $191 million in revenue. The biotech stock called for Hetlioz to generate $108 million to $118 million in sales. It sees $72 million to $82 million from Fanapt sales.

Vanda stock has Composite and Relative Strength ratings of 90 out of a best-possible 99 from Investor's Business Daily. Vanda stock is ranked No. 12 out of 515 biotech stocks. In morning action, biotech stocks collectively edged up a fraction.

Biotech stocks are currently ranked No. 49 out of 197 groups tracked by IBD.

YOU MIGHT ALSO LIKE:

New Option Strategy Limits Risk Around Earnings

How Many Shares Do You Buy For A Position? This Tool Does The Math

How To Trade Growth Stocks: Why You Should Buy On The Stock Market Follow-Through Day

The post This Biotech Stock Briefly Edged Into Buy Zone On Earnings Crush appeared first on Investor's Business Daily.


61. Roku Stock Dives As Streaming Video Platform Disappoints On GrowthПт., 09 нояб.[−]

Roku stock fell Thursday after the streaming video platform reported decelerating growth in the third quarter. Roku ( ROKU) also is facing new competition from cable giant Comcast ( CMCSA).

X

On the stock market today, Roku stock tumbled 22.3% to 45.74. It closed below its 200-day moving average line, a key support level. Roku stock hit a record high of 77.57 on Oct. 1. It went public at $14 a share in September 2017.

Late Wednesday, the Los Gatos, Calif.-based company said it lost 9 cents a share on sales of $173.4 million in the September quarter. Analysts expected it to lose 13 cents a share on sales of $171 million, according to Zacks Investment Research. Roku earnings got a boost from higher-than-expected hardware sales and gross profit. Platform sales, primarily advertising, came in lighter than expected in the third quarter.

Wedbush Securities analyst Michael Pachter said Roku stock has "outsized growth potential," but its results have to keep pace to justify its "premium valuation."

"Roku again beat expectations, but not as convincingly as it has in the past," Pachter said in a report. He reiterated his outperform rating and 12-month price target of 65.

Roku Earnings Report Shows Decelerating Sales Growth

The company reported year-over-year revenue growth of 39% in the third quarter. That's down from 57% growth in the second quarter. Its higher-margin platform segment saw sales rise 74% in the September quarter, vs. 96% growth in the June quarter and 106% growth in the March quarter.

Roku's streaming video platform is a popular way for TV viewers to access content from such internet services as Netflix ( NFLX), Amazon.com ( AMZN), Hulu and Alphabet's ( GOOGL) YouTube.

It sells streaming video hardware and licenses a smart-TV operating system to television makers. But advertising on its platform is its fastest-growing business. Roku sells advertising on its Roku Channel and third-party ad-supported channels.

Comcast Looks To Sell Streaming Video Hardware

Comcast next year plans to introduce a new product for broadband-only subscribers to access internet television services, CNBC reported Wednesday. It would aggregate certain popular streaming apps such as Netflix and Amazon, the report said. The device would come with a voice-activated remote control.

Needham analyst Laura Martin said Roku has been beating hardware rivals such as Amazon and Google.

"We don't expect Comcast to be any more successful at competing with Roku than Amazon and Google have been to date," she said in a report.

RELATED:

Roku Stock Falls Late Despite Beating Third-Quarter Estimates

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Roku Stock Dives As Streaming Video Platform Disappoints On Growth appeared first on Investor's Business Daily.


62. AstraZeneca Breaks Out As CEO Predicts 'Sustained Growth' StreakПт., 09 нояб.[−]

AstraZeneca ( AZN) stock bullishly broke out Thursday after the pharma giant returned to sales growth, claiming the third quarter to be "the start of a period of sustained growth for years to come."

X

On the stock market today, AstraZeneca stock popped 3.7%, to 40.65. AstraZeneca stock broke out of a flat base with a buy point at 40.26, in higher-than-average volume. Shares hit their highest point in four years.

During the third quarter, product sales grew 9% in constant currency to $5.27 billion.

Product sales spent the previous two quarters in decline, last growing 3% in constant currency in late 2017. The third quarter of 2018 was the pharma giant's best quarter of product sales growth in four years.

"Today marks an important day for the future of AstraZeneca, with the performance in the quarter and the year to date showing what we expect will be the start of a period of sustained growth for years to come," Chief Executive Pascal Soriot said in a prepared statement.

Sales Of Cancer Treatments Pop

Soriot identified cancer treatments Tagrisso, Imfinzi and Lynparza — the latter of which is being jointly developed and commercialized with Merck ( MRK) — as key drivers of growth. He also noted diabetes treatment Farxiga and asthma treatment Fasenra.

During the third quarter, Tagrisso brought in $506 million in sales, leading Imfinzi and Lynparza, which generated a respective $187 million and $169 million. Sales of cancer treatments in total grew 57% in constant currency to nearly $1.6 billion.

Farxiga sales grew 27% to $355 million. But total sales of AstraZeneca's cardiovascular, renal and metabolism drugs slipped 3% and were near $1.7 billion.

Asthma treatment Fasenra brought in $86 million, contributing to a 5% increase in sales of respiratory drugs. Total sales in that unit were $1.14 billion.

Revenue Beat?

But total third-quarter revenue of $5.34 billion dipped 13% in constant currency. That beat the view of analysts polled by Zacks Investment Research for $5.12 billion. Other analysts expected $5.49 billion in total revenue, but FactSet modeled $5.27 billion.

Core earnings of 71 cents per share — which excludes some items — fell 33%. But that beat expectations for 33 cents from Zacks and about 65 cents from FactSet. Other views suggested the pharma giant would earn 40 cents per share, excluding items.

For the year, AstraZeneca guided to adjusted earnings of $3.30-$3.50 per share and a low-single digit percentage increase in product sales. Analysts had forecast adjusted income of $1.67 per share on $22.2 billion in revenue.

YOU MIGHT ALSO LIKE:

The Basics: How To Analyze A Stock's Cup-With-Handle Base

IBD Stock Of The Day

How To Trade: Should You Buy A Stock Ahead Of Its Earnings Report?

The post AstraZeneca Breaks Out As CEO Predicts 'Sustained Growth' Streak appeared first on Investor's Business Daily.


63. Apple Stock Gets Price-Target Hike On Services PotentialПт., 09 нояб.[−]

Apple's ( AAPL) services business is "taking the growth baton from iPhone," Morgan Stanley said Thursday. The investment bank raised its price target on Apple stock after studying the growth potential for the company's broad services business.

X

Morgan Stanley analyst Katy Huberty reiterated her overweight rating on Apple stock and upped her price target to 253 from 226. Apple stock dipped 0.4% to close at 208.49 on the stock market today.

"We think the market underestimates both growth and value impact of Apple's Services business," she said in a report to clients. "With a maturing, more engaged iOS user base and broadening portfolio of Services, we believe Services represents the key growth driver for Apple over the next 5 years."

Huberty believes Apple can sustain annual growth of at least 20% over the next five years. Wall Street analyst estimates have Apple's services business slowing to a growth rate of the midteens by fiscal 2020. Apple's fiscal 2019 started on Sept. 30.

Apple Stock Well Off Recent High

Apple stock hit a record high of 233.47 on Oct. 3. It tumbled last week after giving weaker-than-expected holiday sales guidance. Apple also spooked investors by announcing that it will no longer disclose unit sales of iPhones and other hardware. Analysts took that as a sign that iPhone unit sales are going to turn negative on a year-over-year basis soon.

"While the market read announced changes to Apple financial disclosures negatively last week, we view it as a corroborating data point that Apple is approaching a services-led margin inflection, similar to when Amazon ( AMZN) began breaking out AWS (Amazon Web Services) revenue and profits in Q1 2015," she said.

Apple services iCloud and AppleCare are approaching an inflection point for growth, following the App Store, she said.

Other key Apple services include Apple Music, Apple Pay and a possible streaming video offering.

RELATED:

Apple iPhone XR Sales Called 'Weaker Than Expected'

Apple Stock Dives On Light Outlook, Move To Hide iPhone Unit Sales

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Apple Stock Gets Price-Target Hike On Services Potential appeared first on Investor's Business Daily.


64. TripAdvisor Stock Jumps As Third-Quarter Earnings Crush EstimatesПт., 09 нояб.[−]

TripAdvisor ( TRIP) reported third-quarter results Thursday that smashed earnings estimates but slightly missed on revenue. TripAdvisor stock soared on the news.

X

A web travel site, TripAdvisor earnings came in at an adjusted 72 cents per share, soundly beating the average estimate of analysts polled by Zacks Investment Research for 47 cents. TripAdvisor earnings doubled from the year-ago period. It reported revenue of $458 million — up 4% and below analyst views for $468 million.

TripAdvisor stock rocketed 15.3% higher to close at 66.93 on the stock market today.

"What we worry about most for TripAdvisor is that Booking Holdings ( BKNG) and Expedia ( EXPE) will step up marketing spending in 2019," Needham analyst Laura Martin wrote in a note to clients. "Expedia and Booking will each report over $5 billion of marketing spending in 2018 compared with TripAdvisor's total revenue of $1.6 billion, which makes it hard for it to compete in the hotel business."

TripAdvisor Stock

Martin maintained a hold rating on the company. TripAdvisor stock is up 80% this year.

The company is a leading provider of online travel services, covering accommodations, airlines and restaurants. It also has more than 702 million user reviews.

Hotel revenue for the quarter was $305 million, down 2% from the year-ago period.

Booking, formerly known as Priceline, reported third-quarter earnings after the market close Monday that matched revenue estimates but fell short on earnings.

YOU MIGHT ALSO LIKE:

Square Stock Falls As Earnings Guidance Misses On Profit Margins

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post TripAdvisor Stock Jumps As Third-Quarter Earnings Crush Estimates appeared first on Investor's Business Daily.


65. Tesla Names Robyn Denholm To Replace Elon Musk As ChairmanЧт., 08 нояб.[−]

Tesla ( TSLA) chose Robyn Denholm to succeed Elon Musk as board chair, selecting an independent director to contend with the electric vehicle maker's mercurial chief executive officer following his run-ins with regulators and investors.

X

Denholm, 55, is of two women on Tesla's nine-member board. She will assume the Tesla chairman role immediately. A director since 2014, she will leave her position as CFO and head of strategy at Australian phone company Telstra Corp. at the end of her six-month notice period.

The appointment marks the end of an era for Musk, 47, who became chairman when he led a $7.5 million initial investment in Tesla in April 2004. Musk will remain CEO and a board director, but the fallout from his Twitter posts — which started with a claim that he secured funding and support to buy out investors at $420 a share — will last for years to come.

"While Denholm is technically an independent member of the board, she has been part of the Musk team for some time now and that suggests she will not be up to the task of checking Musk's worst instincts," said Stephen Diamond, a professor of law at Santa Clara University who specializes in corporate governance. "And, of course, that was the whole point of the SEC settlement."

Tesla SEC Settlement

Tesla was little changed before Thursday's open in the stock market. Tesla stock closed Wednesday at 348.16 in New York, up 12% this year.

Ceding the role of chairman was a condition of the accord Musk reached with the U.S. Securities and Exchange Commission in September to settle fraud charges related to his tweets on taking the company private.

In addition to agreeing to a three-year ban from serving in the job, Musk and Tesla agreed that the company would add two new independent directors to the board by late December. The Tesla board is actively continuing the search to fill those posts.

Denholm, who has only been in the Telstra CFO job for a little over a month, said she plans to devote herself full time to Tesla when her obligations to the Melbourne-based telecommunications company are complete. She won't take on another job.

"I believe in this company, I believe in its mission and I look forward to helping Elon and the Tesla team achieve sustainable profitability and drive long-term shareholder value," Denholm said in the statement.

Denhold Worked At Toyota, Sun Micro

Denholm's appointment may come as a surprise to some after she ruled herself out to Australian media just a month ago. It's not clear what convinced her to give up the CFO job at one of that country's most prominent companies for the even more high-profile task of chairing Tesla.

Denholm worked previously at Toyota Motor ( TM), Sun Microsystems and Juniper Networks ( JNPR), where she was chief financial and operations officer.

"Robyn has extensive experience in both the tech and auto industries, and she has made significant contributions as a Tesla board member over the past four years in helping us become a profitable company," Musk said in the statement. "I look forward to working even more closely with Robyn as we continue accelerating the advent of sustainable energy."

In typical style, he followed the official comment up with a tweet, thanking Robyn for "joining the team," adding that he looks "forward to working together."

Tesla Board Criticized

The Tesla board, which includes Musk's brother Kimbal, has long come under fire from corporate governance experts for lacking independence and being comprised of Musk loyalists.

Several are investors in or directors at SpaceX, the closely held rocket company that Musk also runs. That includes Steve Jurvetson, who's been on a leave of absence for roughly a year, since accusations of misconduct spurred his resignation from the venture capital firm he co-founded.

The new chairman isn't likely to influence Musk's behavior, said Frank Schwope, an analyst with NordLB in Germany.

"She's from Musk's inner circle and is unlikely to put obstacles in the way of decisions," Schwope said. "This exercise, brought on by the SEC deal, was to teach Musk a lesson and this is an easy way to fulfill the requirement."

Directors will create a permanent committee to ensure implementation of the terms of the SEC settlement, which include setting up procedures and controls to oversee Musk's communications — including his tweets. Tesla has to employ or designate a securities lawyer to review messages that senior officers send through Twitter and other social media.

A union-affiliated investor group and officials representing major pension funds in four states called on Tesla to go beyond the terms of the SEC settlement to fix its corporate governance issues. In a letter, the group called for the creation and release of a plan to refresh the board and for timelines to be set for some members to leave.

YOU MIGHT ALSO LIKE:

These 2 IBD 50 Stocks Skyrocket On Earnings; Futures

Tesla Stock Jumps As It Smashes Estimates, Shows A Profit

IBD Stock Of The Day

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

China Rival To Tesla Reports Wide Loss As Production Kicks In

The post Tesla Names Robyn Denholm To Replace Elon Musk As Chairman appeared first on Investor's Business Daily.


66. 'Red Dead' Game Publisher Take-Two Blasts Through Quarterly EstimatesЧт., 08 нояб.[−]

Video game publisher Take-Two Interactive Software ( TTWO) late Wednesday smashed Wall Street's targets for the September quarter and guided higher. Take-Two stock rose in extended trading.

X

The New York City-based company earned an adjusted $1.05 a share on net bookings of $583.4 million in its fiscal second quarter ended Sept. 30. Analysts expected it to earn 93 cents a share on sales of $549.9 million, according to Thomson Reuters. In the year-earlier period, Take-Two earned an adjusted $1.09 a share on net bookings of $557 million.

Take-Two said the successful launch of critically acclaimed Western game "Red Dead Redemption 2" gave it confidence to raise its guidance.

For the December quarter, Take-Two guided to adjusted earnings per share of $2.55 on net bookings of $1.425 billion. That's based on the midpoint of its outlook. Wall Street was predicting $2.59 in earnings per share on sales of $1.35 billion.

For the fiscal year ended March 31, Take-Two guided to adjusted earnings per share of $4.63 on net bookings of $2.85 billion. Wall Street was looking for $4.73 in earnings per share and $2.85 billion in sales.

Take-Two Stock Rises In After-Hours Trading

Take-Two stock increased 4.5% in after-hours trading on the stock market today. During the regular session, it climbed 1.7% to 125.81.

The company's top-performing game franchises last quarter included "Grand Theft Auto 5," "Grand Theft Auto Online," "NBA 2K19" and "WWE SuperCard."

"Looking ahead, we have a strong development pipeline across our labels and are exceedingly well positioned for long-term growth and margin expansion," Chief Executive Strauss Zelnick said in a news release.

RELATED:

Turtle Beach Skids On Slowing Sales Outlook For Gaming Headsets

Activision Blizzard Mobile Game 'Diablo Immortal' Gets Upbeat Outlook

The post 'Red Dead' Game Publisher Take-Two Blasts Through Quarterly Estimates appeared first on Investor's Business Daily.


67. Roku Stock Falls Late Despite Beating Third-Quarter EstimatesЧт., 08 нояб.[−]

Streaming video platform Roku ( ROKU) late Wednesday beat Wall Street's estimates for the third quarter and guided higher for the current quarter. But Roku stock tumbled in extended trading.

X

The Los Gatos, Calif.-based company lost 9 cents a share on sales of $173.4 million in the September quarter. Analysts expected it to lose 12 cents a share on sales of $169 million, according to Thomson Reuters. In the year-earlier period, Roku lost an adjusted 10 cents a share on sales of $124.8 million.

Roku raised its outlook for the full year based on its results. It now expects 2018 revenue to increase 42% year over year. That's up from its target of 40% given last quarter and 31% projected at the start of the year. Wall Street analysts had been modeling Roku's sales to rise 41% year over year to $722.85 million in 2018.

Roku stock fell 12.5%, near 51.50, in after-hours trading on the stock market today. During the regular session, Roku stock jumped 5.8% to 58.86.

The company also upped its outlook for full-year gross profit margin to 63%. That compares with its prior target of 61% last quarter and 43% at the start of the year.

Massive Shift To TV Streaming Just Starting

Roku executives cited a continued strong advertising business and better-than-expected demand for streaming players for its third-quarter beat.

"We are just starting to witness the massive transition of TV viewing and TV advertising to streaming," Roku Chief Executive Anthony Wood and Chief Financial Officer Steve Louden said in a letter to shareholders.

They added, "Roku is leading the way on the technology front with an operating system that is purpose-built for TV — vs. more heavyweight mobile operating systems — and innovative services like the Roku Channel."

Roku ended the third quarter with 23.8 million active accounts, up 43% year over year. That's up 1.8 million from the second quarter. Average revenue per user increased 37% year over year to a record $17.34.

RELATED:

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

Roku Stock Upgraded On Ad-Supported Streaming Video Growth

The post Roku Stock Falls Late Despite Beating Third-Quarter Estimates appeared first on Investor's Business Daily.


68. Alarm.com Stock Jumps As Earnings, Guidance Top EstimatesЧт., 08 нояб.[−]

Alarm.com Holdings ( ALRM) jumped late Wednesday after it reported third-quarter profit that blew past estimates. Alarm.com stock jumped 16.4% to 55 in after-hours trading on the stock market today.

X

A cloud security company, Alarm.com earnings were an adjusted to 36 cents a share. That was up 33% from a year ago, with revenue rising 24% to $111.8 million, topping analyst estimates.

A year earlier, Alarm.com earnings came in at 27 cents a share on sales of $90 million. Analysts expected Alarm.com earnings to come in at 25 cents a share on sales of $97 million for the period ended Sept. 30.

Alarm.com's biggest customers are companies that sell alarm-monitoring services.

Alarm.com Stock: Guidance Hiked

The company forecast full-year 2018 revenue of $408.6 million at its midpoint of guidance. Analysts had projected $390.4 million.

Alarm.com said it expects full-year earnings of $1.28 a share vs. estimates of $1.20.

"Our service providers continued to succeed in the market and expand their use of Alarm.com's smart home and business services," Chief Executive Steve Trundle said in a news release. "The Alarm.com team also extended our technology advantage with the introduction of new products, including our video analytics service."

YOU MAY ALSO LIKE:

After Hours: Seven Notable Stocks Moving On Earnings Late

Cybersecurity Stocks To Watch Amid Shift To Cloud, AI Software Tools

Looking For Potential Breakout Stocks? Start With These Lists

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Alarm.com Stock Jumps As Earnings, Guidance Top Estimates appeared first on Investor's Business Daily.


69. Square Stock Falls As Earnings Guidance Misses On Profit MarginsЧт., 08 нояб.[−]

Square ( SQ) on Wednesday reported adjusted third-quarter profit and revenue that topped expectations, but its December-quarter earnings outlook fell below estimates. Square stock dropped in after-hours trading.

X

Square said adjusted earnings were 13 cents a share, up 86% from a year ago, with revenue rising 51% to $882 million, topping estimates. A year earlier, Square earned 7 cents a share on sales of $585 million. Analysts expected Square to report earnings of 11 cents on sales of $861 million for the period ended Sept 30.

The company said adjusted revenue jumped 68% to $431 million, topping estimates of $414 million. Square said Q3 adjusted EBITDA — earnings before interest, taxes, depreciation and amortization —increased 107% to $71 million. That topped estimates of $65.9 million.

The digital payment processor's guidance for December-quarter profit and adjusted EBITDA missed views.

Square Margin Outlook Disappoints

Square said it expects adjusted profit per share of 12 cents to 13 cents, below analyst estimates of a 15 cents. The company forecast adjusted EBITDA in a range of $75 million to $80 million. Analysts had modeled $81.4 million.

The digital payment processor forecast revenue in a range of $895 million to $905 million. That beat estimates of $891 million.

Square stock fell 5% to 78.66 in after-hours trading in the stock market today.

Square stock had gained 123% as of the close of Wednesday's regular session. However, shares in Square are down from an intraday high of 101 on Oct. 1. Shares fell to 64.50 on Oct. 30 before clawing back a bit.

San Francisco-based Square's credit-card readers plug into mobile phones and tablets. In addition, the company provides software for point-of-sale systems and back offices in order to manage inventory and other tasks. It also offers customer relationship management software.

YOU MAY ALSO LIKE:

After Hours: Seven Notable Stocks Moving On Earnings Late

How Cloud Computing Upgrade Cycle To 400G Could Drive Tech Stocks

Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The Edge

Cybersecurity Stocks To Watch Amid Shift To Cloud, AI Software Tools

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Square Stock Falls As Earnings Guidance Misses On Profit Margins appeared first on Investor's Business Daily.


70. Qualcomm Stock Falls On Weak December-Quarter Sales GuidanceЧт., 08 нояб.[−]

Wireless chipmaker Qualcomm ( QCOM) late Wednesday beat Wall Street's targets for its fiscal fourth quarter, but it guided much lower on sales in the current quarter. Qualcomm stock fell in extended trading.

X

The San Diego-based company earned an adjusted 90 cents a share on sales of $5.8 billion in the quarter ended Sept. 30. Analysts expected it to earn 83 cents a share on sales of $5.52 billion. On a year-over-year basis, earnings per share and sales both fell 2%.

For the December quarter, Qualcomm expects to earn an adjusted $1.10 a share on sales of $4.9 billion. That's based on the midpoint of its guidance. Wall Street was modeling Qualcomm to earn 95 cents a share on sales of $5.57 billion.

Qualcomm stock fell 3.2% in after-hours trading on the stock market today. During the regular session, it dipped 0.7% to 63.21.

Apple-Qualcomm Case Headed To Trial

Based on its fiscal first-quarter targets, Qualcomm sees its earnings per share declining 12% year over year, with sales down 20%.

Qualcomm's protracted legal dispute with customer Apple ( AAPL) has hurt its financial results. Apple and its contract manufacturers are withholding patent royalty payments to Qualcomm until the dispute is resolved. Qualcomm claims Apple owes it $7 billion in unpaid royalties.

CNBC reported Wednesday that Apple is not in talks to settle the disagreement and is preparing for trial.

RELATED:

AMD Stock Rises As Amazon Web Services Uses Its Epyc Chips

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Qualcomm Stock Falls On Weak December-Quarter Sales Guidance appeared first on Investor's Business Daily.


71. CyberArk Stock Soars As Earnings Beat Estimates, Guidance Tops ViewsЧт., 08 нояб.[−]

CyberArk Software ( CYBR) late Wednesday reported third-quarter profit that blew past analyst estimates while its December-quarter earnings outlook also topped expectations. CyberArk stock jumped in after-hours trading.

X

The cybersecurity firm said that adjusted third-quarter earnings were 48 cents a share, up 92% from a year ago, with revenue rising 31% to $84.7 million, topping estimates. A year earlier, CyberArk earnings came in at 25 cents a share on sales of $65 million.

Analysts expected CyberArk earnings to be 27 cents on sales of $78.8 million for the period ended Sept. 30.

The cybersecurity firm said third-quarter license revenue jumped 29% to $46.1 million. That topped estimates of $42 million.

CyberArk Earnings Guidance Tops Views

CyberArk said it expects profit of 59 cents in the December quarter at its midpoint of guidance. Analysts had projected earnings of 51 cents a share.

The cybersecurity firm said it expects revenue in a range of $94.75 million to $96.25 million. Analysts had predicted $95 million.

Hackers often aim to compromise networks by targeting employees or management with administrative access to company computer systems. CyberArk's software monitors and manages privileged accounts.

CyberArk stock jumped 10.4% to 79.15 in after-hours trading on the stock market today.

Shares in CyberArk had gained 61% from a year ago as of Wednesday's market close. IBD's Computer-Software Security group is ranked No. 43 out of 197 industry sectors.

YOU MAY ALSO LIKE:

After Hours: Seven Notable Stocks Moving On Earnings Late

How Cloud Computing Upgrade Cycle To 400G Could Drive Tech Stocks

Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The Edge

Cybersecurity Stocks To Watch Amid Shift To Cloud, AI Software Tools

Improve Your Investing Results With This Simple 3-Step Routine

The post CyberArk Stock Soars As Earnings Beat Estimates, Guidance Tops Views appeared first on Investor's Business Daily.


72. Twilio Stock Surges As Communications Software Drives Revenue GrowthЧт., 08 нояб.[−]

Twilio ( TWLO) stock rocketed more than 35% higher Wednesday as analysts cheered the company's accelerating revenue growth.

X

The maker of communications software late Tuesday reported third-quarter revenue of $169 million, up 68%. The company said earnings were 7 cents vs. an 8-cent loss a year earlier.

"Twilio delivered revenue of $168.9 million, which is 12% above the midpoint of guidance and, outside of last quarter, is the largest beat in the company's history, and representing its fourth straight quarter of acceleration," Piper Jaffray analyst Alex Zukin said in a report to clients.

Twilio stock catapulted by 35.4% to close at 96.19 on the stock market today. With the gain, it surged past a technical buy point of 88.98.

New Cloud Software

Twilio's core product has been a software platform that app developers use for text messaging and other communications. The company enables app developers to embed software interfaces for programs used in messaging, voice, chat and video.

Twilio early this year rolled out its own Flex brand of cloud software for corporate customer-service departments.

For the December quarter, Twilio said it expects revenue of $184 million, topping predictions of $161 million. Twilio forecast earnings in a range of 3 to 4 cents a share. Analysts had estimated a 2-cent profit.

Twilio in October agreed to buy SendGrid ( SEND) for $2 billion in stock. SendGrid sells a cloud-based email marketing platform.

"We believe Twilio has a significant opportunity ahead, with future incremental growth coming from upselling Flex offerings and cross-selling voice/text products to SendGrid's customer base," said Ittai Kidron, an Oppenheimer analyst, in a report.

YOU MAY ALSO LIKE:

Cloud Computing Spurs Business Communication Bonanza, Lifts RingCentral, Slack

Cloud Computing: Find Top Cloud Stocks And Track Industry Trends

Improve Your Investing Results With This Simple 3-Step Routine

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Twilio Stock Surges As Communications Software Drives Revenue Growth appeared first on Investor's Business Daily.


73. Why This Highly Rated Medical Tech Stock Could Expand Its Market By 70%Чт., 08 нояб.[−]

Abiomed ( ABMD) stock surged Wednesday after an analyst upgraded it ahead of a key presentation for its pump used by heart-attack patients. On the stock market today, Abiomed stock leapt 5.7%, to 412.10.

X

Over the weekend, Abiomed will present data from a study of its Impella CP heart pump. If successful, Abiomed could expand its total addressable market by 230,000 patients in the U.S.

The study "could result in a paradigm shift from the current standard of care and drive an inflection in valuation," Morgan Stanley analyst David Lewis said in a note to clients. He upgraded Abiomed stock to an overweight rating and raised his price target by 100 to 496.

Abiomed stock is highly rated with a best-possible Investor's Business Daily Composite Rating of 99 and a Relative Strength Rating of 96 out of a top 99.

Abiomed's Heart Pump

Abiomed tested its Impella CP pump in 50 patients undergoing severe heart attacks.

Traditional heart-attack treatment focuses on speed, "equating a delay in treatment time to an increase in muscle loss." Despite improved treatment times, a quarter of patients with severe heart attacks experience heart failure after one year, Lewis said.

This suggests "additional strategies are needed to improve outcomes in this population," Lewis said.

So, Abiomed tested the theory that its Impella CP heart pump could take on the work of the heart's largest chamber for 30 minutes prior to treatment. The treatment involves using a catheter to place a stent and open up narrowed blood vessels for heart-attack patients.

"Simply put, the trial suggests that assisting the heart in pumping blood and letting it rest prior to treating the blockage in the coronary artery can result in improved outcomes," Lewis said.

Abiomed will provide the study results midmorning on Nov. 11 during the American Heart Association's Scientific Sessions in Chicago.

Heart-Attack Patient Market

Lewis is bullish on the study's chances. Easing the organ's burden gives the body a window of time to salvage tissue for heart-attack patients. This means the heart would incur only limited damage from lacking blood supply.

If successful, Abiomed would add to its current 335,000-patient market in the U.S., he said.

"Assuming a $20,000 average sales price for Impella implies an incremental $4.5 billion annual market opportunity," he said. "But Abiomed will need to run a larger trial prior to approval for indication expansion into STEMI (a severe form of heart attack)."

He assumes Abiomed could grab approval in 2023. That's based on one year of enrollment in a study, a year of patient follow-up and a year for approval.

YOU MIGHT ALSO LIKE:

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Breakouts Identify Stocks On The Rise With Big Potential

Earnings Calendar, Analyst Estimates And Stocks To Watch

The post Why This Highly Rated Medical Tech Stock Could Expand Its Market By 70% appeared first on Investor's Business Daily.


74. Etsy Stock Soars As Third-Quarter Results Beat EstimatesЧт., 08 нояб.[−]

Etsy stock rocketed higher by double-digits Wednesday, following its quarterly earnings report late Tuesday that beat estimates. Etsy ( ETSY) also raised revenue guidance for the year.

X

In its third-quarter report after the market close Tuesday, Etsy earnings came in at an adjusted 15 cents a share. That's up 36% from the year-ago period and beat analyst estimates of 7 cents. Revenue rose 41% to $150.3 million, ahead of forecasts for $149.9 million.

Etsy stock soared 23.7%, closing at 50.01 on the stock market today. The stock jumped above its 50-day moving average in high volume.

The company's e-commerce platform deals in handmade goods, vintage items and other arts and crafts. Gross merchandise sales topped $922.5 million in the third quarter, up 20% from the year-ago period.

"Etsy posted an impressive third quarter and we think that product improvements are driving a higher sustainable growth rate," KeyBanc Capital Markets analyst Edward Yruma wrote in a report to clients. He has a price target of 59 on Etsy stock and a rating of overweight.

Etsy Guidance Raised

In the Etsy earnings report, the company raised 2018 guidance for gross merchandise sales and revenue. It expects gross merchandise sales growth in the range of 19% to 20%, up from previous guidance of 18% to 20%.

It expects revenue for 2018 in the range of $596 million to $600 million. That's up from previous guidance of $587 million to $596 million.

Etsy also announced the approval of a plan to repurchase up to $200 million of its common stock. Etsy stock has more than doubled in price this year. The company held its initial public offering in June 2015, pricing shares at 16.

YOU MIGHT ALSO LIKE:

Why The Split Congress May Be The Best Stock Market Election Outcome

Dow Jones Futures Jump On Election Results; 7 Big Movers On Earnings

The post Etsy Stock Soars As Third-Quarter Results Beat Estimates appeared first on Investor's Business Daily.


75. Dish Stock Falls As Pay-TV Subscriber Losses Accelerate, Profit BeatsЧт., 08 нояб.[−]

Dish Network ( DISH) reported third-quarter profit Wednesday that topped expectations but the satellite TV broadcaster lost a net 341,000 in pay-TV customers. Dish stock rebounded during the company's earnings call after falling more than 3% in earlier trading.

X

The satellite TV broadcaster reported profit of 82 cents a share, up 44% from a year earlier. Dish earnings showed revenue fell 5% to $3.4 billion, in line with estimates. A year earlier, Dish earnings came in at 57 cents a share on sales of $3.58 billion. Analysts expected Dish earnings of 67 cents on sales of $3.4 billion for the period ended Sept. 30.

Dish said it lost 367,000 satellite TV customers in the September quarter. That was partially offset by an added 26,000 subscribers for its Sling-branded web TV services. Sling growth, though, has been decelerating. In the September 2017 quarter, Dish added a total of 16,000 net pay-TV customers.

Dish Earnings: Univision Woes

Dish's programming dispute with Univision Communications elevated subscriber losses, says Craig Moffett, analyst at MoffettNathanson.

"It is likely that as many as 10% of Dish's subscribers are on their Dish Latino package ... and for these subscribers, Univision is almost certainly the majority of their viewing," Moffett said in a report to clients. "Dish's satellite subscriber losses were much worse than expected, with subscriber growth re-accelerating to an 8.7% decline, no doubt in no small measure because of the Univision blackout."

Dish Stock: 5G Troubles

Dish has amassed wireless spectrum for 5G wireless services. But the value of its airwaves has been undercut by the proposed merger of T-Mobile US ( TMUS) with Sprint ( S) as well as upcoming government auctions.

Dish's attempts to find a wireless or internet partner to build out a network has turned up empty. The pay-TV company needs to build out a wireless network soon or it could lose spectrum licenses.

Verizon Communications ( VZ) has stated no interest in acquiring the declining satellite TV business.

Dish stock climbed 2% to close at 32.12 on the stock market today.

YOU MAY ALSO LIKE:

How Cloud Computing Upgrade Cycle To 400G Could Drive Tech Stocks

Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The Edge

Cybersecurity Stocks To Watch Amid Shift To Cloud, AI Software Tools

Improve Your Investing Results With This Simple 3-Step Routine

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Dish Stock Falls As Pay-TV Subscriber Losses Accelerate, Profit Beats appeared first on Investor's Business Daily.


76. This Pharma Stock Broke Out In Bullish Fashion — Here's WhyЧт., 08 нояб.[−]

Horizon Pharma ( HZNP) stock broke out in bullish fashion Wednesday after topping third-quarter views on gout treatment sales that spiked 64% year over year.

X

On the stock market today, Horizon stock jumped 16%, to 22.44. Earlier, Horizon stock touched a two-year high. Shares broke out of a consolidation with a buy point at 21.35 in higher-than-average volume.

Piper Jaffray analyst David Amsellem called Horizon stock "one of the most attractive longer-term growth stories among mid-to-larger cap pharma companies." He reiterated his overweight rating and 25 price target on Horizon stock.

Total revenue of $325.3 million and adjusted profit of 65 cents per share easily topped analyst estimates for $311.8 million and 49 cents, respectively, Amsellem said. On a year-over-year basis, revenue grew 20% and adjusted earnings popped 150%.

Gout Treatment Sales Fly

But analysts were more interested in sales of gout treatment Krystexxa. Krystexxa brought in $70.2 million in sales, flying 64% year over year. That beat expectations for $68.6 million in sales of the gout treatment, Mizuho analyst Irina Koffler said in a note to clients.

Horizon reiterated its guidance for full-year sales of the gout treatment to grow 65%.

During the quarter, the total number of Krystexxa vials grew to around 5,000, advancing from 4,000 and 3,200 in the prior two periods, Piper Jaffray's Amsellem said.

"Notably, management stated that the volume growth this year is coming from both existing and new prescribers," he said. "This suggests to us that the growth is not simply a function of the growing body of data surrounding ways to mitigate the risk of immunogenicity."

Tests show that gout treatment with Krystexxa can result in abnormal immune reactions, or immunogenicity. But physicians are working to pair Krystexxa with medicines that could help ease those reactions, Amsellem said.

"That should drive not only more patient growth but also longer treatment duration," he said.

Horizon also is working to expand Krystexxa to patients with kidney disease. That's because patients with chronic gout often also have other disorders, including chronic kidney disease.

"Management suggested (without providing specifics) that it is gaining significant traction among this audience," Amsellem said.

Horizon also is working on a next-generation gout treatment known as HZN-003. The pharma plans to have a Phase 1 test in 2020. It's possible the newer gout treatment could require less frequent dosing relative to Krystexxa.

Ultrarare Disease Drugs Pop

Amsellem also noted that Horizon is seeing some success for its ultrarare disease drugs, Ravicti and Procysbi. During the quarter, Ravicti sales grew nearly 19% to $60.4 million. Sales of Procysbi advanced more than 23% to $41.4 million.

Ravicti treats urea cycle disorders. A urea cycle disorder results when a patient is deficient in one of six enzymes in the urea cycle. These enzymes are responsible for removing ammonia from the bloodstream. Elevated blood ammonia can cause brain damage, coma or death.

Procysbi is a treatment for an inherited condition called nephropathic cystinosis. In this, an amino acid called cystine builds up within the cells, causing damage. The disease can affect many systems in the body, especially the kidneys and eyes.

All together, sustainable and aggressive Krystexxa volume/sales, steady growth of Ravicti and Procysbi, and a future thyroid eye disease treatment position Horizon Pharma stock for a compound annual EBITDA — earnings before interest, taxes, depreciation and amortization — growth rate "that is solidly in the double digits," Amsellem said.

For the year, Horizon confirmed its prior guidance for $1.17 billion to $1.2 billion in net sales. It now expects adjusted EBITDA to be in the range of $420 million to $430 million.

YOU MIGHT ALSO LIKE:

Chart Reading For Beginners: 3 Telltale Clues To Look For In Your Stocks

Looking For The Next Nvidia? Start With These 3 Steps

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

The post This Pharma Stock Broke Out In Bullish Fashion — Here's Why appeared first on Investor's Business Daily.


77. IBD 50 Pharma Stock Topples As Cancer Drug Lags ExpectationsЧт., 08 нояб.[−]

Shares of IBD 50 stock Jazz Pharmaceuticals ( JAZZ) collapsed Wednesday after the drugmaker missed third-quarter expectations for cancer treatment Vyxeos and cut its guidance for 2018.

X

On the stock market today, Jazz stock toppled 14.6%, to 140.41, in massive volume. Jazz stock has a best-possible Investor's Business Daily Composite Rating of 99 and is No. 45 on the IBD 50.

Analysts remained bullish on Jazz stock after its third-quarter flop. Piper Jaffray analyst David Amsellem noted narcolepsy treatment Xyrem, the brand name for sodium oxybate, grew 18% to $357.3 million. But cancer treatment Vyxeos brought in $21.04 million, lagging by $12 million.

"Though it is not lost on us that Vyxeos is in choppy waters, we nonetheless continue to believe that the fortunes of Jazz ultimately are strongly tethered to the sustainability of the oxybate franchise," he said in a note to clients.

Jazz Stock Dips On Guidance Cut

Jazz also cut its guidance for Vyxeos sales for the second consecutive quarter. The pharma stock now sees full-year sales of $95 million to $110 million, down from its prior view for $115 million to $135 million.

"Management conceded that it continues to face barriers to broad Vyxeos adoption in secondary acute myeloid leukemia patients," Amsellem said.

Mizuho analyst Irina Koffler called the guidance cut "particularly frustrating" given the fact Jazz lowered its guidance for Vyxeos in the second quarter as well. She kept her neutral rating and 173 price target on Jazz stock.

Piper Jaffray's Amsellem noted Jazz's bigger opportunity continues to lie in Xyrem. Xyrem sales easily beat the consensus for $346.8 million. Further, volume grew 9% during the quarter.

"The key broader theme we would be mindful of is that Jazz is very much still and will continue to be an oxybate-focused company, given that Xyrem is likely to account for north of 80% of corporate EBITDA (earnings before interest, taxes, depreciation and amortization) in 2019," he said.

Xyrem will keep patent protection until 2023. At that point, sales of cancer treatment Vyxeos may become more consequential, he said.

YOU MIGHT ALSO LIKE:

Still The No. 1 Rule For Stock Market Investors: Always Cut Your Losses Short

Looking For The Next Breakout Stocks? Start With These Lists

CAN SLIM Trading: Can You Make Big Profits With Just A Little Cash? Yes, Here's The Way

The post IBD 50 Pharma Stock Topples As Cancer Drug Lags Expectations appeared first on Investor's Business Daily.


78. Apple iPhone XR Sales Called 'Weaker Than Expected'Чт., 08 нояб.[−]

Apple ( AAPL) is likely to lower production of its iPhone XR smartphones this quarter because of slower-than-forecast sales of the midrange handsets, an equity analyst said Wednesday. At the same time, Apple is seen boosting production of its high-end iPhone XS devices.

X

"After the first two weeks, we believe the iPhone XR sell-through rate continues to be weaker than we initially expected," Rosenblatt Securities analyst Jun Zhang said in a report to clients. "This leads us to believe that Apple may begin another round of iPhone XR production cuts for calendar Q4. We believe Apple may reduce production for the iPhone XR by an additional 4 million to 5 million units for calendar Q4."

Meanwhile, Apple may increase iPhone XS production by 1 million to 2 million units. That's due to promotions for the holiday season by some wireless carriers, Zhang said.

Component shipments to Apple's contract manufacturers began slowing this week, he said. That includes shipments of high-density interconnect circuit boards.

Chip Issues Could Be Slowing iPhone XR Production

The slowdown in component purchases could be related to quality issues related to power amplifier chips from Skyworks Solutions ( SWKS), Zhang said.

"It is rare for Apple to make such dramatic production changes before the holiday season," he said. "We will continue to track iPhone holiday season sell-through rates in order to see if the production cuts are more attributable to Skyworks' PA (power amplifier) quality issues or if Apple is taking a more conservative approach to prepare for further softness in demand."

Zhang reiterated his neutral rating on Apple stock with a price target of 200. Apple stock rose 3% to 209.95 on the stock market today.

He forecast Apple to ship 82 million iPhone units in the fourth quarter. That was unchanged from the same period a year earlier.

"Our 82-million-unit estimate faces downside risk if sell-through rates do not improve during the holiday season or if Skyworks' PA issue continues into calendar Q1," he said.

On Monday, Japan-based Nikkei reported that Apple has told contract manufacturers Foxconn and Pegatron to suspend plans for additional production lines dedicated to the iPhone XR.

The iPhone XR went on sale Oct. 26 after a week of preorders. It starts at $749 and features a 6.1-inch LCD screen. The iPhone XS and XS Max went on sale on Sept. 21, starting at $999 and $1,099, respectively. The iPhone XS features a 5.8-inch OLED screen, while the XS Max has a 6.5-inch OLED screen.

RELATED:

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

Apple Stock Dives On Light Outlook, Move To Hide iPhone Unit Sales

The post Apple iPhone XR Sales Called 'Weaker Than Expected' appeared first on Investor's Business Daily.


79. Turtle Beach Skids On Slowing Sales Outlook For Gaming HeadsetsЧт., 08 нояб.[−]

Turtle Beach stock received two price-target cuts on Wednesday amid signs of slowing growth ahead for the gaming headset maker.

X

Oppenheimer analyst Andrew Uerkwitz slashed his price target on Turtle Beach ( HEAR) to 24 from 35, but reiterated his outperform rating.

Wedbush Securities analyst Michael Pachter lowered his price target to 30 from 42, but kept his outperform rating.

Turtle Beach stock tumbled 13% to 18.89 on the stock market today. The stock notched a four-year high of 34.50 on Aug. 7.

The San Diego-based company late Tuesday posted better-than-expected results for the third quarter and guided above views for the fourth quarter. Some news accounts indicated that Turtle Beach fell short of expectations due to reports of analyst estimates being higher.

Turtle Beach sales growth is expected to decelerate for the third quarter in a row in the December quarter. And 2019 will face some difficult comparisons to 2018.

Turtle Beach Facing Tough Year-Over-Year Comparisons

"We expect 2019 sales to show decline year over year due to the extraordinary growth in 2018," Uerkwitz said in a report.

That said, he still likes the company, which has a dominant market share in gaming headsets.

"As for 2019, while we believe a year-over-year sales decline is probable, the balance sheet transformation HEAR accomplished in 2018 will allow it to deliver stable long-term growth beyond 2019," Uerkwitz said.

Pachter noted that headset demand remains strong, but Turtle Beach is facing increased competition that could pressure average selling prices. Rivals include Logitech International ( LOGI), Kingston Technology, Razer, SteelSeries and others.

"We think Battle Royale-style games will continue to expand, and think that Turtle Beach's recent expansion into the PC gaming headset market could drive substantial growth long-term," Pachter said in a report. "However, while demand is clearly growing, ASPs are compressing and competition may make revenue growth elusive."

Pachter called Turtle Beach's fourth-quarter guidance "disappointing."

For the fourth quarter, Turtle Beach expects to earn $1.02 a share on sales of $94 million. Wall Street expected $1.01 a share on sales of $89.3 million. In the year-earlier period, the company earned $1.16 a share on sales of $79.7 million.

RELATED:

Track Stock Market Data On The S&P 500, Nasdaq, Dow Jones And SPDR ETFs

The post Turtle Beach Skids On Slowing Sales Outlook For Gaming Headsets appeared first on Investor's Business Daily.


80. Match Stock Tumbles As Revenue, Earnings Forecast DisappointСр., 07 нояб.[−]

Match Group stock fell after hours Tuesday as the company reported third-quarter revenue and profit that topped expectations but forecast December-quarter revenue below views.

X

Match Group ( MTCH) said adjusted earnings were 44 cents a share, up 131% from a year ago. Revenue rose 29% to $444 million, topping analyst estimates. A year earlier, Match Group earnings were 19 cents a share on sales of $343 million. Analysts expected Match Group earnings of 36 cents on sales of $436.6 million for the period ended Sept. 30.

The company reported EBITDA — earnings before interest, taxes, depreciation and amortization — of $165 million. That's up 37% from a year earlier and edging past estimates of $164 million.

The Match Group earnings report said the September quarter ended with 8.1 million paying subscribers, topping estimates of 8.04 million.

Match Group Stock Short Interest High

For the December quarter, Match Group forecast revenue of $445 million at its midpoint of guidance. Analysts had projected $454 million for the owner of mobile dating app Tinder and online dating websites.

Match Group said it expects fourth-quarter EBITDA in a range of $165 million to $170 million, below estimates of $171 million.

Match Group stock plunged 11% to 45.75 in after-hours trading on the stock market today. Heading into earnings, nearly half of Match Group's shares had been shorted, analysts said. Match Group stock was up 85% from a year ago as of Tuesday's market close.

Match Group Earnings: Parent IAC To Report

The company's parent, IAC/InterActiveCorp. ( IAC), reports earnings Wednesday. IAC consolidates the results of Match and Angi Homeservices. ( ANGI). IAC's other assets include Vimeo and search-engine Ask.com.

One overhang on Match stock has been that Facebook ( FB) could launch a competing mobile dating service. Another is that rival Bumble may launch an initial public offering next year.

Mobile dating app Tinder has been a growth engine for MatchGroup. But subscriber growth has slowed at older online dating websites, forcing Match Group to up investments in those websites.

Match Group is ranked No. 4 in the IBD 50 roster of growth companies.

YOU MAY ALSO LIKE:

How Cloud Computing Upgrade Cycle To 400G Could Drive Tech Stocks

Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The Edge

Cybersecurity Stocks To Watch Amid Shift To Cloud, AI Software Tools

Improve Your Investing Results With This Simple 3-Step Routine

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Match Stock Tumbles As Revenue, Earnings Forecast Disappoint appeared first on Investor's Business Daily.


81. Twilio Stock Jumps As Earnings, Guidance Top Analyst EstimatesСр., 07 нояб.[−]

Twilio stock jumped Tuesday after it reported third-quarter profit and revenue that beat expectations while its December quarter outlook also topped analyst estimates.

X

Twilio stock jumped 11.2% to 78.91 in after-hours trading on the stock market today.

A maker of communications software, Twilio ( TWLO) said earnings were 7 cents a share as the company swung to a profit from a year ago. The company also said revenue jumped 68% to $169 million.

A year earlier, Twilio reported a loss of 8 cents a share on sales of $100.5 million. Analysts expected Twilio to report earnings of 2 cents on sales of $150.5 million for the period ended Sept. 30.

For the December quarter, Twilio said it expects revenue of $184 million, topping predictions of $161 million. Twilio forecast earnings in a range of 3 to 4 cents a share. Analysts had estimated a 2-cent profit.

The company enables app developers to embed software interfaces for programs used in messaging, voice, chat and video. Twilio in October agreed to buy SendGrid ( SEND) for $2 billion in stock.

SendGrid sells a cloud-based email marketing platform. It competes with privately held SparkPost, MailChimp and others.

YOU MAY ALSO LIKE:

After Hours: 7 Top Stocks Moving On Earnings; Futures Eye Elections

How Cloud Computing Upgrade Cycle To 400G Could Drive Tech Stocks

Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The Edge

Cybersecurity Stocks To Watch Amid Shift To Cloud, AI Software Tools

Improve Your Investing Results With This Simple 3-Step Routine

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Twilio Stock Jumps As Earnings, Guidance Top Analyst Estimates appeared first on Investor's Business Daily.


82. This 99 Composite Rating Pharma Tumbled On Quarterly Sales LagСр., 07 нояб.[−]

Jazz Pharmaceuticals ( JAZZ) crumbled late Tuesday after the top-rated pharma stock missed sales expectations in the third-quarter and issued 2018 guidance that lagged analyst views.

X

In after-hours trading on the stock market today, Jazz stock collapsed 9%. During the regular session, Jazz stock rose 1.4%, to 164.41, on the stock market today. Jazz stock is highly rated with a best-possible Composite Rating of 99.

For its third quarter, Jazz earnings came in at an adjusted $3.58 per share, rising 11%, to top estimates from analysts polled by Zacks Investment Research for $3.33. Total revenue grew 18% to $469.4 million, but missed expectations for $482 million.

Xyrem, Jazz's biggest drug, generated $357.3 million in sales, rising 18%. Xyrem is a narcolepsy treatment.

Sales of cancer treatment Erwinaze/Erwinase declined 16% to $41.1 million. Jazz cited ongoing supply issues which have negatively impacted the pharma's ability "to provide patients with this important component of the treatment regimen for acute lymphoblastic leukemia."

Defitelio revenue increased 16% to $36.18 million. Defitelio treats a rare liver disease.

"The company continues to expect inter-quarter variability in Defitelio net sales given that hepatic vino-occlusive disease is an ultrarare disease," Jazz said in a news release.

Meanwhile, sales of cancer treatment Vyxeos brought in $21.04 million, advancing from $9.72 million in the year-ago period.

For the year, Jazz earnings guidance came in at $12.75-$13.25 per share on $1.86 billion to $1.9 billion in sales. Analysts called for adjusted income of $13.10 a share on $1.92 billion in sales.

YOU MIGHT ALSO LIKE:

After Hours: 7 Top Stocks Moving On Earnings; Futures Eye Elections

IBD Stock Of The Day Aims For Third Quarter Of Double-Digit Growth

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

How Many Shares Do You Buy For A Position? This Tool Does The Math

The post This 99 Composite Rating Pharma Tumbled On Quarterly Sales Lag appeared first on Investor's Business Daily.


83. Tableau Software Stock Up On Quarterly ResultsСр., 07 нояб.[−]

Tableau Software ( DATA) smashed earnings estimates but missed on revenue during its fiscal third quarter. Tableau stock was up on the news.

X

Tableau earnings came in at an adjusted 7 cents per share, well ahead of the average estimate for an 11-cent loss. The provider of data analytics and business intelligence software reported revenue of $239.6 million, missing views for $242 million, up 11% from the year-ago period.

Tableau stock was up 7.5%, near 112.90, during after-hours trading on the stock market today.

During the third quarter, Tableau repurchased 282,387 shares of Class A common stock for $30 million.

Tableau Software ended the quarter with $639.2 million in cash and equivalents.

(An earlier version of this story incorrectly said Tableau Software beat revenue estimates.)

YOU MIGHT ALSO LIKE:

Amazon Picks Neighborhood In Queens, N.Y., As Other Location For HQ2

The post Tableau Software Stock Up On Quarterly Results appeared first on Investor's Business Daily.


84. Turtle Beach Falls As Gaming Headset Maker Points To Slowing SalesСр., 07 нояб.[−]

Video game headset maker Turtle Beach ( HEAR) late Tuesday beat Wall Street's targets for the third quarter and guided modestly higher. But Turtle Beach stock tumbled in extended trading.

X

The San Diego-based company earned 91 cents a share on sales of $74.4 million in the September quarter. Analysts expected it to earn 77 cents a share on sales of $74 million, according to Zacks Investment Research. In the year-earlier period, it lost 4 cents a share on sales of $36 million. Some reports Tuesday had put the consensus estimate for earnings per share at $1.02 a share for the third quarter.

Turtle Beach stock plunged 12.5% in after-hours trading on the stock market today. During the regular session, it climbed 4.5% to 21.71.

For the fourth quarter, Turtle Beach expects to earn $1.02 a share on sales of $94 million. Wall Street expected $1.01 a share on sales of $89.3 million. In the year-earlier period, the company earned $1.16 a share on sales of $79.7 million. If it hits those numbers, its earnings per share will fall 12% year over year and its sales will rise 18%. Sales growth would decelerate for the third quarter in a row in the December quarter.

Turtle Beach blamed the expected decline in earnings per share on an increase in the number of diluted shares and an increase in the estimated effective tax rate to about 9%.

Strong Headset Sales Expected This Holiday Season

Still, the company remains optimistic about its prospects, given continued strong demand for gaming headsets. Turtle Beach also said it has gained market share compared with 2017 figures.

"Our outperformance in a strong market can be seen in NPD's latest U.S. and Canada console headset update," Chief Executive Juergen Stark said in a news release. "Year-to-date through September 2018, our revenue share increased 490 basis points to 45.2% from 40.3% in the same period in 2017."

Also, Turtle Beach's sales growth of 106% outpaced the total gaming headset market, which was up 84%, he said.

Stark said he expects continued strong headset sales, particularly among "battle royale" game players, in the upcoming holiday season.

(Editor's note: This article was changed on Wednesday to reflect revised consensus estimates for earnings per share for the third quarter.)

RELATED:

Activision Blizzard Mobile Game 'Diablo Immortal' Gets Upbeat Outlook

Headset Maker Hoping For Sales Lift From 'Black Ops 4,' 'Red Dead' Games

The post Turtle Beach Falls As Gaming Headset Maker Points To Slowing Sales appeared first on Investor's Business Daily.


85. Etsy Stock Jumps As Quarterly Results Beat EstimatesСр., 07 нояб.[−]

Etsy stock jumped Tuesday as it reported third-quarter earnings after the market close that beat on the top and bottom line. An e-commerce site, Etsy ( ETSY) also raised revenue guidance for the year.

X

Etsy earnings came in at an adjusted 15 cents a share, beating analyst estimates of 7 cents. The company reported revenue of $150.3 million, beating forecasts for $149.9 million and up 41% from the year-ago period.

Etsy stock rose 13%, near 45.70, during after-hours trading on the stock market today.

The company deals in handmade goods, vintage items and other arts and crafts. Gross merchandise sales topped $922.5 million in the third quarter, up 20% from the year-ago period.

The company raised 2018 guidance for gross merchandise sales and revenue. It expects gross merchandise sales growth in the range of 19% to 20%, up from previous guidance of 18% to 20%.

In the Etsy earnings report, the company said it expects revenue for 2018 in the range of $596 million to $600 million. That's up from previous guidance of $587 million to $596 million.

Etsy Stock Has Doubled

The company also announced the approval of a plan to repurchase up to $200 million of its common stock. Etsy stock has doubled in price this year.

"We achieved several key milestones," said Josh Silverman, Etsy chief executive, in prepared remarks. "Our new pricing structure was put to work by increasing investments in marketing and product initiatives to fuel growth. We also completed a major step in our migration to the cloud, a key foundational investment as we scale for future growth."

YOU MIGHT ALSO LIKE:

After Hours: 7 Top Stocks Moving On Earnings; Futures Eye Elections

Amazon Picks Neighborhood In Queens, N.Y., As Other Location For HQ2

The post Etsy Stock Jumps As Quarterly Results Beat Estimates appeared first on Investor's Business Daily.


86. This Highly Rated Medtech Just Crushed Quarterly ExpectationsСр., 07 нояб.[−]

Genomic Health ( GHDX) stock popped late Tuesday after the highly rated medical technology company handily beat third-quarter expectations and crushed guidance views.

X

In after-hours trading on the stock market today, Genomic Health stock jumped 3.2%. At the close of the stock market, Genomic Health stock dipped a fraction, to 70.79.

For the third quarter, Genomic Health reported adjusted income of $13.3 million. That works out to 35 cents per share vs. a 3-cent gain, excluding items, in the year-ago period. Analysts polled by Zacks Investment Research called for a gain of 7 cents per share.

Sales hit a record, growing 23% to $101.3 million. That also topped analyst estimates for $94 million. In the U.S., product sales of $85.8 million also increased 23%.

The biggest chunk of Genomic Health's sales in the quarter came from a test to determine if breast cancer has recurred in a patient. Sales of the Oncotype DX Breast Recurrence Score tests were $76.7 million in the U.S., advancing 24%.

Cancer Test Gains

A similar test to determine the unique biology of prostate cancer in men generated $6.9 million in U.S. sales, rising 28%. International product revenue of $15.5 million grew 22%.

Genomic Health also raised its guidance for the year. It now sees adjusted earnings of $1.03-$1.08 per share, up from its prior view for 39-56 cents. That topped analyst views for 54 cents.

The firm also called for $389 million to $391 million in revenue, above its earlier outlook for $366 million to $382 million. Analysts predicted $381 million.

Genomic Health stock is highly rated within the medical-products industry group, with best-possible Composite and Relative Strength ratings of 99.

YOU MIGHT ALSO LIKE:

After Hours: 7 Top Stocks Moving On Earnings; Futures Eye Elections

IBD Stock Of The Day Aims For Third Quarter Of Double-Digit Growth

Can CRISPR And These 3 Small Biotechs Cure 10,000 Diseases?

Stock Market Forecast For The Next Six Months: What Can You Expect?

Making Money In Stocks: How To Find The Correct Buy Point

The post This Highly Rated Medtech Just Crushed Quarterly Expectations appeared first on Investor's Business Daily.


87. Mallinckrodt Pops On Quarter Beat As Lilly Dips On Mixed ReportСр., 07 нояб.[−]

Mallinckrodt ( MNK) soared early Tuesday after the pharma stock outperformed quarterly views, though Eli Lilly ( LLY) toppled on its mixed report.

X

On the stock market today, Mallinckrodt stock surged 9.1% to close at 29.64. Lilly stock tumbled 3.9% to 105.90.

Fellow pharma stock Bausch Health ( BHC) surged 4.5% to 26.72 on its quarterly beat. Lilly spinoff Elanco Animal Health ( ELAN) also topped estimates during its first quarter trading on the stock market, and shares climbed 1.7% to 33.81.

Lilly Tops Earnings Views, But Sales Lag

For the third quarter, Lilly's adjusted earnings of $1.39 per share beat the forecast of analysts polled by Zacks Investment Research for $1.37. But $6.06 billion in sales lagged analyst views for $6.11 billion. On a year-over-year basis, sales rose 7% and adjusted profit grew 32%.

The strong earnings led Lilly to raise its 2018 outlook. Now, the pharma stock expects to earn $5.55-$5.60 per share excluding items, up from its prior view for $5.40-$5.50. Lilly also raised the low end of its revenue prediction. It now sees $24.3 billion to $24.5 billion.

"The increase in the low end of the revenue range from prior guidance is due to strong performance across the pharmaceutical portfolio, particularly in diabetes," Lilly said in a news release. Previously, Lilly had forecast $24 billion to $24.5 billion.

At the midpoint, Lilly's adjusted earnings view beat analyst predictions by about 10 cents. Sales were slightly short of expectations for $24.48 billion.

Diabetes drugs Trulicity, Basaglar and Jardiance grew robustly during the quarter, rising a respective 55%, 38% and 31%. Together, the three diabetes treatments generated more than $1.18 billion in third-quarter sales.

The best growth came from psoriasis treatment Taltz, which brought in $263.9 million, advancing 74%. Sales of cancer treatment Lartruvo grew 41% to $76.9 million.

Older diabetes treatments were sluggish. Sales of Humalog dipped 5% to $664.6 million and Trajenta slipped 12% to $135.7 million. Both belong to Lilly's list of established drugs. Of the 10 drugs in that list, only chemotherapy Alimta and diabetes drug Humulin grew.

Mallinckrodt Beats Expectations

Mallinckrodt offered a "nice beat-and-raise" during its third-quarter report. Sales grew 6.7% in constant currency to $640 million, topping the view of analysts polled by Zacks for $633 million. Adjusted earnings of $2.10 a share rose 15.4% and beat by 31 cents.

H.P. Acthar Gel sales were $290.1 million, slipping 6% on prior reports of patients experiencing withdrawal issues. But Mizuho analyst Irina Koffler noted that beat views for $279.2 million. The drug treats spasms in babies and exacerbations of multiple sclerosis.

"This brand will now have several quarters of easy comps (comparisons) due to last year's payer disruption," Koffler said in a report.

Sales of lung disease drug Inomax advanced 6% to $133.2 million, Mallinckrodt said in a news release. Immunology drug Therakos generated $60 million, rising 8.6% in constant currency. Pain reliever Ofirmev brought in $87.1 million, growing 15.5%.

For the year, Mallinckrodt now sees adjusted earnings of $7-$7.20 per share, well above the analyst view for $6.71. The pharma stock previously guided to $6.50-$6.90 per share.

YOU MIGHT ALSO LIKE:

Regeneron Earnings Easily Beat Views

Which Companies Are Now Outperforming 95% Of All Stocks?

The Best Defense Stocks For Today — And The Future

Hold Or Sell Alibaba Stock? It Depends On Your Time Frame

The post Mallinckrodt Pops On Quarter Beat As Lilly Dips On Mixed Report appeared first on Investor's Business Daily.


88. Amazon Picks Neighborhood In Queens, N.Y., As Other Location For HQ2Ср., 07 нояб.[−]

Amazon.com ( AMZN) has reportedly selected the Long Island City neighborhood in Queens, N.Y., as the second location for a new headquarters, dubbed HQ2, in addition to the Crystal City area of Arlington, Va.

X

The New York Times late Monday first reported that Amazon selected Long Island City, based on "people familiar with the decision-making process."

Previously, the Wall Street Journal reported that Amazon was in late-stage talks with Crystal City, Dallas and New York City.

The selection of Crystal City and Long Island City, if accurate, would culminate a yearlong search by Amazon for a second headquarters, which it called HQ2.

HQ2 Selection Process

At the time, Amazon asked local and state governments to submit proposals for developing a facility it expects will cost more than $5 billion in construction, bringing as many as 50,000 high-paying jobs. Amazon was founded and is based in Seattle, where it is one of the city's biggest employers.

The e-commerce giant at the time said that HQ2 would be a complete headquarters for Amazon, not a satellite office.

The reported decision to split HQ2 among two cities is a surprise announcement. Amazon is reportedly finalizing plans to have a total of 50,000 employees in two locations. It already has more employees in those two areas than anywhere else outside of Seattle, the New York Times reported.

It's unclear if Amazon would call both locations headquarters or if they would be large satellite offices.

Amazon stock added 0.9% to close at 1,642.81 on the stock market today.

YOU MIGHT ALSO LIKE:

Amazon Offering Free Shipping Without Minimum Purchase Over Holidays

Here Are Your 20 Cities Vying For Amazon's New Headquarters

Attract Customers By Offering Something More Alluring Than The Competition

Amazon Stock Quotes, Company News And Chart Analysis

The post Amazon Picks Neighborhood In Queens, N.Y., As Other Location For HQ2 appeared first on Investor's Business Daily.


89. Regeneron Crushes Profit Views, But Cuts A Key Piece Of Its OutlookСр., 07 нояб.[−]

Regeneron Pharmaceuticals ( REGN) crushed Wall Street's third-quarter profit views by 66 cents, though sales of eye drug Eylea lagged outside the U.S.

X

On the stock market today, Regeneron stock added 0.8% to close at 357.61, after earlier jumping as much as 3.4%. At the stock market close on Monday, Regeneron stock rose 0.7%, to 354.93. Shares of partner Sanofi ( SNY) dipped 0.4% to 44.62.

For the third quarter, Eylea sales in the U.S. advanced more than 7% to $1.02 billion. Raymond James analyst Laura Chico said in a note to clients that U.S. Eylea sales beat views for $1.01 billion.

But outside the U.S., Eylea brought in $654.6 million, lagging expectations for $664 million, she said. On a year-over-year basis, Eylea sales outside the U.S. rose north of 16%. Bayer ( BAYRY) reports net product sales of Eylea outside the U.S.

Regeneron Cuts Sanofi Collaboration Guidance

During the quarter, Regeneron recorded total revenue of $1.663 billion in sales, rising 11% to top estimates from analysts polled by Zacks Investment Research for $1.659 billion. Adjusted profit spiked 47% to $5.87, crushing views for $5.21.

Regeneron partners with Sanofi on Dupixent, which treats eczema and asthma. That drug generated $262.6 million in global sales. and beat views by $14 million, Raymond James' Chico said. Also Tuesday, Regeneron said the Food and Drug Administration granted Dupixent priority review as an eczema treatment in adolescents.

But other Sanofi-partnered drugs Praluent and Kevzara missed expectations. Praluent works to lower "bad" LCL cholesterol. Kevzara treats rheumatoid arthritis. The misses weren't a surprise. Sanofi reported sales for those medicines last week.

Collaboration revenue was mixed, Chico said. Revenue from Sanofi was $256.3 million, lagging the consensus for $273 million. Revenue collected from the Bayer collaboration was $264.4 million, beating expectations for $260 million.

Regeneron cut its expectations for full-year collaboration revenue from Sanofi to $430 million to $455 million, down from $455 million to $485 million previously.

YOU MIGHT ALSO LIKE:

Two More Drugmakers Deliver Strong Earnings, Including This Giant

Looking For Growth? Take A Look At These Biotechnology Stocks

Best Dividend Stocks: 5 High-Yield Stocks Beating The S&P 500

Speedy Medtech: Why These Fast-Growing Stocks Should Be On Your Radar

The post Regeneron Crushes Profit Views, But Cuts A Key Piece Of Its Outlook appeared first on Investor's Business Daily.


90. Activision Blizzard Mobile Game 'Diablo Immortal' Gets Upbeat OutlookСр., 07 нояб.[−]

"Diablo Immortal," a new mobile video game from Blizzard Entertainment, received a negative response from hard-core fans hoping for a sequel to the franchise for personal computers. But Wall Street analysts say the new mobile game still should be a profitable one for parent company Activision Blizzard ( ATVI).

X

Blizzard announced " Diablo Immortal" on Friday at its BlizzCon convention in Anaheim, Calif. The event attracted more than 40,000 gamers. Coming soon, "Diablo Immortal" is a massively multiplayer online action role-playing game for Google Android and Apple ( AAPL) iOS devices. It is being developed by Blizzard and NetEase ( NTES), a longtime partner of Blizzard in China.

Blizzard did not announce a release date for the game, but analysts expect it to come out sometime in 2019.

When Blizzard announced "Diablo Immortal," attendees at BlizzCon booed. Fans have been anticipating "Diablo 4," a PC game sequel. Gamers on social media criticized the new mobile title for looking like a retread of current NetEase game "Crusaders of Light."

Wall Street analysts this week had upbeat assessments about "Diablo Immortal." Morgan Stanley analyst Brian Nowak said he is "bullish" on the Diablo mobile game.

China Market Key For 'Diablo Immortal'

If "Diablo Immortal" can get a user base as large as "Honor of Kings" from Tencent ( TCEHY), the profits could be significant, he said. Nowak estimated 73 cents to $1.68 of annual earnings per share. But "Diablo Immortal" has the potential to be even larger since it will be launched globally, he said. By contrast, "Honor of Kings" is largely in China only, but it still has 200 million monthly active users.

Macquarie analyst Benjamin Schachter said Blizzard made a mistake in announcing "Diablo Immortal" at BlizzCon.

"Mobile is a significant opportunity for Activision Blizzard, particularly in Asia," he said in a report to clients. "However, what in hindsight appears to be a misstep, Blizzard made the marquee product announcement at its convention filled with hard-core PC gamers. (The new title is) a mobile game for a franchise that hasn't had a new PC installment in over six years."

Blizzard also is clearly focused on China with "Diablo Immortal," hence its partnership with NetEase, he said.

Any Potential Elsewhere?

Cowen analyst Doug Creutz said "Diablo Immortal" looks like a hit in China, but questioned its potential elsewhere.

"The game could have meaningful success in China but is unlikely to break out in Western markets," he said in a report.

Wedbush analyst Michael Pachter said "Diablo Immortal" could contribute high-margin revenue of up to $300 million annually.

Activision Blizzard stock dipped a fraction to 64.25 on the stock market today. On Monday, it tumbled 6.7% to 64.34.

RELATED:

Electronic Arts Tops Quarterly Views, But EA Stock Falls On Outlook

Take-Two Stock Jumps On Huge Debut For 'Red Dead' Video Game

The post Activision Blizzard Mobile Game 'Diablo Immortal' Gets Upbeat Outlook appeared first on Investor's Business Daily.


91. Square Stock Could Be Volatile On Earnings Report, Says AnalystСр., 07 нояб.[−]

Look for volatility when Square ( SQ) reports earnings on Wednesday, with margin forecasts a key, says one analyst. Square stock has dropped 24% in five weeks heading into earnings.

X

"All the ingredients for volatility are there, especially with a healthy mix of retail (investors) thrown into the mix," Morgan Stanley analyst James Faucette said in a report to clients.

Analysts estimate adjusted profit of 11 cents, up 57% from a year ago for the maker of credit card readers. Revenue is expected to rise 47% to $861 million, including acquisitions.

Square stock gained 3.1% to close at 77.31 on the stock market today. Square stock hit an intraday high of 101 on Oct. 1. Shares fell to 64.50 on Oct. 30 before clawing back a bit.

"Our sense that previously frustrated shorts who had abandoned their positions have been re-emboldened, crowding negative positioning," Faucette said. "At the same time, we think a lot of institutions that own the name have let the stock run well past their respective internal price targets, and are hoping for one last squeeze before fading the position."

Square EBITDA Margins Key

Faucette says management commentary on 2019 EBITDA — earnings before interest, taxes, depreciation and amortization — margin expansion could move the stock following the release of earnings.

At RBC Capital, analyst Daniel Perlin also sees margin guidance as key.

"The balancing act between growing EBITDA margins and reinvesting back into new product initiatives has been a consistent question," Perlin said in his note to clients. "Thus far, the margin expansion story has been significant, which we expect to continue. The question remains as to the level of reinvestment required to support all the new product initiatives Square is bringing to the market, while at the same time expanding geographically."

San Francisco-based Square's credit card readers plug into mobile phones and tablets. In addition, the company provides software for point-of-sale systems and back offices in order to manage inventory and other tasks. It also offers customer relationship management software.

YOU MAY ALSO LIKE:

How Cloud Computing Upgrade Cycle To 400G Could Drive Tech Stocks

Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The Edge

Cybersecurity Stocks To Watch Amid Shift To Cloud, AI Software Tools

Improve Your Investing Results With This Simple 3-Step Routine

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Square Stock Could Be Volatile On Earnings Report, Says Analyst appeared first on Investor's Business Daily.


92. Zebra Technologies Hits Record High On Third-Quarter BeatСр., 07 нояб.[−]

Zebra Technologies ( ZBRA) on Tuesday reported better-than-expected sales and earnings for the third quarter thanks to strong demand for its enterprise asset tracking systems. Zebra stock jumped on the news.

X

The Lincolnshire, Ill.-based company earned an adjusted $2.88 a share on sales of $1.09 billion in the September quarter. Analysts expected it to earn $2.60 a share on sales of $1.06 billion. On a year-over-year basis, earnings per share rose 54% while sales climbed 17%.

For the current quarter, Zebra Technologies expects to earn an adjusted $2.90 a share on sales of $1.11 billion. That's based on the midpoint of its guidance. Wall Street was modeling earnings per share of $2.73 on sales of $1.1 billion. Based on its outlook, Zebra expects earnings per share to rise 24% and sales to increase 8.5% in the December quarter.

Zebra stock surged 6.4% to 178.74 on the stock market today. It notched a record high of 184.57 in intraday trading after clearing a buy point of 179.57. Zebra stock had been consolidating for the past eight weeks.

Zebra Technologies Boasts Broad-Based Demand

"Our exceptional third-quarter results were driven by broad-based demand for our solutions and disciplined operational execution," Chief Executive Anders Gustafsson said in a news release.

He added, "Our leading portfolio of solutions, investments in our employees and innovation, and strong order backlog provide us confidence for a strong finish to the year and solid momentum into 2019."

Zebra's third-quarter results include its acquisition of Xplore Technologies, a maker of rugged tablet computers for enterprise customers. It bought Xplore for $87 million in cash.

Zebra Technologies makes rugged mobile computers, RFID tracking chips, and bar code scanners and printers enhanced with software and services to enable real-time enterprise visibility of inventory and other assets. It offers products and services for retail, health care, manufacturing, transportation and other industries.

Zebra Chief Financial Officer Olivier Leonetti told Investor's Business Daily that the company is seeing strength across regions, vertical markets and product lines.

"We feel positive about the future of the company," he said. Zebra is helping companies solve important problems, such as improving productivity, compliance and customer service, he said.

YOU MIGHT ALSO LIKE:

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

How To Invest In Growth Stocks: Timeless Market Wisdom From A Legendary Trader

The post Zebra Technologies Hits Record High On Third-Quarter Beat appeared first on Investor's Business Daily.


93. AMD Stock Rises As Amazon Web Services Uses Its Epyc ChipsСр., 07 нояб.[−]

Advanced Micro Devices ( AMD) and Amazon ( AMZN) Web Services on Tuesday announced the availability of the first AMD Epyc processors on the Amazon Elastic Compute Cloud. AMD stock popped on the news.

X

At its Next Horizon conference, AMD revealed that its Epyc processors would go in Amazon's cloud computing data centers.

"The availability of multiple AMD Epyc processor-powered instances on Amazon EC2 marks a significant milestone in the growing adoption of our high-performance CPUs (central processing units) with cloud service providers," Forrest Norrod, senior vice president and general manager for AMD's Datacenter and Embedded Solutions Business Group, said in a news release.

AMD said its processors will offer "exceptional performance per dollar for general purpose and memory optimized workloads" on the cloud computing service.

AMD Stock Retreats From Early Gains

AMD stock jumped as much as 8.8% to 21.65 in intraday trading on the stock market today. It settled back for a gain of 3.9% to close at 20.68.

Processors for data centers have been among the most robust chip markets in recent quarters.

Last week, Xilinx ( XLNX) surged on a news report that it had won a big chip order from Microsoft's ( MSFT) Azure cloud-computing unit. Bloomberg said Xilinx would replace server chips made by Intel ( INTC).

RELATED:

NXP Semiconductors Pops On Third-Quarter Earnings Beat

Qorvo Stock Rises On Quarterly Earnings Beat, But Outlook Light

The post AMD Stock Rises As Amazon Web Services Uses Its Epyc Chips appeared first on Investor's Business Daily.


94. Fabrinet Stock Jumps As Earnings, Guidance Top Views Amid China TariffsСр., 07 нояб.[−]

Fabrinet stock shot up Tuesday after the company notched a beat-and-raise fiscal first quarter. The ongoing trade battle between the U.S. and China will provide upside, one analyst said.

X

Shares in Fabrinet ( FN), a contract manufacturer specializing in optical products, gained 10.6% to close at 50 on the stock market today. Fabrinet stock jumped above a technical buy point of 49.07 with the gain. In intraday trading, Fabrinet stock had soared as much as 16%.

The U.S. trade battle with China provides a boost for Fabrinet, says Needham analyst Alex Henderson. Manufacturing is moving outside China because of tariffs placed of products imported into the U.S., he says. Fabrinet has a manufacturing plant in Thailand.

"As companies flee China, Fabrinet is benefiting and seeing rapid uptake of capacity commitments," Henderson said in a report to clients.

The company said revenue rose 6% to $377.2 million, blowing past analyst estimates of $352 million. Profit jumped 23% to 92 cents. Analysts projected 81 cents.

Fabrinet Stock: Expanding Production

For the December quarter, Fabrinet said it expects revenue of $384 million at its midpoint. That topped estimates of $366 million. Fabrinet forecast earnings in a range of 91 cents to 94 cents a share, above forecasts for 84 cents.

The company provides manufacturing for optical components, industrial lasers and sensors.

"Fabrinet is well ahead of plan on new floor space commitments for its new 550,000-square-foot plant," Henderson said. "With commitments to over 50% of the floor space, Fabrinet is likely to be pushed to starting the build on the next plant ahead of schedule."

At Piper Jaffray, analyst Tim Jensen also has a buy rating on Fabrinet stock.

"Fabrinet's results confirm our thesis that the telco side of optics and select datacom segments ( silicon photonics) are experiencing the beginnings of an upgrade cycle," he said in his note to clients.

Fabrinet stock had been consolidating amid October's sell-off in many technology companies.

YOU MAY ALSO LIKE:

How Cloud Computing Upgrade Cycle To 400G Could Drive Tech Stocks

Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The Edge

Cybersecurity Stocks To Watch Amid Shift To Cloud, AI Software Tools

Improve Your Investing Results With This Simple 3-Step Routine

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Fabrinet Stock Jumps As Earnings, Guidance Top Views Amid China Tariffs appeared first on Investor's Business Daily.


95. Symantec Stock Jumps On Report Thoma Bravo Seeks AcquisitionСр., 07 нояб.[−]

Symantec stock shot up Tuesday on a report private equity firm Thoma Bravo has expressed an interest in acquiring the cybersecurity specialist.

X

Symantec ( SYMC) stock jumped 12.6% to close at 22.54 on the stock market today. The talks are early stage, Reuters reported.

Thoma Bravo has built up its computer security holdings. A Symantec acquisition would further build those up.

Thoma Bravo recently agreed to buy Imperva for $2.1 billion. Last year, it acquired security software maker Barracuda Networks for $1.6 billion.

And in July, Thoma Bravo took a majority stake in Centrify. Centrify is a rival of CyberArk Software ( CYBR). CyberArk reports earnings on Wednesday.

Symantec Stock: Acquisitions

Symantec itself has been making its own purchases to spur growth. It acquired Blue Coat Systems in 2016 for $4.65 billion. One Symantec acquisition was LifeLock, a provider of consumer identity-theft protection services, for $2.3 billion.

Symantec last week reported third quarter revenue and profit that fell from a year earlier but still topped estimates.

In May, Symantec stock plunged after the Mountain View, Calif.-based company disclosed an internal accounting probe. Then during the summer, activist investor Starboard Value disclosed a nearly 6% stake in the company. Private equity firms Bain Capital and Silver Lake are also investors in Symantec.

Symantec recently said the probe would result in only minor adjustments to financials in fourth quarter 2018 and first quarter 2019.

YOU MAY ALSO LIKE:

How Cloud Computing Upgrade Cycle To 400G Could Drive Tech Stocks

Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The Edge

Cybersecurity Stocks To Watch Amid Shift To Cloud, AI Software Tools

Improve Your Investing Results With This Simple 3-Step Routine

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Symantec Stock Jumps On Report Thoma Bravo Seeks Acquisition appeared first on Investor's Business Daily.


96. Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The EdgeВт., 06 нояб.[−]

Hangar Technology wants to shake up the drone market by getting rid of human pilots. But the bigger story might be how the startup uses the next big thing in cloud computing, called edge computing.

X

Edge computing deploys data processing, storage and networking close to sensors and where other data originate. The goal is to process and analyze data locally in real time rather than send it to faraway data centers in the internet cloud and wait for a response of, say, 150 milliseconds.

That sliver of time matters in some applications: A self-driving car that needs to detect a pedestrian or storm-damaged sign. A doctor who performs remote surgery using augmented reality tools. A video surveillance system equipped with facial recognition to identify a known shoplifter or terror suspect. Sensors that detect repairs needed on robotic arms in factories and oilfield pumps.

Edge computing is the next step that companies like Amazon.com ( AMZN) are taking to expand the cloud. Incumbents mean to protect millions or billions of dollars in their revenue from poaching by edge upstarts. Companies new and old are developing relevant hardware and software.

"I'm convinced edge computing is here to stay," said Marco Argenti, vice president of technology for Amazon Web Services. "It's a natural evolution. Not all data needs to be transferred to the cloud to be processed. There might be bandwidth costs, cellular costs or it may be difficult to connect to the cloud. Or, you just need to react really fast, like in the case of a robot."

That's what Texas-based Hangar thinks. It has teamed with Vapor IO, which makes mini data centers, to bring cloud computing closer to drones, making them more nimble. The mini data centers will sit at the bottom of cellphone towers and other spots near where the drones fly.

"We're building our entire technology platform to operate in a future where we don't need people in the loop," said Jacob Rachniowski, Hangar's director of enterprise solutions.

Cloud Computing, Decentralized

Centralized cloud computing could soon be old hat. Today's internet "cloud" is made up of huge racks of computer servers packed into data centers. Some 200 warehouse-size, high-performance, " hyperscale" data centers span the U.S., says Synergy Research Group.

They're operated by Amazon, Microsoft ( MSFT), Alphabet's ( GOOGL) Google, Apple ( AAPL), Facebook ( FB) and other tech companies as well as data center firms like Equinix ( EQIX).

A number of startups — including Vapor IO, EdgeMicro, Cloudflare, Packet and others — aim to challenge these giants and make edge computing a reality.

Many incumbents in the tech industry are investing in edge computing. Among them are Dell Technologies ( DVMT), Hewlett Packard Enterprise ( HPE), Crown Castle ( CCI), Cisco Systems ( CSCO) and wireless firms Verizon Communications ( VZ) and AT&T ( T).

How Can You Handle This Market? Start With These 3 Steps

Amazon, Microsoft and Google are the biggest providers of public cloud computing services. But powerhouse Amazon Web Services, or AWS, also offers edge computing software and services, primarily for web-connected devices on what is called the Internet of Things.

"Our philosophy is that edge is really an extension of the cloud, down to the tiniest device. There is no edge without the cloud — otherwise you're going back 15 years," Amazon Web Services' Argenti told IBD

Cloud Computing Revenue At Risk

But the idea is that data collected on the edge supposedly will be parsed for what's most important, and the rest will be sent to the cloud. The idea is to cut down on what's eventually sent to centralized clouds, saving time and money.

The big question is how much data processing will take place locally rather than being crunched at giant data centers. Revenue could shift to edge computing companies from the cloud's current leaders.

Amazon's cloud computing revenue is nearing a $25 billion annual run rate. And AWS revenue popped 49% in the June quarter.

Microsoft's Azure cloud computing services exceeds $9.8 billion in revenue while a similar Google venture tops $3.6 billion, says a Jefferies report. Data center tech providers — such as chipmaker Nvidia ( NVDA) and equipment maker Arista Networks ( ANET) — have a stake in how edge computing evolves.

Some expect the demise of centralized cloud computing. Peter Levine, managing partner at venture firm Andreessen Horowitz, predicted in a late 2016 video presentation that new edge apps "will obviate cloud computing as we know it."

Edge Computing 'Will Eat The Cloud'

Gartner Group, in a 2017 report, predicted that "The Edge Will Eat the Cloud."

"The edge will create some serious winners and losers, both in terms of vendors and businesses," said Thomas Bittman, a Gartner analyst, in a blog post.

But John Apostolopoulos, vice president of Cisco's enterprise networking business, sees plenty of growth ahead for both centralized cloud computing and edge computing.

"The pie is going to expand dramatically," he said. "The cloud is going to continue being important and it's going to grow. The edge, though, is going to grow much more than it has in the past and create a lot of value for customers. It's not going to be one or the other."

Apostolopoulos points to retailers like Walmart ( WMT) as an example. With edge computing, he says they'll be able to bring cloudlike software applications to hundreds of stores "at the push of a button." The retail apps would process data from store cameras or sensor networks locally.

Walmart is building its own internal cloud network as its rivalry with Amazon heats up.

Traditional cloud services will keep growing as large companies move business workloads to AWS, Microsoft's Azure and other services, analysts say. Many emerging apps such as video surveillance will require the massive, data-crunching power of centralized cloud computing.

Hangar Technology's Drones

At Hangar, Rachniowski notes that a next-generation drone would still upload video at the end of each day to a traditional cloud provider, like AWS, for analysis.

Hangar plans to have its drones pop out of the mini data centers and fly off. With the help of precision location tools, they'll be controlled remotely, most likely with 5G wireless.

Taking drone pilots out of the equation may be a tall order. Federal regulators now require each commercial drone to have its own ground-based pilot who stays within that aircraft's line-of-sight.

Hangar's customers inspect construction and energy sites using conventional drones. With edge computing, the company hopes to take video data of construction sites, bridges or oil and gas pipelines and whisk them to mini data centers for fast processing and analysis. Pilots no longer will be needed to unload small data storage cards from drones.

It's an ambitious goal, aimed at improving drone economics. The drone market is tough. Well-funded drone startup Airware closed in September. It burned up $118 million in funding. Rachniowski insists the move to remote piloting is necessary.

"Digitizing the real world, deep data analysis, adjusting flight plans, will require edge computing to help us make educated decisions in real time," he said.

Cloud Computing Data Delays

Edge computing targets emerging apps that require real-time decision-making. Giant hyperscale data centers often sit tens or hundreds of miles from where data generates. It takes 150 to 200 milliseconds for data to go to a cloud services provider and back. That time span is called latency.

A 150-millisecond delay is no problem if you're searching for a restaurant on your smartphone. But cloud latency has been a hurdle for multiplayer online video gaming and other markets.

Edge computing aims to process data locally and cut the time to 5 to 10 milliseconds or below. On a factory floor or in a hospital bed, the difference can be meaningful.

"New economy companies and data in general is moving to the cloud and the cloud is moving to the edge," said Cole Crawford, founder and chief executive of Vapor IO. Its investors include cell tower operator Crown Castle and Berkshire Partners. Vapor aims to deploy 100 edge mini data center sites around the U.S. by 2020, up from two now.

"Deep learning analytics, data storage, all that stuff can live in hyperscale data centers for a very long time," he said. "I do believe that high-performance, high-touch apps that require low latency, low jitter are going to be located at the edge and there's going to be a lot of it."

Artificial Intelligence Fuels The Edge

Some technologies associated with edge computing — including artificial intelligence, augmented reality, 5G wireless, autonomous vehicles and the industrial Internet of Things — are still nascent.

Artificial intelligence is just starting to be used in cloud computing. AI software programs — made of computer algorithms — analyze huge amounts of data to identify patterns and predict outcomes. AI is being used in cybersecurity, health care and other industries. A big part of Nvidia's growth has come from selling AI chips to cloud data centers.

Tractica, a market research firm, forecasts that AI edge device shipments will boom to 2.6 billion units annually by 2025. That's up from 161 million in 2018. Edge devices include smartphones, smart home speakers, IoT cameras, drones, self-driving cars and manufacturing robots.

Google reportedly is developing a version of an AI chip used in data centers for edge applications. ARM, a chip designer now owned by Japan-based SoftBank ( SFTBY), also is developing devices for edge applications.

Edge computing applications will require more computer memory horsepower to process AI, said a Guggenheim report in March.

"While most of today's machine learning takes place entirely inside the cloud, executing more (machine learning) at the edge has implications across the tech supply chain," said Robert Cihra, a Guggenheim analyst.

Edge Computing And 5G Wireless

AT&T and Verizon still test next-generation 5G services using high radio frequencies. They see 5G improving mobile video and providing "fixed" broadband to residential customers.

AT&T and Verizon also are testing 5G for enterprise applications that could use private wireless communications. As part of that, AT&T and Verizon are deploying new network software for flexible, "intelligent edge" services.

5G wireless will help make the cloud ubiquitous, says Ihab Tarazi, chief technology officer of startup Packet. Tarazi has also been the tech chief at Equinix and a vice president of engineering at Verizon.

"Wireless architectures are evolving and will be huge enablers," Tarazi said. "The cloud is going to extend, filling in all the empty gaps to the edge."

The startup's investors include SoftBank, Dell Technologies Capital and Samsung Next. Packet is teaming with another SoftBank-owned firm, wireless services provider Sprint ( S), and Ericsson ( ERICY) to offer managed services for the Internet of Things.

Packet on Nov. 6 said it was partnering with SBA Communications ( SBAC) to deploy its first Boston-area edge data center location at a cell phone tower.

Packet positions itself as an alternative to AWS. The startup has put cloud hardware in 18 smaller data centers located in metro areas. It plans to add 50 more. Customers can customize their cloud hardware and use open source software to develop edge applications.

Cloud Computing Economics, Pricing

Enterprise customers will wait for edge pricing to be attractive, as they have in the case of cloud computing. Amazon, in its early days as a cloud services provider, continually slashed prices to attract customers.

Cloud computing titans prospered under a shared infrastructure model. Clients rent computing resources via the web. It's unclear whether a multitenant business model will emerge for local, mini data centers.

Schneider Electric, EdgeConneX and EdgeMicro are among providers of mini data centers. The data centers, about the size of a shipping container, cost around $280,000 to deploy in edge sites, not including servers, switches and other equipment, says a Credit Suisse report. Aside from power and cooling, the mini data centers provide wireless antennas and fiber-optic network connections.

According to an IDC survey, large companies have an interest in delivering new digital services closer to customers. But they worry about the upfront costs in edge computing.

"We've seen a few vendors exit the micro data center space because of the level of customization and not a lot of demand made it unprofitable," said IDC analyst Jennifer Cooke.

Operators of large data centers, such as Equinix and Digital Realty ( DLR), have yet to jump into local data centers.

"The engineering case for deploying equipment closer to the edge of the network makes sense to us; the economics remain a big question mark," said MoffettNathanson analyst Nick Del Deo, who follows the data center industry. He says it's unclear whether wireless firms want to invest in edge infrastructure themselves.

Dell, HPE Eye Edge Computing

Microsoft, though, has disclosed plans to invest $5 billion in IoT and the edge over the next four years. HPE has bet $4 billion on intelligent edge technology.

For computer server makers like Dell and HPE, edge computing could be a chance to rebound. Corporate spending on internal data centers has dropped as more business workloads shift to the public cloud.

Many tech industry incumbents are eyeing the rise of edge computing.

"It's an opportunity to serve a converged infrastructure," said Jim Davis, analyst at Edge Research Group. "Some of these companies have broad product lines and they're looking at a new environment."

VMware, Cisco, Nokia Moves

VMware ( VMW), a Dell subsidiary, in September announced new software for edge computing. Cisco is building specialized servers for the edge. Telecom gear makers Ericsson and Nokia ( NOK) are developing edge computing gateways.

Analysts expect next-generation content delivery networks, from startups Cloudflare and Fastly, to handle edge applications.

Wells Fargo, in a September report on edge services, said it expects the cloud computing titans to prosper.

"Although edge computing is still in its early days, we view Amazon and Microsoft as having the most comprehensive portfolio of edge-to-cloud technologies and a generally available edge platform — followed by Google," the report said.

Scale Computing, a startup that makes servers and data storage systems for edge computing, in late October raised $35 million in a funding round. China's Lenovo is a new investor.

YOU MAY ALSO LIKE:

Cloud Computing: Find Top Cloud Stocks And Track Industry Trends

Looking For Potential Breakout Stocks? Start With These Lists

Improve Your Investing Results With This Simple 3-Step Routine

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Next Big Thing In Cloud Computing Puts Amazon And Its Peers On The Edge appeared first on Investor's Business Daily.


97. Cloud Computing: Find Top Cloud Stocks And Track Industry TrendsВт., 06 нояб.[−]

Cloud computing offers investors a wide range of opportunities that span internet infrastructure, as well as consumer and business services delivered via fast connections to the web. The industry leaders and top cloud stocks cover a similarly wide range, from Amazon.com ( AMZN) and Google parent Alphabet ( GOOGL) to Microsoft ( MSFT), Alibaba ( BABA) and Oracle ( ORCL).

X

To visualize the internet cloud, think of warehouse-sized data centers packed with computer servers and data storage systems. Then think of the cloud supply chain.

Companies such as Intel ( INTC), artificial intelligence (AI) leader Nvidia ( NVDA) and Micron Technology ( MU) sell chips built into servers. Fiber-optic device makers sell parts for high-speed communications networks. Seagate Technology sells solid-state data storage systems. Arista Networks ( ANET) and Cisco Systems ( CSCO) sell specialized network switches and routers that make the cloud superfast.

Cloud Computing And Top Cloud Stocks

Google Cloud-Computing Unit Gets New Boss, A Former Oracle ExecutiveAlphabet on Friday said it's replacing the head of its Google cloud-computing business, Diane Greene, with former Oracle executive Thomas Kurian. Google said Kurian is joining the unit on Nov. 26. He will... Read More
Top Stocks: This Tech Leader Shows Unusual Strength In Tough MarketCyberArk Software is holding firmly above its 50-day moving average at a time when many top stocks are trading well below the support line. The security software maker gapped up out of... Read More
Stock Market News: Nasdaq Reverses Higher On Trade-Talk OptimismIt was another volatile session for the stock market in afternoon trading Thursday, but buyers clearly had the upper hand. The Nasdaq erased a 0.9% early loss and was up 1.3% with... Read More
Election Results Confirm Stock Market Rally; Twilio, CyberArk, Ulta Hot; Square, Activision Not: Weekly ReviewThe stock market rally had a follow-through day Wednesday following midterm election results. The Dow Jones, S&P 500 index and Nasdaq composite rallied, though techs in particular pulled back late in the... Read More
Who Joins Square On This List Of Today's Fastest-Growing Companies?What do Square, Abiomed and ServiceNow have in common with Momo and IPO stocks PetIQ and Vici Properties? They've all earned a spot on the latest list of today's fastest-growing companies. The biggest stock market... Read More
View More Cloud Computing Articles

Cloud Computing Services

The biggest buyers of data center infrastructure are Amazon Web Services, Microsoft's Azure and Alphabet's Google, as well as consumer-facing companies like Apple ( AAPL) and Facebook ( FB).

Cloud computing services are new growth engines for AWS, Microsoft and Google. Companies rent their powerful computers and software platforms to process business workloads remotely via the web. Apple relies on cloud infrastructure for its fast-growing services business, whisking music and other content to iPhones.

Companies like Salesforce.com ( CRM) that offer subscription-based software-as-a-services (SaaS) arrived before the term cloud computing was coined. Many SaaS companies are now working with AWS and other cloud vendors to reach new markets.

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

YOU MAY ALSO LIKE:

AI News: Artificial Intelligence Trends And Top AI Stocks

FANG Stocks News: Facebook, Amazon, Netflix, Google

Best Stocks To Buy And Watch

The post Cloud Computing: Find Top Cloud Stocks And Track Industry Trends appeared first on Investor's Business Daily.


98. Tesla (TSLA) Stock Quotes, Company News And Chart AnalysisВт., 06 нояб.[−]
X


TSLA Stock Quote
| TSLA Ratings

Tesla Stock News & Analysis

Market Slashes Gains As Apple Stock Hits New LowThe major stock indexes rallied in today's stock market on slowing inflation but gains faded as Apple moved to new recent lows. The Labor Department reported slower-than-expected core CPI inflation in October.... Read More
These 4 Stock Leaders Try To Withstand The Recent Market WeaknessThe tech-heavy Nasdaq composite continued to show significant weakness in the stock market today. The Nasdaq declined over 2% midday Monday, continuing lower after Friday's 1.7% fall. With the stock market back... Read More
Stocks Slip After Market Rally, But These Stocks Are Making NoiseStocks faded at Thursday's open as the market paused following Wednesday's big gains, and investors awaited a rate-policy announcement from the Federal Reserve. Earnings-related losses cut broadly across early trade. Qualcomm dragged... Read More
Tesla Names Robyn Denholm To Replace Elon Musk As ChairmanTesla chose Robyn Denholm to succeed Elon Musk as board chair, selecting an independent director to contend with the electric vehicle maker's mercurial chief executive officer following his run-ins with regulators and... Read More
Nio Earnings: China Rival To Tesla Reports Wide Loss As Production Kicks InNio reported a wider-than-expected loss and lower-than-forecast sales Tuesday morning, marking the Chinese luxury electric vehicle Tesla challenger's first earnings report as a publicly listed company. Production and deliveries of its luxury SUV,... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

More Technology Stocks Coverage

Latest FANG Stocks News: Facebook, Amazon, Netflix, Google

Apple (AAPL) Stock Quotes And Company News

View More Tech Stocks

The post Tesla (TSLA) Stock Quotes, Company News And Chart Analysis appeared first on Investor's Business Daily.


99. Mylan Jumps After Reiterating 2018 Outlook Despite Quarterly Sales DipВт., 06 нояб.[−]

Mylan ( MYL) stock surged late Monday after the generic pharma reiterated its 2018 guidance despite missing third-quarter sales expectations.

X

In after-hours trading on the stock market today, Mylan stock jumped 5.8%, near 33.20. At the close on the stock market, Mylan stock lost 1%, ending the regular session at 31.37. More broadly, pharmaceutical stocks wrapped the day up nearly 2%.

For the third quarter, Mylan reported adjusted earnings of $1.25 per share on $2.86 billion in sales. Adjusted profit beat the prediction from analysts polled by Zacks Investment Research for $1.17, but sales narrowly missed the $2.87 billion view.

On a year-over-year basis, adjusted profit jumped 14%, while sales fell 4%. Chief Executive Heather Bresch reiterated confidence in Mylan's future despite near-term challenges amid continuing pressure on drug prices in the U.S.

"Our confidence in the company's bright future extends well beyond any single factor or particular quarter, including the short-term macro turbulence our industry is experiencing," she said in a written statement.

Neulasta Biosimilar Offsets EpiPen

During the quarter, North American sales slipped 14% to $1.01 billion. Mylan noted the dip was due to lower volume of existing products, like its emergency allergic reaction injection, EpiPen. That was partially offset by new products, such as its biosimilar of Amgen's ( AMGN) drug, Neulasta.

In August, Teva Pharmaceutical ( TEVA) gained approval to launch a generic version of Mylan's drug, EpiPen. Further compounding Mylan's struggles, EpiPen is facing supply constraints, which has led the Food and Drug Administration to list it in shortage.

Biosimilars, though, remain a highlight for Mylan. Biosimilars are nearly identical copies of branded biologic drugs. This includes Fulphila, a biosimilar of Amgen's Neulasta. Neulasta is a bone marrow-stimulating drug for cancer patients.

"Year-to-date, we have launched nearly 475 new products across our segments, including a record number of complex generics and biosimilars for Mylan," Bresch said. "These medicines represent many different therapeutic categories, channels and dosage forms."

Mylan sales in Europe inched up to $1.04 billion. Revenue from the rest of the world grew 4% to $773.7 million. Mylan also reported $35.1 million in other revenues, rising 14%.

Mylan reiterated its guidance for the full year. In the second quarter, the generic pharma guided to adjusted earnings of $4.55-$4.90 per share on $11.25 billion to $12.25 billion. Analysts project adjusted earnings of $4.62 per share on $11.5 billion in sales for the year.

YOU MIGHT ALSO LIKE:

Looking For The Next Nvidia? Start With These 3 Steps

Which Stocks Are Showing Rising Relative Strength?

How To Tame A Volatile Swing Trade With A Half Position

The post Mylan Jumps After Reiterating 2018 Outlook Despite Quarterly Sales Dip appeared first on Investor's Business Daily.


100. RingCentral Stock Rises As Earnings, Revenue Top EstimatesВт., 06 нояб.[−]

RingCentral ( RNG) on Monday reported third-quarter profit and revenue ahead of analyst views and forecast December quarter sales and earnings slightly above Wall Street estimates. RingCentral stock climbed in after-hours trading.

X

The enterprise software maker said adjusted earnings were 19 cents a share, up 46% from a year ago, with revenue rising 33% to $174 million. Analysts expected RingCentral to report earnings of 16 cents on sales of $166.7 million for the period ended Sept. 30.

A year earlier, RingCentral earned 13 cents a share on sales of $130 million.

RingCentral said third-quarter software subscription revenue jumped 32% to $158 million. That topped estimates of $153.3 million.

For the December quarter, RingCentral said it expects revenue in a range of $179 million to $182 million. The company forecast adjusted earnings of 18 cents a share at its midpoint of guidance, a penny above estimates.

RingCentral Stock: Competing With Slack, 8x8

Shares in the maker of cloud-based business communications software were up 4% to 78 in after-hours trading in the stock market today. In Monday's regular session, RingCentral stock fell 2.6% to 75.04. RingCentral stock was up 70% from a year ago.

The company's cloud communications platform offers customers voice, chat, conferencing and application integration.

RingCentral competes with startup Slack Technologies, as well as 8x8 ( EGHT) and Five9 ( FIVN).

YOU MAY ALSO LIKE:

Cloud Computing Spurs Business Communication Bonanza, Lifts RingCentral, Slack

Cloud Computing: Find Top Cloud Stocks And Track Industry Trends

Improve Your Investing Results With This Simple 3-Step Routine

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post RingCentral Stock Rises As Earnings, Revenue Top Estimates appeared first on Investor's Business Daily.



 
Каталог RSS-каналов (лент) — RSSfeedReader
Всего заголовков: 100
По категориям:
Все заголовки
AAPL (23)
ABBV (2)
ABMD (2)
AI (2)
ALRM (1)
ALXN (1)
AMAT (2)
Amazon Stock News (8)
AMD (1)
AMGN (4)
AMZN (13)
ANET (2)
ANGI (1)
Apple Stock News (12)
ARNA (1)
ARRS (1)
Artificial Intelligence (4)
ATHM (1)
ATVI (3)
Auto Industry News & Stocks To Watch (1)
AZN (5)
BABA (5)
BAYRY (1)
BHC (2)
BHVN (1)
BIDU (1)
BIIB (2)
Biotech And Pharma Stock News (27)
BKNG (1)
BMRN (1)
BMY (3)
BOLD (1)
BZUN (1)
CALX (1)
CBS (1)
CCI (1)
CELG (2)
Chinese Stocks To Watch (4)
Chip Stocks Semiconductor Industry News (11)
CHTR (1)
Click (16)
Cloud Computing (3)
CMCSA (2)
COMM (1)
CRM (2)
CRNT (1)
CSCO (3)
CYBR (2)
DATA (1)
DBX (1)
DIS (1)
DISH (1)
DLR (1)
Dow Jones Industrial Average Stock News (3)
DVMT (1)
EA (1)
Earnings (51)
EGHT (1)
ELAN (1)
ENDP (2)
EQIX (1)
ERICY (1)
ETSY (2)
Evergreen (3)
EXPE (1)
Facebook Stock News (2)
FANG Stocks: Facebook Amazon Netflix Google (7)
FB (9)
FIVN (1)
FN (1)
FNSR (2)
GHDX (1)
GILD (3)
GMED (2)
GOOGL (8)
Google Stock News (3)
GSK (1)
HEAR (2)
HON (1)
HPE (1)
HX (1)
HZNP (2)
IAC (1)
IIVI (2)
ILMN (1)
Industry Trends And Stock News (10)
INGN (1)
INTC (5)
IONS (1)
IPO News (5)
JAZZ (2)
JD (2)
JNJ (1)
JNPR (1)
LITE (6)
LLY (3)
LOGI (1)
MCHP (2)
MNK (2)
MRK (4)
MSFT (5)
MTCH (1)
MU (1)
MYL (2)
Netflix Stock News (3)
NFLX (6)
NKTR (1)
NOK (1)
NTES (1)
NVDA (6)
NVS (3)
ONCE (2)
OPRA (1)
ORCL (2)
PFE (3)
PRAH (1)
PYPL (3)
QCOM (4)
QRVO (3)
QURE (1)
REGN (3)
Retail And E-Commerce Stocks And Industry News (1)
REZI (1)
RNG (1)
ROKU (3)
S (2)
SBAC (1)
SBUX (1)
SEND (2)
SFTBY (1)
SLDB (1)
SNAP (1)
SNY (5)
SONO (2)
SQ (2)
SRPT (1)
SWKS (5)
SYMC (1)
T (2)
TBPH (1)
TCEHY (2)
Tech Earnings (52)
Technology (84)
Telecom Stocks To Watch And Industry News (2)
Tesla Stock News (1)
TEVA (2)
TM (1)
TMUS (1)
TRIP (1)
TSLA (7)
TSM (1)
TSRO (2)
TTD (1)
TTWO (4)
TWLO (2)
UBNT (1)
UTHR (1)
VMW (2)
VNDA (1)
VZ (2)
WMT (2)
XLNX (2)
YELP (1)
ZBRA (1)
ZTS (1)
По датам:
Все заголовки
2018-11-17, Сб. (8)
2018-11-16, Пт. (9)
2018-11-15, Чт. (7)
2018-11-14, Ср. (4)
2018-11-13, Вт. (11)
2018-11-12, Пн. (2)
2018-11-10, Сб. (7)
2018-11-09, Пт. (16)
2018-11-08, Чт. (15)
2018-11-07, Ср. (16)
2018-11-06, Вт. (5)
По авторам:
Все заголовки
ALLISON GATLIN (26)
BRIAN DEAGON (13)
ED CARSON (1)
IBD STAFF (10)
PATRICK SEITZ (29)
REINHARDT KRAUSE (21)